

Chapter 2400 Biotechnology

2401	Introduction	2421.02	Summary of the Requirements of the Sequence Rules
2402	The Deposit Rules	2421.03	Notification of a Failure to Comply
2403	Deposit of Biological Material	2421.04	Future Changes to the Sequence Rules
2403.01	Material Capable of Self- Replication	2422	Nucleotide and/or Amino Acid Sequence Disclosures in Patent Applications
2403.02	Plant Material	2422.01	Nucleotide and/or Amino Acids Disclosures Requiring a Sequence Listing
2404	Need or Opportunity to Make a Deposit	2422.02	The Requirement for Exclusive Conformance; Sequences Presented in Drawing Figures
2404.01	Biological Material That Is Known and Readily Available to the Public	2422.03	Sequence Listing Submission
2404.02	Biological Material That Can Be Made or Isolated Without Undue Experimentation	2422.03(a)	Sequence Listings Submitted as ASCII Text Files via EFS-Web
2404.03	Reference to a Deposit in the Specification	2422.04	The Requirement for a Computer Readable Copy of the Official Copy of the Sequence Listing
2405	Acceptable Depository	2422.05	Request for Transfer of Computer Readable Form
2406	Time of Making an Original Deposit	2422.06	Requirement for Statement Regarding Content of Official and Computer Readable Copies of Sequence Listing Requirements for Compliance, Statements Regarding New Matter, and Sanctions for Failure to Comply
2406.01	Description in Application Specification	2422.07	Presumptions Regarding Compliance
2406.02	Deposit After Filing Date - Corroboration	2422.08	Box Sequence; Hand Delivery of Sequence Listings and Computer Readable Forms
2406.03	Possible Loss of U.S. Filing Date in Other Countries	2423	Symbols and Format To Be Used for Nucleotide and/or Amino Acid Sequence Data
2407	Replacement or Supplement of Deposit	2423.01	Format and Symbols To Be Used in Sequence Listings
2407.01	In a Pending Application	2423.02	Depiction of Coding Regions
2407.02	After a Patent Has Issued	2423.03	Presentation and Numbering of Sequences
2407.03	Failure to Replace	2424	Requirements for Nucleotide and/or Amino Acid Sequences as Part of the Application Papers
2407.04	Treatment of Replacement	2424.01	Informational Requirements for the Sequence Listing
2407.05	Exemption From Replacement	2424.02	Sequence Listing Numeric Identifiers
2407.06	Replacement May Not Be Recognized	2424.03	Additional Miscellaneous Requirements
2408	Term of Deposit	2425	Form and Format for Nucleotide and/or Amino Acid Sequence Submissions in Computer Readable Form
2409	Viability of Deposit		
2410	Furnishing of Samples		
2410.01	Conditions of Deposit		
2410.02	Certification of Statement of Availability of Deposit		
2411	Examination Procedures		
2411.01	Rejections Based on Deposit Issue		
2411.02	Replies to Rejections Based on Deposit Issue		
2411.03	Application in Condition for Allowance Except for Deposit [Reserved]		
2411.04	[Reserved]		
2411.05	Content of Application with Respect to Deposited Material		
2412-2419	[Reserved]		
2420	The Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures - the Sequence Rules		
2421	Overview of the Sequence Rules		
2421.01	Definition of “Sequence Listing” and “CRF”		

- 2426 Amendments to or Replacement of Sequence Listing and Computer Readable Copy Thereof**
- 2427 Form Paragraphs**
- 2428 Sample Statements**
- 2429 Helpful Hints for Compliance**
- 2430 Patent Information**
- 2431 Sample Sequence Listing**
- 2432-2433 [Reserved]**
- 2434 Examination of Patent Applications Claiming Large Numbers of Nucleotide Sequences**
- 2435 Publishing of Patents and Patent Application Publications with Lengthy Sequence Listings**

2401 Introduction [R-07.2015]

This chapter provides guidance on the practices and procedures pertaining to the rules for deposits of biological materials for patent purposes ([37 CFR 1.801 - 1.809](#)) and the rules for the requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures ([37 CFR 1.821 - 1.825](#)).

2402 The Deposit Rules [R-07.2015]

37 CFR 1.801 Biological material.

For the purposes of these regulations pertaining to the deposit of biological material for purposes of patents for inventions under [35 U.S.C. 101](#), the term biological material shall include material that is capable of self-replication either directly or indirectly. Representative examples include bacteria, fungi including yeast, algae, protozoa, eukaryotic cells, cell lines, hybridomas, plasmids, viruses, plant tissue cells, lichens and seeds. Viruses, vectors, cell organelles and other non-living material existing in and reproducible from a living cell may be deposited by deposit of the host cell capable of reproducing the non-living material.

Every patent must contain a written description of the invention sufficient to enable a person skilled in the art to which the invention pertains to make and use the invention. Where the invention involves a biological material and words alone cannot sufficiently describe how to make and use the invention in a reproducible manner, access to the biological material may be necessary for the satisfaction of the statutory requirements for patentability under [35 U.S.C. 112](#). Courts have recognized the necessity and desirability of

permitting an applicant for a patent to supplement the written disclosure in an application with a deposit of biological material which is essential to meet some requirement of the statute with respect to the claimed invention. See, e.g., *Ajinomoto Co. v. Archer-Daniels-Midland Co.*, 228 F.3d 1338, 1345-46, 56 USPQ2d 1332, 1337-38 (Fed. Cir. 2000), *cert. denied*, 121 S.Ct. 1957 (2001)(explaining how deposit may help satisfy enablement requirement); *Enzo Biochem, Inc. v. Gen-Probe, Inc.*, 323 F.3d 956, 63 USPQ2d 1609 (Fed. Cir. 2002)(deposit may satisfy the written description requirement); *In re Argoudelis*, 434 F.2d 666, 168 USPQ 99 (CCPA 1970). To facilitate the recognition of deposited biological material in patent applications throughout the world, the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure was established in 1977, and became operational in 1981. The Treaty requires signatory countries, like the United States, to recognize a deposit with any depository which has been approved by the World Intellectual Property Organization (WIPO).

The deposit rules ([37 CFR 1.801 - 1.809](#)) set forth examining procedures and conditions of deposit which must be satisfied in the event a deposit is required. The rules do not address the substantive issue of whether a deposit is required under any particular set of facts.

See [PCT Rule 13bis](#) and [MPEP § 1823.01](#) for the requirements under the PCT for a reference to a deposited biological material in an international application.

2403 Deposit of Biological Material [R-07.2015]

[37 CFR 1.801](#) indicates that the rules pertaining to deposits for purposes of patents for inventions under [35 U.S.C. 101](#) are intended to relate to biological material. For the purposes of these rules, the term “biological material” is defined in terms of a non-exhaustive list of representative materials which can be deposited in accordance with the procedures defined in these rules. These rules are intended to address procedural matters in the deposit of biological material for patent purposes. They are not

designed to decide substantive issues such as whether a deposit of a particular organism or material would be recognized or necessary for the purposes of satisfying the statutory requirements for patentability under [35 U.S.C. 112](#). The issue of the need to make a deposit of biological material typically arises under [35 U.S.C. 112\(a\)](#) with regard to the enablement requirement, although the issue may also arise under the written description or best mode requirement of the statute. Deposit issues may also arise under [35 U.S.C. 112\(b\)](#) with respect to the claims.

[37 CFR 1.801](#) does not attempt to identify what biological material either needs to be or may be deposited to comply with the requirements of [35 U.S.C. 112](#). For the most part, this issue must be addressed on a case-by-case basis. Thus, while the Office does not currently contemplate that there would be any situations where a material that is not capable of self-replication either directly or indirectly would be acceptable as a deposit, an applicant is clearly not precluded by these rules from attempting to show in any given application why the deposit of such a material should be acceptable to satisfy the requirements of [35 U.S.C. 112](#). The examiner is cautioned against requiring that a specific biological material be deposited where the applicant can show that a deposit of starting material that is currently not available to the public would allow the skilled artisan to make and use the claimed invention. For example, where a claimed invention is drawn to a plant having novel properties produced by the insertion of a proprietary gene at a specific loci, the plant per se need not be deposited if deposit of a vector or hybridoma containing the gene would enable one of ordinary skill in the art to make and use the claimed invention without undue experimentation.

2403.01 Material Capable of Self-Replication [R-08.2012]

Biological material includes material that is capable of self-replication either directly or indirectly. Direct self-replication includes those situations where the biological material reproduces by itself. Representative examples of materials capable of self-replication are defined in the rule. Indirect self-replication is meant to include those situations where the biological material is only capable of

replication when another self-replicating biological material is present. Self-replication after insertion in a host is one example of indirect self-replication. Examples of indirect replicating biological materials include viruses, phages, plasmids, symbionts, and replication defective cells. The list of representative examples of each type of replicating material includes viruses to demonstrate that the two lists in the rule are not intended to be mutually exclusive.

2403.02 Plant Material [R-10.2019]

Although plant material is included within the scope of the definition of biological material for purposes of patents for plant inventions under [35 U.S.C. 101](#), the rules on deposits are not applicable to applications filed under the Plant Patent Act ([35 U.S.C. 161-164](#)). The Office is of the view that a deposit is not required under the present provisions of [35 U.S.C. 162](#). Thus, a deposit is not necessary for the grant of a plant patent under the provisions of [35 U.S.C. 161-164](#). See also [MPEP § 1605](#). As with other biological material deposited for purposes of patents for inventions under [35 U.S.C. 101](#), the deposit of plant material together with the written specification must enable those skilled in the art to make and use the claimed invention, in accordance with the requirements of [35 U.S.C. 112](#).

As with some types of reproducible biological material, seeds can be reproduced only after a growing season which may be relatively long. Although the rules do not specify a specific number of seeds to be deposited to meet the requirements of these rules, so long as the number of seeds deposited complies with the requirements of the Budapest Treaty International Depositary Authority (IDA) where the deposit is made, the USPTO would consider such a compliant submission as satisfying the rules under [37 CFR 1.801](#) through [1.809](#). Note that the American Type Culture Collection (ATCC), a Budapest IDA, requires a minimum deposit of 625 seeds; other IDAs may have different minimum requirements. Accordingly, any depositor should confirm that the number submitted to a specific IDA complies with that IDA's requirements for seed deposits.

2404 Need or Opportunity to Make a Deposit [R-08.2012]

37 CFR 1.802 Need or opportunity to make a deposit.

(a) Where an invention is, or relies on, a biological material, the disclosure may include reference to a deposit of such biological material.

(b) Biological material need not be deposited unless access to such material is necessary for the satisfaction of the statutory requirements for patentability under [35 U.S.C. 112](#). If a deposit is necessary, it shall be acceptable if made in accordance with these regulations. Biological material need not be deposited, *inter alia*, if it is known and readily available to the public or can be made or isolated without undue experimentation. Once deposited in a depository complying with these regulations, a biological material will be considered to be readily available even though some requirement of law or regulation of the United States or of the country in which the depository institution is located permits access to the material only under conditions imposed for safety, public health or similar reasons.

(c) The reference to a biological material in a specification disclosure or the actual deposit of such material by an applicant or patent owner does not create any presumption that such material is necessary to satisfy [35 U.S.C. 112](#) or that deposit in accordance with these regulations is or was required.

[37 CFR 1.802\(a\)](#) permits a deposit of a biological material to be referenced in a patent application where an invention is, or relies on, a biological material. The invention may rely on a biological material for the purposes of making or using the invention, either as a preferred mode or an alternative mode of operation. A reference to a deposit may be included in a specification even though the deposit is not required to satisfy the requirements of [35 U.S.C. 112](#).

There is no necessary implication or presumption that can or should be made about the need for a deposit simply because reference to a deposit is made in an application disclosure, as noted in paragraph (c). As noted in paragraph (b), biological material need not be deposited unless access to such material is necessary for the satisfaction of the statutory requirements for patentability under [35 U.S.C. 112](#) and that access is not otherwise available in the absence of a deposit. Where a deposit is required to provide the necessary access, a deposit is acceptable for patent purposes only where it is made in accordance with these regulations. Even where access to biological material is required to satisfy these statutory requirements, a deposit may not be necessary if access sufficient to satisfy these requirements is otherwise available.

2404.01 Biological Material That Is Known and Readily Available to the Public [R-07.2015]

In an application where the invention required access to specific biological material, an applicant could show that the biological material is accessible because it is known and readily available to the public. The concepts of “known and readily available” are considered to reflect a level of public accessibility to a necessary component of an invention disclosure that is consistent with an ability to make and use the invention. To avoid the need for a deposit on this basis, the biological material must be both known and readily available - neither concept alone is sufficient. A material may be known in the sense that its existence has been published, but is not available to those who wish to obtain that particular known biological material. Likewise, a biological material may be available in the sense that those having possession of it would make it available upon request, but no one has been informed of its existence.

The Board has held that a description of the precise geographic location of marine tunicates, as a biological material, used in a claimed invention was adequate to satisfy the enablement requirement of [35 U.S.C. 112](#). See *Ex Parte Rinehart*, 10 USPQ2d 1719 (Bd. Pat. App. & Int. 1985). The term “readily” used in the phrase “known and readily available” is considered appropriate to define that degree of availability which would be reasonable under the circumstances. If the biological material and its natural location can be adequately described so that one skilled in the art could obtain it using ordinary skill in the art, the disclosure would appear to be sufficient to meet the enablement requirement of [35 U.S.C. 112](#) without a deposit so long as its degree of availability is reasonable under the circumstances.

By showing that a biological material is known and readily available or by making a deposit in accordance with these rules, applicant does not guarantee that such biological material will be available forever. Public access during the term of the patent may affect the enforceability of the patent. Although there is a public interest in the availability of a deposited biological material during and after the period of enforceability of the patent, there

should not be any undue concern about continued access to the public. See [37 CFR 1.806](#) (the term of deposit is “at least thirty (30) years and at least five (5) years after the most recent request” for a sample; the agreement sufficiently ensures that the deposit will be “available beyond the enforceable life of the patent”). Unless there is a reasonable basis to believe that the biological material will cease to be available during the enforceable life of the patent, current availability would satisfy the requirement. The incentives provided by the patent system should not be constrained by the mere possibility that a disclosure that was once enabling would become non-enabling over a period of time through no fault of the patentee. *In re Metcalfe*, 410 F.2d 1378, 161 USPQ 789 (CCPA 1969).

If an applicant has adequately established that a biological material is known and readily available, the Office will accept that showing. In those instances, however, the applicant takes the risk that the material may cease to be known and readily available. Such a defect cannot be cured by reissue after the grant of a patent.

On the other hand, *Ex parte Humphreys*, 24 USPQ2d 1255 (Bd. Pat. App. & Int. 1992), held that the only manner in which applicants could satisfy their burden of assuring public access to the needed biological material, and, thereby, compliance with the enablement requirement of [35 U.S.C. 112](#), was by making an appropriate deposit. The fact that applicants and other members of the public were able to obtain the material in question from a given depository prior to and after the filing date of the application in issue did not establish that upon issuance of a patent on the application that such material would continue to be accessible to the public. The applicants did not make of record any of the facts and circumstances surrounding their access to the material in issue from the depository, nor was there any evidence as to the depository’s policy regarding the material if a patent would have been granted. Further, there was no assurance that the depository would have allowed unlimited access to the material if the application had matured into a patent.

There are many factors that may be used as indicia that a biological material is known and readily

available to the public. Relevant factors include commercial availability, references to the biological material in printed publications, declarations of accessibility by those working in the field, evidence of predictable isolation techniques, or an existing deposit made in accordance with these rules. Each factor alone may or may not be sufficient to demonstrate that the biological material is known and readily available. Those applicants that rely on evidence of accessibility other than a deposit take the risk that the patent may no longer be enforceable if the biological material necessary to satisfy the requirements of [35 U.S.C. 112](#) ceases to be accessible.

The Office will accept commercial availability as evidence that a biological material is known and readily available only when the evidence is clear and convincing that the public has access to the material. See the final rule entitled “*Deposit of Biological Materials for Patent Purposes*,” 54 FR 34864, 34875 (August 22, 1989). A product could be commercially available but only at a price that effectively eliminates accessibility to those desiring to obtain a sample. The relationship between the applicant relying on a biological material and the commercial supplier is one factor that would be considered in determining whether the biological material was known and readily available. However, the mere fact that the biological material is commercially available only through the patent holder or the patent holder’s agents or assigns shall not, by itself, justify a finding that the necessary material is not readily available, absent reason to believe that access to the biological material would later be improperly restricted.

The mere reference to a deposit or the biological material itself in any document or publication does not necessarily mean that the deposited biological material is readily available. Even a deposit made under the Budapest Treaty and referenced in a United States or foreign patent document would not necessarily meet the test for known and readily available unless the deposit was made under conditions that are consistent with those specified in these rules, including the provision that requires, with one possible exception ([37 CFR 1.808\(b\)](#)), that all restrictions on the accessibility be irrevocably removed by the applicant upon the granting of the

patent. *Ex parte Hildebrand*, 15 USPQ2d 1662 (Bd. Pat. App. & Int. 1990).

A deposit of biological material cited in a U.S. patent need not be made available if it was not required to satisfy [35 U.S.C. 112](#). For this reason, [37 CFR 1.808\(c\)](#) provides that upon request made to the Office, the Office will certify whether a deposit has been stated to have been made under conditions which make it available to the public as of the issue date. See [37 CFR 1.808\(c\)](#) and [MPEP § 2410.02](#) for the requirements of the request. The Office will not certify that the aforementioned statement has been made unless:

(A) the deposit was necessary to overcome a rejection under [35 U.S.C. 112](#),

(B) there is, in the record, a statement by the examiner that a rejection would have been made “but for” the deposit (assumes deposit information in record, as filed),

(C) the record otherwise clearly indicates that the deposit was made under Budapest Treaty, and that all restrictions imposed by the depositor on the availability to the public of the deposited material will be irrevocably removed upon the granting of the patent (with the possible exception of requiring the request for the deposit to be in the format specified in [37 CFR 1.808\(b\)](#)), or

(D) the record otherwise clearly indicates that an acceptable non-Budapest Treaty deposit was made and that all restrictions imposed by the depositor on the availability to the public of the deposited material will be irrevocably removed upon the granting of the patent (with the possible exception of requiring the request for the deposit to be in the format specified in [37 CFR 1.808\(b\)](#)).

If a deposit is not made under the conditions set forth in [37 CFR 1.808\(a\)](#), the deposit cannot be relied upon for other purposes, e.g., the deposit cannot be relied upon by a third party to establish “known” and “readily available” in another application. See [37 CFR 1.808](#) and [MPEP § 2410](#) and [§ 2410.02](#).

Once a deposit is made in a depository complying with these rules, and under conditions complying with these rules, a biological material will be considered to be readily available even though some

requirement of law or regulation in the United States or in the country where the depository institution is located permits access to the material only under conditions imposed for health, safety or similar reasons. This provision is consistent with the Budapest Treaty (Article 5) and is designed to permit the patenting of inventions involving materials having restricted distribution, where the restrictions are imposed for the public, as opposed to the private, welfare.

2404.02 Biological Material That Can Be Made or Isolated Without Undue Experimentation [R-08.2012]

Applicant may show that a deposit is not necessary even though specific biological materials are required to practice the invention if those biological materials can be made or isolated without undue experimentation. Deposits may be required to support the claims if an isolation procedure requires undue experimentation to obtain the desired biological material. *Ex Parte Jackson*, 217 USPQ 804 (Bd. App. 1982). No deposit is required, however, where the required biological materials can be obtained from publicly available material with only routine experimentation and a reliable screening test. *Tabuchi v. Nubel*, 559 F.2d 1183, 194 USPQ 521 (CCPA 1977); *Ex Parte Hata*, 6 USPQ2d 1652 (Bd. Pat. App. & Int. 1987).

2404.03 Reference to a Deposit in the Specification [R-08.2012]

[37 CFR 1.802\(c\)](#) specifically provides that the mere reference to a biological material in the specification disclosure or the actual deposit of such material does not create any presumption that such referenced or deposited material is necessary to satisfy [35 U.S.C. 112](#), or that a deposit in accordance with these regulations is or was required. It should be noted, however, that a reference to a biological material, present in an application upon filing, may form the basis for making a deposit, where required, after the filing date of a given application but that the reference to the biological material, itself, cannot be added after filing without risking the prohibited introduction of new matter ([35 U.S.C. 132](#)). See the

discussion of the Lundak application in [MPEP § 2406.01](#).

2405 Acceptable Depository [R-07.2015]

37 CFR 1.803 Acceptable depository.

(a) A deposit shall be recognized for the purposes of these regulations if made in

(1) any International Depository Authority (IDA) as established under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, or

(2) any other depository recognized to be suitable by the Office. Suitability will be determined by the Commissioner on the basis of the administrative and technical competence, and agreement of the depository to comply with the terms and conditions applicable to deposits for patent purposes. The Commissioner may seek the advice of impartial consultants on the suitability of a depository. The depository must:

(i) Have a continuous existence;

(ii) Exist independent of the control of the depositor;

(iii) Possess the staff and facilities sufficient to examine the viability of a deposit and store the deposit in a manner which ensures that it is kept viable and uncontaminated;

(iv) Provide for sufficient safety measures to minimize the risk of losing biological material deposited with it;

(v) Be impartial and objective;

(vi) Furnish samples of the deposited material in an expeditious and proper manner; and

(vii) Promptly notify depositors of its inability to furnish samples, and the reasons why.

(b) A depository seeking status under paragraph (a)(2) of this section must direct a communication to the Commissioner which shall:

(1) Indicate the name and address of the depository to which the communication relates;

(2) Contain detailed information as to the capacity of the depository to comply with the requirements of paragraph (a) (2) of this section, including information on its legal status, scientific standing, staff and facilities;

(3) Indicate that the depository intends to be available, for the purposes of deposit, to any depositor under these same conditions;

(4) Where the depository intends to accept for deposit only certain kinds of biological material, specify such kinds;

(5) Indicate the amount of any fees that the depository will, upon acquiring the status of suitable depository under paragraph (a) (2) of this section, charge for storage, viability statements and furnishings of samples of the deposit.

(c) A depository having status under paragraph (a)(2) of this section limited to certain kinds of biological material may

extend such status to additional kinds of biological material by directing a communication to the Commissioner in accordance with paragraph (b) of this section. If a previous communication under paragraph (b) of this section is of record, items in common with the previous communication may be incorporated by reference.

(d) Once a depository is recognized to be suitable by the Commissioner or has defaulted or discontinued its performance under this section, notice thereof will be published in the Official Gazette of the Patent and Trademark Office.

[37 CFR 1.803](#) indicates that a depository will be recognized as acceptable for the purposes of these regulations if it is either an International Depository Authority (IDA) established under the Budapest Treaty, or if it is a depository recognized as suitable by the Commissioner. After the effective date of these regulations, a deposit of biological material which is made in a depository which is not recognized as acceptable under this regulation will not be considered as satisfying the requirements of [35 U.S.C. 112](#). See *Ex parte Humphreys*, 24 USPQ2d 1255 (Bd. Pat. App. & Int. 1992). On the other hand, if a deposit is not required to satisfy the requirements of [35 U.S.C. 112](#), it is permissible to make reference to such a deposit even though it may not be in a depository or made under the conditions which are acceptable under these regulations. As new depositories are recognized as suitable by the Commissioner, their identity will be announced in the *Official Gazette*.

An organization may be recognized as suitable by the Office if the procedure and conditions specified in [37 CFR 1.803\(a\)\(2\)](#) and [37 CFR 1.803\(b\)](#) are followed. Generally, it is not the intention of the Office to recognize as suitable any organization where the need for a suitable depository for patent purposes is being met by depositories recognized as IDAs under the Budapest Treaty. Suitability will be judged by the Commissioner, based on need and the information supplied by the organization seeking status, and information obtained from other sources that may be consulted.

While there is a desire to provide flexibility to a patent applicant in selecting an appropriate depository, these rules are not intended to permit each patent applicant to become its own depository since both the patent owner and the public have an interest in the continued availability and accessibility of the deposit during the enforceable life of the

patent, and the public has a continuing interest in its availability when the patent is no longer enforceable. The concept of a depository independent of the control of the depositor or an IDA as an acceptable depository is based on the need and desire to ensure the safe and reliable storage of a deposited biological material under circumstances that are substantially free of the opportunity for intentional mishandling or negligent handling of the deposited material. The use of an independent depository or internationally recognized depository will tend to preserve the integrity of the deposit process against those that may accidentally alter the deposited material, may wish to tamper with the deposited material or may wish to resume control of its availability when the patent is no longer enforceable, and will tend to preserve the interest of the public in the access to the biological material once the term of the patent expires.

When a depository having status under [37 CFR 1.803\(a\)\(2\)](#) seeks to change the kinds of biological materials that it will accept and maintain for the purposes of these rules, a communication requesting such a change should be directed to the Commissioner containing the information requested in [37 CFR 1.803\(b\)](#). When such a change is requested, the requesting depository should provide a complete list of the kinds of biological materials it will accept.

[37 CFR 1.803\(d\)](#) indicates that once a depository is recognized as suitable for the purposes of this rule, or has defaulted or discontinued its performance under this section, notice thereof will be published in the *Official Gazette* of the Patent and Trademark Office. The mere fact that a deposit has been made in an IDA recognized under the Budapest Treaty does not mean that the terms of the deposit meet either the requirements of the Budapest Treaty or the deposit regulations. Many of the depositories recognized under the Budapest Treaty have many different arrangements under which biological material may be stored.

The World Intellectual Property Organization (WIPO) publishes a Guide to the Deposit of Micro-organisms under the Budapest Treaty (WIPO Publication No. 661 (E)) on the procedures and requirements concerning the deposit of biological

material, including procedures for obtaining a sample of deposited material, in each of the international depository authorities. The Guide and a list of current IDAs under the Budapest Treaty are available at www.wipo.int/treaties/en/registration/budapest/.

2406 Time of Making an Original Deposit [R-07.2015]

37 CFR 1.804 Time of making an original deposit.

(a) Whenever a biological material is specifically identified in an application for patent as filed, an original deposit thereof may be made at any time before filing the application for patent or, subject to [§ 1.809](#), during pendency of the application for patent.

(b) When the original deposit is made after the effective filing date of an application for patent, the applicant must promptly submit a statement from a person in a position to corroborate the fact, stating that the biological material which is deposited is a biological material specifically identified in the application as filed.

[37 CFR 1.804](#) specifies the time for making an original deposit to fulfill the requirements of [35 U.S.C. 112](#). For the reasons discussed throughout this section, it is recommended that a deposit be made before the filing date of the application. However, for the purposes of complying with the requirements of [35 U.S.C. 112](#), a deposit of a biological material may be made at any time before filing the application for patent or during the pendency of the application subject to the conditions of [37 CFR 1.809](#). Where a deposit is needed to satisfy the requirements of [35 U.S.C. 112](#) and it is made during the pendency of the application, it must be made no later than the time period set by the examiner at the time the Notice of Allowance and Issue Fee Due is mailed. However, a necessary deposit need not be made by an applicant until the application is in condition for allowance so long as the applicant provides a written assurance that an acceptable deposit will be made on or before the payment of the issue fee. This written assurance must provide sufficiently detailed information to convince the examiner that there is no outstanding issue regarding deposits that needs to be resolved. Note that while [37 CFR 1.804](#) permits making a deposit after the filing date of an application, in many countries the deposit must be made before the filing date of the application. See [MPEP § 2406.03](#).

Insofar as the rules do not permit post-issuance original deposits, the failure to make an original deposit in an application cannot be cured by filing a reissue application or instituting a reexamination proceeding. However, if an amendment of claims in a reexamination proceeding raises the need for a deposit, an original deposit may be made during the reexamination proceeding.

2406.01 Description in Application Specification [R-07.2015]

[37 CFR 1.804\(a\)](#) specifies not only a permissible time frame for making an original deposit, but also specifies that the biological material deposited must be specifically identified in the application for patent as filed. The requirement for a specific identification is consistent with the description requirement of [35 U.S.C. 112](#) and provides an antecedent basis for the biological material which either has been or will be deposited before the patent is granted.

The description in the Lundak application as filed (now U.S. Patent No. 4,594,325) provides a suitable illustration of the specific identification and description which are required in an application as filed. In that application, an immortal B-cell line was disclosed and claimed. The cell line was referred to in the application, as filed, as WI-L2-729 HF2. The methods of obtaining and using this cell line were also described in the application as filed. A deposit of the cell line was made with the American Type Culture Collection (ATCC) about a week after the application was filed in the United States. The United States Court of Appeals for the Federal Circuit held that the requirements of access by the Office to a sample of the cell line during pendency, and public access after grant, were met by Lundak's procedures. The Court further held that the addition of information designating the depository, accession number, and deposit date of the deposited cell line in ATCC after the filing date did not violate the prohibition against new matter in [35 U.S.C. 132](#). *In re Lundak*, 773 F.2d 1216, 227 USPQ 90 (Fed. Cir. 1985). However, it must be clear from the application as filed that the invention claimed and described in the specification "was fully capable of being reduced to practice (i.e., no technological problems, the resolution of which would require more than ordinary skill and reasonable time,

remained in order to obtain an operative, useful process)." *Feldman v. Aunstrup*, 517 F.2d 1351, 1355, 186 USPQ 108, 113 (CCPA 1975), *cert. denied*, 424 U.S. 912 (1976).

2406.02 Deposit After Filing Date - Corroboration [R-08.2012]

When the original deposit is made after the effective filing date of an application for patent, an applicant is required to promptly submit a statement from a person in a position to corroborate that the biological material which is deposited is a biological material specifically identified in the application (the filing date of which is relied upon) as filed. The nature of this corroboration will depend on the circumstances in the particular application under consideration, including the length of time between the application filing date and the date of deposit. While few, if any, situations can be imagined where the description requirement of [35 U.S.C. 112](#) can be satisfied where the biological material was not in existence at the time of filing, the rules will not preclude such a situation as there is no requirement in the patent law that an actual reduction to practice occur as a condition precedent to filing a patent application.

2406.03 Possible Loss of U.S. Filing Date in Other Countries [R-07.2015]

Those applicants intending to file patent applications in a country other than the United States relying upon biological material that must be deposited to satisfy the requirements of [35 U.S.C. 112](#) when the application is filed in the United States are cautioned that in many countries the deposit must be made before the filing date of the priority application in order to obtain foreign priority rights. Thus, while the deposit of a biological material subsequent to the effective filing date of a United States application may be relied upon to comply with [35 U.S.C. 112](#), an applicant may not be able to rely on the filing date of such a U.S. application if a patent is sought in certain countries other than the United States.

2407 Replacement or Supplement of Deposit [R-08.2012]

37 CFR 1.805 Replacement or supplement of deposit.

(a) A depositor, after receiving notice during the pendency of an application for patent, application for reissue patent or reexamination proceeding, that the depository possessing a deposit either cannot furnish samples thereof or can furnish samples thereof but the deposit has become contaminated or has lost its capability to function as described in the specification, shall notify the Office in writing, in each application for patent or patent affected. In such a case, or where the Office otherwise learns, during the pendency of an application for patent, application for reissue patent or reexamination proceeding, that the depository possessing a deposit either cannot furnish samples thereof or can furnish samples thereof but the deposit has become contaminated or has lost its capability to function as described in the specification, the need for making a replacement or supplemental deposit will be governed by the same considerations governing the need for making an original deposit under the provisions set forth in [§ 1.802\(b\)](#). A replacement or supplemental deposit made during the pendency of an application for patent shall not be accepted unless it meets the requirements for making an original deposit under these regulations, including the requirement set forth under [§ 1.804\(b\)](#). A replacement or supplemental deposit made in connection with a patent, whether or not made during the pendency of an application for reissue patent or a reexamination proceeding or both, shall not be accepted unless a certificate of correction under [§ 1.323](#) is requested by the patent owner which meets the terms of paragraphs (b) and (c) of this section.

(b) A request for certificate of correction under this section shall not be granted unless the certificate identifies:

- (1) The accession number for the replacement or supplemental deposit;
- (2) The date of the deposit; and
- (3) The name and address of the depository.

(c) A request for a certificate of correction under this section shall not be granted unless the request is made promptly after the replacement or supplemental deposit has been made and the request:

- (1) Includes a statement of the reason for making the replacement or supplemental deposit;
- (2) Includes a statement from a person in a position to corroborate the fact, and stating that the replacement or supplemental deposit is of a biological material which is identical to that originally deposited;
- (3) Includes a showing that the patent owner acted diligently —

(i) In the case of a replacement deposit, in making the deposit after receiving notice that samples could no longer be furnished from an earlier deposit; or

(ii) In the case of a supplemental deposit, in making the deposit after receiving notice that the earlier deposit had become contaminated or had lost its capability to function as described in the specification;

(4) Includes a statement that the term of the replacement or supplemental deposit expires no earlier than the term of the deposit being replaced or supplemented; and

(5) Otherwise establishes compliance with these regulations.

(d) A depositor's failure to replace a deposit, or in the case of a patent, to diligently replace a deposit and promptly thereafter request a certificate of correction which meets the terms of paragraphs (b) and (c) of this section, after being notified that the depository possessing the deposit cannot furnish samples thereof, shall cause the application or patent involved to be treated in any Office proceeding as if no deposit were made.

(e) In the event a deposit is replaced according to these regulations, the Office will apply a rebuttable presumption of identity between the original and the replacement deposit where a patent making reference to the deposit is relied upon during any Office proceeding.

(f) A replacement or supplemental deposit made during the pendency of an application for patent may be made for any reason.

(g) In no case is a replacement or supplemental deposit of a biological material necessary where the biological material, in accordance with [§ 1.802\(b\)](#), need not be deposited.

(h) No replacement deposit of a biological material is necessary where a depository can furnish samples thereof but the depository for national security, health or environmental safety reasons is unable to provide samples to requesters outside of the jurisdiction where the depository is located.

(i) The Office will not recognize in any Office proceeding a replacement deposit of a biological material made by a patent owner where the depository could furnish samples of the deposit being replaced.

[37 CFR 1.805](#) relates to the deposit of a biological material to replace or supplement a previous deposit. The term “replacement” is directed to those situations where one deposit is being substituted for another. An applicant may have greater latitude in replacing a deposit during the pendency of an application than after the patent is granted. Replacement will typically take place where the earlier deposit is no longer viable. The term “supplement” is directed to those situations where the earlier deposit is still viable in the sense that it is alive and capable of replication either directly or indirectly, but has lost a quality (e.g., purity, functionality) it allegedly possessed at the time the application was filed.

2407.01 In a Pending Application [R-07.2015]

Pursuant to [37 CFR 1.805\(a\)](#), an applicant is required to notify the Office when it obtains information that the depository possessing a deposit referenced in an application cannot furnish samples of the deposit. When the Office is so informed or otherwise

becomes aware that samples of the deposited material cannot be furnished by the depository, the examiner will treat the application as if no deposit existed. A replacement or supplemental deposit must be made if access to the deposited material is necessary to satisfy the requirements for patentability under [35 U.S.C. 112](#). A replacement or supplemental deposit will be accepted if it meets all the requirements for making an original deposit.

It should be noted that in a pending application, an applicant need not replace the identical material previously deposited, but may make an original deposit of a biological material which is specifically identified and described in the application as filed. Whether this alternative deposit will meet the requirements of [35 U.S.C. 112](#) with respect to the claimed subject matter must be resolved by the examiner on a case-by-case basis. The conditions in [37 CFR 1.802\(b\)](#) and [37 CFR 1.804\(b\)](#) must be satisfied.

2407.02 After a Patent Has Issued [R-07.2015]

A patent owner is required to notify the Office when it obtains information that a depository possessing a deposit referenced in a patent cannot furnish samples of the deposit. Failure to diligently replace the deposit and promptly thereafter request a certificate of correction which meets the terms of [37 CFR 1.805\(b\)](#) and [37 CFR 1.805\(c\)](#) will cause the patent involved to be treated in any Office proceeding as if no deposit were made.

A replacement or supplemental deposit made in connection with a patent, whether or not made during the pendency of an application for reissue patent or a reexamination proceeding or both, shall not be accepted unless a certificate of correction under [37 CFR 1.323](#) is requested which meets the terms of [37 CFR 1.805\(b\)](#) and [37 CFR 1.805\(c\)](#) for replacement or supplemental deposits. See [MPEP § 1411.01](#) for including changes that were made by a certificate of correction to the original patent grant in a reissue application, and [MPEP § 2219](#) for including a copy of any certificate of correction to the original patent grant as part of a request for *ex parte* reexamination.

[37 CFR 1.805\(b\)](#) and [37 CFR 1.805\(c\)](#) specify the procedures that a patent owner may follow to ensure that a patent contains the appropriate information about a deposited biological material in the event that a replacement or supplemental deposit is made after the patent is granted. [37 CFR 1.805\(b\)](#) describes the information which must be contained in the certificate of correction, whereas [37 CFR 1.805\(c\)](#) describes the information which must be provided in the request to make the correction.

A request for a certificate of correction of a patent under [37 CFR 1.805\(b\)](#) and [37 CFR 1.805\(c\)](#) will not be granted where no original deposit was made before or during the pendency of the application which matured into the patent. A patent defective because of lack of a necessary deposit is necessarily fatally defective for failure to comply with the first paragraph of [35 U.S.C. 112](#). Reissue is not available in such cases. See *In re Hay*, 534 F.2d 917, 189 USPQ 790 (CCPA 1976).

2407.03 Failure to Replace [R-08.2012]

[37 CFR 1.805\(d\)](#) sets forth the Office position that the failure to make a replacement deposit in a case pending before the Office, for example a reissue or reexamination proceeding, where a deposit is considered to be necessary to satisfy the requirements of [35 U.S.C. 112](#), shall cause the application or patent involved to be treated in any Office proceeding as if no deposit were made. The provisions of [37 CFR 1.805\(g\)](#) indicate that a replacement need not be made where, at the point in time when replacement would otherwise be necessary, access to the necessary biological material was otherwise available. For example, a replacement deposit would not be required under the circumstances where access to the necessary biological material was established through commercial suppliers.

2407.04 Treatment of Replacement [R-08.2012]

[37 CFR 1.805\(e\)](#) indicates that the Office will apply a rebuttable presumption of identity between the replacement deposit and an original deposit where a patent making reference to the deposit is relied on during any Office proceeding. This means that where

a replacement deposit is permitted and made, the examiner will assume that the same material as described in the patent is accessible from the identified depository unless evidence to the contrary comes to the attention of the Office.

An applicant for patent may make a replacement deposit during the pendency of the application for any reason. The provisions of [37 CFR 1.805\(f\)](#) recognize that since an original deposit may be made during the pendency of the application subject to the conditions of [37 CFR 1.809](#), a replacement deposit logically cannot be held to any higher standard or any further requirements.

2407.05 Exemption From Replacement [R-08.2012]

The provisions of [37 CFR 1.805\(h\)](#) indicate that a replacement deposit is not required even though the depository cannot furnish samples, under certain conditions, to those requesting a sample outside of the jurisdiction where the depository is located. The conditions are specified in this paragraph as being limited to national security, health or environmental safety reasons. See also Article 5 of the Budapest Treaty.

2407.06 Replacement May Not Be Recognized [R-07.2015]

[37 CFR 1.805\(i\)](#) indicates that the Office will not recognize in any Office proceeding a replacement deposit made by the patent owner where the depository could furnish samples of the original deposit being replaced. The best evidence of what was originally deposited should not be lost through destruction or replacement if made in association with an existing patent. A supplemental deposit may be accepted in an Office proceeding, however, depending on the circumstances in each case.

2408 Term of Deposit [R-07.2015]

37 CFR 1.806 Term of deposit.

A deposit made before or during pendency of an application for patent shall be made for a term of at least thirty (30) years and at least five (5) years after the most recent request for the furnishing of a sample of the deposit was received by the depository. In any case, samples must be stored under

agreements that would make them available beyond the enforceable life of the patent for which the deposit was made.

The term of deposit must satisfy the requirements of the Budapest Treaty which sets a term of at least 30 years from the date of deposit and at least 5 years after the most recent request for the furnishing of a sample of the deposit was received by the depository. In the event that the 30-year term of deposit covers the 17-year term or 20-year term of the patent (see [MPEP § 2701](#)) plus 6 years to include the Statute of Limitations, no further requirement is necessary. Unless applicant indicates that the deposit has been made under the Budapest Treaty, applicant must indicate the term for which the deposit has been made. The mere possibility of patent term extension or extended litigation involving the patent should not be considered in this analysis.

In the event that the 30-year term of deposit measured from the date of deposit would necessarily terminate within the period of enforceability of the patent (the patent term (see [MPEP § 2701](#)) plus 6 years to include the Statute of Limitations), samples must be stored under agreements that would make them available beyond the enforceable life of the patent for which the deposit was made. No requirement should be made as to any particular period of time beyond the enforceable life of the patent. The purpose of the requirement is to insure that a deposited biological material necessary for the practice of a patented invention would be available to the public after expiration of the patent for which the deposit was made. The term of the deposit must comply with the requirements of each sentence of [37 CFR 1.806](#) whether or not the deposit is made under the Budapest Treaty. A specific statement that the deposit would be stored under agreements that would make them available beyond the enforceable life of the patent for which the deposit was made is required only where the 30-year term of deposit would terminate within the enforceable life of the patent.

2409 Viability of Deposit [R-07.2015]

37 CFR 1.807 Viability of deposit.

(a) A deposit of biological material that is capable of self-replication either directly or indirectly must be viable at the time of deposit and during the term of deposit. Viability may be tested by the depository. The test must conclude only that the deposited material is capable of reproduction. No evidence

is necessarily required regarding the ability of the deposited material to perform any function described in the patent application.

(b) A viability statement for each deposit of a biological material defined in paragraph (a) of this section not made under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure must be filed in the application and must contain:

- (1) The name and address of the depository;
- (2) The name and address of the depositor;
- (3) The date of deposit;
- (4) The identity of the deposit and the accession number given by the depository;
- (5) The date of the viability test;
- (6) The procedures used to obtain a sample if the test is not done by the depository; and
- (7) A statement that the deposit is capable of reproduction.

(c) If a viability test indicates that the deposit is not viable upon receipt, or the examiner cannot, for scientific or other valid reasons, accept the statement of viability received from the applicant, the examiner shall proceed as if no deposit has been made. The examiner will accept the conclusion set forth in a viability statement issued by a depository recognized under [§ 1.803\(a\)](#).

[37 CFR 1.807](#) requires that the deposit of biological material that is capable of self-replication either directly or indirectly must be viable at the time of deposit and during the term of deposit. This requirement for viability is essentially a requirement that the deposited material is capable of reproduction. For the purpose of making a deposit under these rules, there is no requirement that evidence be provided that the deposited material is capable or has the ability to perform any function described in the patent application. However, as with any other issue of description or enablement, if the examiner has evidence or reason to question the objective statements made in the patent application, applicants may be required to demonstrate that the deposited biological material will perform in the manner described.

Under the Budapest Treaty, there is a requirement that the deposit be tested for viability before it is accepted. Thus, a mere statement by an applicant, an authorized representative of applicant or the assignee that the deposit has been accepted under the Budapest Treaty would satisfy [37 CFR 1.807](#). The examiner should note the clear distinction between a statement by the applicant that the deposit

has been made under the Budapest Treaty and one in which the deposit has been made and accepted under the Budapest Treaty. Where a statement is merely an indication that a deposit has been made (with no indication as to whether it has been accepted), there is no assurance that the requirements under [35 U.S.C. 112](#) have been satisfied.

For each deposit which is not made under the Budapest Treaty, a viability statement must be filed in the patent application and contain the information listed in paragraph (b) of this section. Under [37 CFR 1.807\(c\)](#), the examiner will accept the conclusion set forth in a viability statement which is issued by a depository recognized under [37 CFR 1.803\(a\)](#). If the viability test indicates that the deposit is not viable upon receipt, or the examiner cannot, for scientific or other valid reasons, accept the statement of viability received from the applicant, the examiner shall so notify the applicant stating the reasons for not accepting the statement and proceed with the examination process as if no deposit had been made.

2410 Furnishing of Samples [R-08.2012]

37 CFR 1.808 Furnishing of samples.

(a) A deposit must be made under conditions that assure that:

(1) Access to the deposit will be available during pendency of the patent application making reference to the deposit to one determined by the Commissioner to be entitled thereto under [§ 1.14](#) and [35 U.S.C. 122](#), and

(2) Subject to paragraph (b) of this section, all restrictions imposed by the depositor on the availability to the public of the deposited material will be irrevocably removed upon the granting of the patent.

(b) The depositor may contract with the depository to require that samples of a deposited biological material shall be furnished only if a request for a sample, during the term of the patent:

- (1) Is in writing or other tangible form and dated;
- (2) Contains the name and address of the requesting party and the accession number of the deposit; and
- (3) Is communicated in writing by the depository to the depositor along with the date on which the sample was furnished and the name and address of the party to whom the sample was furnished.

(c) Upon request made to the Office, the Office will certify whether a deposit has been stated to have been made under conditions which make it available to the public as of the issue date of the patent grant provided the request contains:

- (1) The name and address of the depository;

- (2) The accession number given to the deposit;
- (3) The patent number and issue date of the patent referring to the deposit; and
- (4) The name and address of the requesting party.

2410.01 Conditions of Deposit [R-07.2015]

[37 CFR 1.808](#) requires that the deposit of biological material be made under two conditions:

(A) access to the deposit will be available during pendency of the patent application making reference to the deposit to one determined by the Commissioner to be entitled thereto under [37 CFR 1.14](#) and [35 U.S.C. 122](#), and

(B) with one exception, that all restrictions imposed by the depositor on the availability to the public of the deposited biological material be irrevocably removed upon the granting of the patent.

The one exception that is permitted is specified in [37 CFR 1.808\(b\)](#) which permits the depositor to contract with the depository to require that samples of a deposited biological material shall be furnished only if a request for a sample, during the term of the patent, meets any one or all of the three conditions specified in this paragraph. These conditions are:

(A) the request is in writing or other tangible form and dated; and/or

(B) the request contains the name and address of the requesting party and the accession number of the deposit; and/or

(C) the request is communicated in writing by the depository to the depositor along with the date on which the sample was furnished and the name and address of the party to whom the sample was furnished.

It should be noted that this exception to the general rule that all restrictions will be removed must be strictly followed and that no variations of this explicit exception will be accepted as meeting the conditions of this section. Although this exception is consistent with the provisions in the Budapest Treaty and its implementing regulations (Rule 11.4), other conditions on accessibility are permitted under the Budapest Treaty as prescribed by national law. Consequently, the mere indication that a deposit has been made and accepted under conditions prescribed

by the Budapest Treaty would satisfy all conditions of these regulations except the requirement that all restrictions on access be removed on grant of the patent. *Ex parte Hildebrand*, 15 USPQ2d 1662 (Bd. Pat. App. & Int. 1990).

2410.02 Certification of Statement of Availability of Deposit [R-07.2015]

Since the mere description of a deposit or identity of a deposit in a patent specification is not necessarily an indication that a requirement for deposit was made or that a deposit which complies with these rules has been made, accessibility to a deposited material referenced in a patent may depend on the satisfaction of conditions not apparent on the face of the patent. For these reasons, and upon request made to the U.S. Patent and Trademark Office, the Office will certify whether a deposit has been stated to have been made under conditions which make it available to the public as of the issue date of the patent grant provided the request is made to a Director of Technology Center (TC) 1600, and contains the following information:

(A) the name and address of the depository;

(B) the accession number given to the deposit;

(C) the patent number and issue date of the patent referring to the deposit; and

(D) the name and address of the requesting party.

Persons requesting a certificate of statement of availability of deposit should contact the TC 1600 Director's office directly, and should not submit a request via the examiner of record.

The Office will not certify whether a deposit has been made under conditions which would make it available to the public until the issuance of a U.S. Patent referencing the deposit. For example, a request for such certification will not be considered where the request is filed with regard to a deposit referenced in an international application filed under the PCT, in an international application that entered the U.S. national stage, or any other U.S. national application, that has not yet issued as a patent.

See also [MPEP § 2404.01](#).

For those deposits made pursuant to the Budapest Treaty, the World Intellectual Property Organization provides a form (Form BP-12) for requesting a certification of legal entitlement to receive samples of deposited microorganisms pursuant to Rule 11.3(a) of the Regulations under the Budapest Treaty. The form is available at www.wipo.int/treaties/en/registration/budapest/guide.

2411 Examination Procedures [R-07.2015]

37 CFR 1.809 Examination procedures.

(a) The examiner shall determine pursuant to [§ 1.104](#) in each application for patent, application for reissue patent or reexamination proceeding if a deposit is needed, and if needed, if a deposit actually made is acceptable for patent purposes. If a deposit is needed and has not been made or replaced or supplemented in accordance with these regulations, the examiner, where appropriate, shall reject the affected claims under the appropriate provision of [35 U.S.C. 112](#), explaining why a deposit is needed and/or why a deposit actually made cannot be accepted.

(b) The applicant for patent or patent owner shall reply to a rejection under paragraph (a) of this section by—

(1) In the case of an applicant for patent, either making an acceptable original, replacement, or supplemental deposit, or assuring the Office in writing that an acceptable deposit will be made; or, in the case of a patent owner, requesting a certificate of correction of the patent which meets the terms of paragraphs (b) and (c) of [§ 1.805](#), or

(2) Arguing why a deposit is not needed under the circumstances of the application or patent considered and/or why a deposit actually made should be accepted. Other replies to the examiner's action shall be considered nonresponsive. The rejection will be repeated until either paragraph (b)(1) of this section is satisfied or the examiner is convinced that a deposit is not needed.

(c) If an application for patent is otherwise in condition for allowance except for a needed deposit and the Office has received a written assurance that an acceptable deposit will be made, the Office may notify the applicant in a notice of allowability and set a three month period of time from the mailing date of the notice of allowability within which the deposit must be made in order to avoid abandonment. This time period is not extendable under [§ 1.136](#) (see [§ 1.136\(c\)](#)).

(d) For each deposit made pursuant to these regulations, the specification shall contain:

- (1) The accession number for the deposit;
- (2) The date of the deposit;
- (3) A description of the deposited biological material sufficient to specifically identify it and to permit examination; and
- (4) The name and address of the depository.

(e) Any amendment required by paragraphs (d)(1), (d)(2) or (d)(4) of this section must be filed before or with the payment of the issue fee (see [§ 1.312](#)).

[37 CFR 1.809](#) sets forth procedures that will be used by the examiner to address a deposit issue. The burden is initially on the Office to establish that access to a biological material is necessary for the satisfaction of the statutory requirements for patentability under [35 U.S.C. 112](#). Once the Office has met this burden, the burden shifts to the applicant or patent owner to demonstrate that access to such biological material either is not necessary, or is already available, or that a deposit of such material will be made in accordance with these regulations.

2411.01 Rejections Based on Deposit Issue [R-07.2015]

Under [37 CFR 1.809\(a\)](#), once the examiner has determined that access to a biological material is necessary, and there is no information that would support the conclusion that access is currently available in accordance with these regulations, the examiner should make an appropriate rejection under [35 U.S.C. 112](#) until such time as a deposit in accordance with these regulations is actually made or a written assurance is received in the patent application that such a deposit will be made upon an indication of allowability of the application. The examiner should clearly indicate the statutory basis for the rejection and the reasons that are relied upon by the examiner to conclude that the application does not comply with some requirement of [35 U.S.C. 112](#). Although not exhaustive, the following grounds of rejection may be applicable in appropriate circumstances:

(A) [35 U.S.C. 112\(a\)](#), *enablement requirement*. Rejection for lack of an enabling disclosure without access to a specific biological material. This ground of rejection should be accompanied by evidence of scientific reasoning to support the conclusion that a person skilled in the art could not make or use the invention defined in and commensurate with the claims without access to the specific biological material. See [MPEP § 2164.06\(a\)](#).

(B) [35 U.S.C. 112\(a\)](#), *written description requirement*. A rejection for lack of written description typically arises in the context that the application as filed does not contain a description to

support an amendment to the specification or claims, although it can arise in the context of original claims. See [MPEP § 2163](#) *et seq.* An amendment to the claims that is not described in the application as filed would justify a rejection of the affected claims under [35 U.S.C. 112\(a\)](#). If an amendment is made to the application, other than the claims, that is not described in the application as filed, this would justify a rejection under [35 U.S.C. 112\(a\)](#) and/or an objection under [35 U.S.C. 132](#) (prohibition against the introduction of new matter) and a requirement that the amendment be canceled.

(C) [35 U.S.C. 112\(a\)](#), *best mode requirement*. A rejection for lack of a best mode will be rare in the *ex parte* examination process because it requires (1) a finding by the examiner that, at the time the application was filed, the inventor(s) knew of a specific material that was considered by the inventor(s) to be better than any other, and (2) if a best mode was contemplated at that time, that the inventor(s) concealed the best mode (accidentally or intentionally) by failing to adequately describe that best mode. See *Chemcast Corp. v. Arco Industries Corp.*, 913 F.2d 923, 16 USPQ2d 1033 (Fed. Cir. 1990). See also [MPEP § 2165](#) *et seq.*

(D) [35 U.S.C. 112\(b\)](#), *requirement to particularly point out and distinctly claim invention*. A rejection for indefiniteness, as applied to a deposit issue, requires the examiner to provide reasons why the terms in the claims and/or scope of the invention are unclear because of an incomplete or inaccurate description or the absence of a reference to a biological material.

(E) [35 U.S.C. 112\(b\)](#), *requirement to claim what the inventor or a joint inventor regards as the invention*. A rejection on the basis that the claims do not set forth the subject matter that the inventor or a joint inventor regards as the invention requires the citation of some evidence, not contained in the application as filed, to support the rejection. *In re Prater*, 415 F.2d 1393, 162 USPQ 541 (CCPA 1969). Any disagreement between the content of the application disclosure and the scope of the claims should be addressed under [35 U.S.C. 112\(a\)](#). See *In re Ehrreich*, 590 F.2d 902, 200 USPQ 504 (CCPA 1979).

Where a deposit is required to satisfy [35 U.S.C. 112](#), a deposit must be made in accordance with these regulations. See [37 CFR 1.802](#). A deposit accepted

in any International Depositary Authority (IDA) under the Budapest Treaty shall be accepted for patent purposes if made under conditions which comply with [37 CFR 1.806](#) and [37 CFR 1.808\(a\)](#) concerning term of deposit and permissible conditions on access once the patent is granted.

2411.02 Replies to Rejections Based on Deposit Issue [R-07.2015]

Once a rejection under [35 U.S.C. 112](#) has been made by the examiner directed to the absence of access to a biological material, applicant may reply, pursuant to [37 CFR 1.809\(b\)\(1\)](#), by either making an acceptable original, replacement, or supplemental deposit in accordance with these regulations, or assuring the Office in writing that an acceptable deposit will be made on or before the date of payment of the issue fee, or by submitting an argument of why a deposit is not required under the circumstances of the application being considered. Other replies to such a rejection by the examiner shall be considered nonresponsive and may result in abandonment of the application. The rejection will be repeated and made final until the requirements of [37 CFR 1.809\(b\)\(1\)](#) are satisfied or the examiner is convinced that a deposit is not required for the claimed subject matter. Once the rejection is made final, the requirements of [37 CFR 1.116](#) apply to further submissions. The written assurance will be accepted by the Office if it clearly states that an acceptable deposit will be made within the required time and under conditions which satisfy these rules. In the case that an acceptable written assurance has been made by the applicant, the rejection under [35 U.S.C. 112](#) directed to the absence of access to the biological material should be removed.

2411.03 Application in Condition for Allowance Except for Deposit [R-07.2015]

As set forth in [37 CFR 1.809\(c\)](#), in the event that an application for patent is otherwise in condition for allowance except for a required deposit and the Office has received a written assurance that an acceptable deposit will be made, the Office may notify the applicant in a notice of allowability and set a three month period of time from the mailing date of the notice of allowability within which the

deposit must be made in order to avoid abandonment. This time period is not extendable under [37 CFR 1.136](#) (see [37 CFR 1.136\(c\)](#)). Failure to make the needed deposit in accordance with this requirement will be considered a failure to prosecute the application under [35 U.S.C. 133](#) and result in abandonment of the application.

Once the deposit has been made, information regarding the deposit, such as the name and address of the depository, the accession number and the date of the deposit, that is to be added to the specification must be added by means of filing an amendment under the provisions of [37 CFR 1.312](#). Such an amendment must be filed before or with the payment of the issue fee. Therefore, applicants need to make any necessary deposit of biological material well prior to payment of the issue fee such that the accession number is received with sufficient time remaining to amend the specification as required by [37 CFR 1.809\(d\)](#) on or before the date the issue fee is paid. See [37 CFR 1.809\(e\)](#).

2411.04 [Reserved]

2411.05 Content of Application with Respect to Deposited Material [R-08.2012]

[37 CFR 1.809\(d\)](#) sets forth the requirements for the content of the specification with respect to a deposited biological material. Specifically, the specification shall contain the accession number for the deposit, the date of the deposit, the name and address of the depository, and a description of the deposited biological material sufficient to specifically identify it and to permit examination. The description also must be sufficient to permit verification that the deposited biological material is in fact that disclosed. Once the patent issues, the description must be sufficient to aid in the resolution of questions of infringement. As a general rule, the more information that is provided about a particular deposited biological material, the better the examiner will be able to compare the identity and characteristics of the deposited biological material with the prior art.

2412-2419 [Reserved]

2420 The Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures - the Sequence Rules [R-07.2015]

The sequence rules ([37 CFR 1.821 -1.825](#)) set forth the requirements pertaining to patent applications containing nucleotide sequence and/or amino acid sequence disclosures. See also [MPEP § 608.05](#) and [§ 2422.03](#).

See [PCT Rule 5](#) and [Rule 13ter](#), and [MPEP § 1823.02](#) and [§ 2422](#), for the requirements under the PCT for international applications that disclose nucleic acid or amino acid sequences.

2421 Overview of the Sequence Rules [R-08.2012]

2421.01 Definition of “Sequence Listing” and “CRF” [R-07.2015]

The sequence rules ([37 CFR 1.821 -1.825](#)) require the use of standard symbols and a standard format for submitting sequence data in most patent applications that disclose nucleic acid or amino acid sequences. For purposes of the sequence rules and the discussion in [MPEP Chapter 2400](#), the phrase “disclose(d) (or disclosure(s) of) nucleic acid or amino acid sequences” is intended to refer to those nucleic acid or amino acid sequences that are described in the patent application by enumeration of their residues and that meet the length thresholds of [37 CFR 1.821\(a\)](#).

[37 CFR 1.821\(c\)](#) requires that applications containing disclosures of nucleotide and/or amino acid sequences that fall within the definitions of [37 CFR 1.821\(a\)](#) contain, as a separate part, a disclosure of the nucleotide and/or amino acid sequences, and associated information, using the format and symbols that are set forth in [37 CFR 1.822](#) and [37 CFR 1.823](#). This separate part of the disclosure is referred to as the “Sequence Listing” (hereinafter alternatively referred to as “sequence listing”). The sequence listing required pursuant to [37 CFR 1.821\(c\)](#) is the

official copy of the sequence listing, and may be submitted as an ASCII text file via EFS-Web, on compact disc, as a PDF submitted via EFS-Web, or on paper. See [MPEP § 2422.03](#) for additional information.

[37 CFR 1.821\(e\)](#) requires that a copy of the sequence listing referred to in [37 CFR 1.821\(c\)](#) must also be submitted in computer readable form (CRF) as an ASCII text file in accordance with the requirements of [37 CFR 1.824](#) (hereinafter “CRF of the sequence listing” or “CRF”). The computer readable form may be submitted on the electronic media permitted by [37 CFR 1.824](#), or may be submitted as an ASCII text file via EFS-Web. See [MPEP § 2422.04](#) for additional information.

2421.02 Summary of the Requirements of the Sequence Rules [R-07.2015]

The sequence rules define a set of symbols and procedures that are both mandatory and the only way that an applicant is permitted to describe information in the sequence listing about a sequence that falls within the definitions used in the rules. Thus, [37 CFR 1.821](#) defines a “sequence” and a sequence listing for the purpose of the rules, the requirements for specific symbols, and formats for the sequence listing, the requirement for a computer readable form (CRF) of the sequence listing and the deadlines for complying with the requirements. [37 CFR 1.822](#) to [37 CFR 1.824](#) set forth detailed descriptions of the requirements that are mandatory for the presentation of sequence data, and [37 CFR 1.825](#) sets forth procedures that are available to an applicant in the event that amendments to the sequence listing or replacement of the CRF of the sequence listing become necessary.

The sequence rules embrace all unbranched nucleotide sequences with ten or more nucleotide bases and all unbranched, non-D amino acid sequences with four or more amino acids, provided that there are at least 10 “specifically defined” nucleotides or 4 “specifically defined” or amino acids. The rules apply to all sequences in a given application, whether claimed or not. All such sequences are relevant for the purposes of building a comprehensive database and properly assessing prior art. It is therefore essential that all sequences,

whether only disclosed or also claimed, be included in the database.

2421.03 Notification of a Failure to Comply [R-07.2015]

With respect to the Office’s determination of compliance with the sequence rules and the opportunities afforded applicants to satisfy the requirements of the rules, applicants will be notified of easily detectable deficiencies early in the application process. Applicants whose computer readable forms are not readable, or are missing mandatory elements, will be notified shortly after receipt of the application by the Office. Applications filed on or after November 29, 2000, will be retained in the Office of Patent Application Processing (OPAP) until any noncompliant sequence listing that renders an application unsuitable for examination is corrected.

OPAP will mail a Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures to applicant listing the requirements that have not been met and setting a two month time period within which to comply with the sequence rules, [37 CFR 1.821 - 1.825](#). Failure to comply with these requirements will result in abandonment of the application under [37 CFR 1.821\(g\)](#). Extension of time may be obtained by filing a petition accompanied by the extension fee under the provisions of [37 CFR 1.136](#).

Patent applications filed under [35 U.S.C. 111](#) on or after December 18, 2013, and international patent applications in which the national stage commenced under [35 U.S.C. 371](#) on or after December 18, 2013, may be subject to reductions in patent terms adjustment pursuant to [37 CFR 1.704\(c\)\(13\)](#) if they are not in condition for examination within eight months from the filing date or date of commencement, respectively. “In condition for examination” includes compliance with [37 CFR 1.821 -1.825](#) (see [37 CFR 1.704\(f\)](#)). Deficiencies of a more sophisticated nature will likely only be detected by the examiner to whom the application is assigned. Applicant will be notified of any errors or inconsistencies detected by the examiner in the next Office action.

A notification of a failure to comply with the sequence rules will be accompanied by an analysis of any submitted computer readable form. Any inquiries regarding a specific computer readable form that has been processed by the Office should be directed to the Sequence Systems Service Center of the Scientific and Technical Information Center at 571-272-2510 or via email at STIC-SSSCHelpdesk@uspto.gov.

2421.04 Future Changes to the Sequence Rules [R-07.2015]

With general regard to the symbols and format to be used for nucleotide and/or amino acid sequence data set forth in [37 CFR 1.822](#) and the form and format for sequence submissions in computer readable form set forth in [37 CFR 1.824](#), the Office intends to accommodate progress in the areas of both standardization and computerization as they relate to sequence data by subsequently amending the rules to take into account any such progress. As the Office progresses in these areas, the Office will do so by the publication of notices in the Official Gazette or formal rulemaking proposals, as appropriate. The Office will also continue work on the preparation of a new World Intellectual Property Organization (WIPO) standard on the presentation of nucleotide and amino acid sequence listings using eXtensible Markup Language (XML) with the members of the Task Force on Sequence Listings created by the Committee on WIPO Standards. See *Request for Comments on the Recommendation for the Disclosure of Sequence Listings Using XML (Proposed ST.26)*, 77 Fed. Reg. 28541 (May 15, 2012), for additional information.

2422 Nucleotide and/or Amino Acid Sequence Disclosures in Patent Applications [R-10.2019]

37 CFR 1.821 Nucleotide and/or amino acid sequence disclosures in patent applications.

(a) Nucleotide and/or amino acid sequences as used in §§ [1.821](#) through [1.825](#) are interpreted to mean an unbranched sequence of four or more amino acids or an unbranched sequence of ten or more nucleotides. Branched sequences are specifically excluded from this definition. Sequences with fewer than four specifically defined nucleotides or amino acids are specifically excluded from this section. “Specifically defined” means those amino acids other than “Xaa” and those nucleotide bases other than “n” defined in accordance with the World Intellectual

Property Organization (WIPO) Handbook on Industrial Property Information and Documentation, Standard ST.25: Standard for the Presentation of Nucleotide and Amino Acid Sequence Listings in Patent Applications (1998), including Tables 1 through 6 in Appendix 2, herein incorporated by reference. (Hereinafter “WIPO Standard ST.25 (1998)”). This incorporation by reference was approved by the Director of the Federal Register in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. Copies of WIPO Standard ST.25 (1998) may be obtained from the World Intellectual Property Organization; 34 chemin des Colombettes; 1211 Geneva 20 Switzerland. Copies may also be inspected at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html. Nucleotides and amino acids are further defined as follows:

(1) *Nucleotides*: Nucleotides are intended to embrace only those nucleotides that can be represented using the symbols set forth in WIPO Standard ST.25 (1998), Appendix 2, Table 1. Modifications, *e.g.*, methylated bases, may be described as set forth in WIPO Standard ST.25 (1998), Appendix 2, Table 2, but shall not be shown explicitly in the nucleotide sequence.

(2) *Amino acids*: Amino acids are those L-amino acids commonly found in naturally occurring proteins and are listed in WIPO Standard ST.25 (1998), Appendix 2, Table 3. Those amino acid sequences containing D-amino acids are not intended to be embraced by this definition. Any amino acid sequence that contains post-translationally modified amino acids may be described as the amino acid sequence that is initially translated using the symbols shown in WIPO Standard ST.25 (1998), Appendix 2, Table 3 with the modified positions; *e.g.*, hydroxylations or glycosylations, being described as set forth in WIPO Standard ST.25 (1998), Appendix 2, Table 4, but these modifications shall not be shown explicitly in the amino acid sequence. Any peptide or protein that can be expressed as a sequence using the symbols in WIPO Standard ST.25 (1998), Appendix 2, Table 3 in conjunction with a description in the Feature section to describe, for example, modified linkages, cross links and end caps, non-peptidyl bonds, etc., is embraced by this definition.

(b) Patent applications which contain disclosures of nucleotide and/or amino acid sequences, in accordance with the definition in paragraph (a) of this section, shall, with regard to the manner in which the nucleotide and/or amino acid sequences are presented and described, conform exclusively to the requirements of §§ [1.821](#) through [1.825](#).

(c) Patent applications which contain disclosures of nucleotide and/or amino acid sequences must contain, as a separate part of the disclosure, a paper copy disclosing the nucleotide and/or amino acid sequences and associated information using the symbols and format in accordance with the requirements of §§ [1.822](#) and [1.823](#). This paper copy is hereinafter referred to as the “Sequence Listing.” Each sequence disclosed must appear separately in the “Sequence Listing.” Each sequence set forth in the “Sequence Listing” shall be assigned a separate sequence identifier. The sequence identifiers shall begin with 1 and increase sequentially by integers. If no sequence is present for a sequence identifier, the code “000” shall be used in place of the sequence. The response for the

numeric identifier <160> shall include the total number of SEQ ID NOs, whether followed by a sequence or by the code “000.”

(d) Where the description or claims of a patent application discuss a sequence that is set forth in the “Sequence Listing” in accordance with paragraph (c) of this section, reference must be made to the sequence by use of the sequence identifier, preceded by “SEQ ID NO:” in the text of the description or claims, even if the sequence is also embedded in the text of the description or claims of the patent application.

(e) A copy of the “Sequence Listing” referred to in paragraph (c) of this section must also be submitted in computer readable form in accordance with the requirements of § 1.824. The computer readable form is a copy of the “Sequence Listing” and will not necessarily be retained as a part of the patent application file. If the computer readable form of a new application is to be identical with the computer readable form of another application of the applicant on file in the Patent and Trademark Office, reference may be made to the other application and computer readable form in lieu of filing a duplicate computer readable form in the new application if the computer readable form in the other application was compliant with all of the requirements of these rules. The new application shall be accompanied by a letter making such reference to the other application and computer readable form, both of which shall be completely identified. In the new application, applicant must also request the use of the compliant computer readable “Sequence Listing” that is already on file for the other application and must state that the paper copy of the “Sequence Listing” in the new application is identical to the computer readable copy filed for the other application.

(f) In addition to the paper copy required by paragraph (c) of this section and the computer readable form required by paragraph (e) of this section, a statement that the content of the paper and computer readable copies are the same must be submitted with the computer readable form, *e.g.*, a statement that “the information recorded in computer readable form is identical to the written sequence listing.”

(g) If any of the requirements of paragraphs (b) through (f) of this section are not satisfied at the time of filing under 35 U.S.C. 111(a) or at the time of entering the national stage under 35 U.S.C. 371, applicant will be notified and given a period of time within which to comply with such requirements in order to prevent abandonment of the application. Any submission in reply to a requirement under this paragraph must be accompanied by a statement that the submission includes no new matter.

(h) If any of the requirements of paragraphs (b) through (f) of this section are not satisfied at the time of filing an international application under the Patent Cooperation Treaty (PCT), which application is to be searched by the United States International Searching Authority or examined by the United States International Preliminary Examining Authority, applicant will be sent a notice necessitating compliance with the requirements within a prescribed time period. Any submission in reply to a requirement under this paragraph must be accompanied by a statement that the submission does not include matter which goes beyond the disclosure in the international application as filed. If applicant fails to timely provide the required computer readable form, the United States International Searching Authority shall search only to the extent that a

meaningful search can be performed without the computer readable form and the United States International Preliminary Examining Authority shall examine only to the extent that a meaningful examination can be performed without the computer readable form.

I. INCORPORATION BY REFERENCE OF WIPO ST.25 (1998) IN 37 CFR 1.821

37 CFR 1.821 incorporates by reference the World Intellectual Property Organization (WIPO) Handbook on Industrial Property Information and Documentation, Standard ST.25 (1998), including Tables 1 through 6 of Appendix 2. Copies may be obtained from the World Intellectual Property Organization; 34 chemin des Colombettes; 1211 Geneva 20 Switzerland. Copies may also be inspected at the Office of the Federal Register, 800 North Capitol Street, NW, Suite 700, Washington, DC 20408. These tables are reproduced below. The 1998 version of WIPO ST.25 is available online at www.wipo.int/standards/en/archives.html. Note that the standard was revised in December 2009, and the current version is available online at www.wipo.int/export/sites/www/standards/en/pdf/03-25-01.pdf.

WIPO Standard ST.25 (1998), Appendix 2, Table 1, provides that the bases of a nucleotide sequence should be represented using the following one-letter symbol for nucleotide sequence characters:

Table 1: List of Nucleotides

Symbol	Meaning	Origin of designation
a	a	adenine
g	g	guanine
c	c	cytosine
t	t	thymine
u	u	uracil
r	g or a	purine
y	t/u or c	pyrimidine
m	a or c	amino
k	g or t/u	keto
s	g or c	strong interactions 3H-bonds
w	a or t/u	weak interactions 2H-bonds
b	g or c or t/u	not a

Symbol	Meaning	Origin of designation
d	a or g or t/u	not c
h	a or c or t/u	not g
v	a or g or c	not t, not u
n	a or g or c or t/u, unknown, or other	any

WIPO Standard ST.25 (1998), Appendix 2, Table 2, provides that modified bases may be represented as the corresponding unmodified bases in the sequence itself, if the modification is further described in numeric identifier <223> of the Feature section of the sequence listing. The symbols from the list below may be used in the description (i.e., the specification and drawing, or in the Feature section of the sequence listing) but these symbols may not be used in the sequence itself. Modifications not listed in Table 2 may also be represented as the corresponding unmodified base in the sequence itself, and the modification should be described using its full chemical name in the Feature section of the sequence listing.

Table 2: List of Modified Nucleotides

Symbol	Meaning
ac4c	4-acetylcytidine
chm5u	5-(carboxyhydroxymethyl)uridine
cm	2'-O-methylcytidine
cmnm5s2u	5-carboxymethylaminomethyl-2-thiouridine
cmnm5u	5-carboxymethylaminomethyluridine
d	dihydrouridine
fm	2'-O-methylpseudouridine
gal q	beta, D-galactosylqueuosine
gm	2'-O-methylguanosine
i	inosine
i6a	N6-isopentenyladenosine
m1a	1-methyladenosine
m1f	1-methylpseudouridine
m1g	1-methylguanosine
m1i	1-methylinosine
m22g	2,2-dimethylguanosine
m2a	2-methyladenosine
m2g	2-methylguanosine
m3c	3-methylcytidine

m5c	5-methylcytidine
m6a	N6-methyladenosine
m7g	7-methylguanosine

mam5u	5-methylaminomethyluridine
mam5s2u	5-methoxyaminomethyl-2-thiouridine
man q	beta, D-mannosylqueuosine
mcm5s2u	5-methoxycarbonylmethyl-2-thiouridine
mcm5u	5-methoxycarbonylmethyluridine
mo5u	5-methoxyuridine
ms2i6a	2-methylthio-N6-isopentenyladenosine
ms2t6a	N-((9-beta-D-ribofuranosyl-2-methylthiopurine-6-yl)carbamoyl)threonine
mt6a	N-((9-beta-D-ribofuranosylpurine-6-yl) N-methylcarbamoyl)threonine
mv	uridine-5-oxyacetic acid-methylester
o5u	uridine-5-oxyacetic acid
osyw	wybutoxosine
p	pseudouridine
q	queuosine
s2t	5-methyl-2-thiouridine
s2c	2-thiocytidine
s2t	5-methyl-2-thiouridine
s2u	2-thiouridine
s4u	4-thiouridine
t	5-methyluridine
t6a	N-((9-beta-D-ribofuranosylpurine-6-yl)-carbamoyl)threonine
tm	2'-O-methyl-5-methyluridine
um	2'-O-methyluridine
yw	wybutosine
x	3-(3-amino-3-carboxy-propyl)uridine, (acp3)u

WIPO Standard ST.25 (1998), Appendix 2, Table 3, provides that the amino acids should be represented using the following three-letter symbols with the first letter as a capital.

Table 3: List of Amino Acids

Symbol	Meaning
Ala	Alanine

Cys	Cysteine
Asp	Aspartic Acid
Glu	Glutamic Acid
Phe	Phenylalanine
Gly	Glycine
His	Histidine
Ile	Isoleucine
Lys	Lysine
Leu	Leucine
Met	Methionine
Asn	Asparagine
Pro	Proline
Gln	Glutamine
Arg	Arginine
Ser	Serine
Thr	Threonine
Val	Valine
Trp	Tryptophan
Tyr	Tyrosine
Asx	Asp or Asn
Glx	Glu or Gln
Xaa	unknown or other

WIPO Standard ST.25 (1998), Appendix 2, Table 4, provides that modified and unusual amino acids may be represented as the corresponding unmodified amino acids in the sequence itself if the modification is further described in numeric identifier <223> of the Feature section of the sequence listing. The symbols from the list below may be used in the description (i.e., the specification and drawings, or in the Feature section of the sequence listing) but these symbols may not be used in the sequence itself. Modifications not listed in Table 4 may also be represented as the corresponding unmodified amino acid in the sequence itself, and the modification should be described using its full chemical name in the Feature section of the sequence listing.

Table 4: List of Modified and Unusual Amino Acids

Symbol	Meaning
Aad	2-Aminoadipic acid
bAad	3-Aminoadipic acid
bAla	beta-Alanine, beta-Aminopropionic acid
Abu	2-Aminobutyric acid
4Abu	4-Aminobutyric acid, piperidinic acid
Acp	6-Aminocaproic acid
Ahe	2-Aminoheptanoic acid
Aib	2-Aminoisobutyric acid
bAib	3-Aminoisobutyric acid
Apm	2-Aminopimelic acid
Dbu	2,4-Diaminobutyric acid
Des	Desmosine
Dpm	2,2' -Diaminopimelic acid
Dpr	2,3-Diaminopropionic acid
EtGly	N-Ethylglycine
EtAsn	N-Ethylasparagine
Hyl	Hydroxylysine
aHyl	allo-Hydroxylysine
3Hyp	3-Hydroxyproline
4Hyp	4-Hydroxyproline
Ide	Isodesmosine
alle	allo-Isoleucine
MeGly	N-Methylglycine, sarcosine
MeIle	N-Methylisoleucine
MeLys	6-N-Methyllysine
MeVal	N-Methylvaline
Nva	Norvaline
Nle	Norleucine
Orn	Ornithine

WIPO Standard ST.25 (1998), Appendix 2, Table 5, provides for feature keys related to DNA sequences.

Table 5: List of Feature Keys Related to Nucleotide Sequences

Key	Description
allele	a related individual or strain contains stable, alternative forms of the same gene which differs from the presented sequence at this location (and perhaps others)
attenuator	(1) region of DNA at which regulation of termination of transcription occurs, which controls the expression of some bacterial operons; (2) sequence segment located

Key	Description
	between the promoter and the first structural gene that causes partial termination of transcription
C_region	constant region of immunoglobulin light and heavy chains, and T-cell receptor alpha, beta, and gamma chains; includes one or more exons depending on the particular chain
CAAT_signal	CAAT box; part of a conserved sequence located about 75 bp up-stream of the start point of eukaryotic transcription units which may be involved in RNA polymerase binding; consensus=GG (C or T) CAATCT
CDS	coding sequence; sequence of nucleotides that corresponds with the sequence of amino acids in a protein (location includes stop codon); feature includes amino acid conceptual translation
conflict	independent determinations of the “same” sequence differ at this site or region
D-loop	displacement loop; a region within mitochondrial DNA in which a short stretch of RNA is paired with one strand of DNA, displacing the original partner DNA strand in this region; also used to describe the displacement of a region of one strand of duplex DNA by a single stranded invader in the reaction catalyzed by RecA protein
D-segment	diversity segment of immunoglobulin heavy chain, and T-cell receptor beta chain
enhancer	a cis-acting sequence that increases the utilization of (some) eukaryotic promoters, and can function in either orientation and in any location (upstream or downstream) relative to the promoter
exon	region of genome that codes for portion of spliced mRNA; may contain 5'UTR, all CDSs, and 3'UTR
GC_signal	GC box; a conserved GC-rich region located upstream of the start point of eukaryotic transcription units which may occur in multiple copies or in either orientation; consensus=GGGCGG
gene	region of biological interest identified as a gene and for which a name has been assigned
iDNA	intervening DNA; DNA which is eliminated through any of several kinds of recombination
intron	a segment of DNA that is transcribed, but removed from within the transcript by splicing together the sequences (exons) on either side of it
J_segment	joining segment of immunoglobulin light and heavy chains, and T-cell receptor alpha, beta, and gamma chains
LTR	long terminal repeat, a sequence directly repeated at both ends of a defined sequence, of the sort typically found in retroviruses
mat_peptide	mature peptide or protein coding sequence; coding sequence for the mature or final peptide or protein product following post-translational modification; the location does not include the stop codon (unlike the corresponding CDS)
misc_binding	site in nucleic acid which covalently or non-covalently binds another moiety that cannot be described by any other Binding key (primer_bind or protein_bind)
misc_difference	feature sequence is different from that presented in the entry and cannot be described by any other Difference key (conflict, unsure, old_sequence, mutation, variation, allele, or modified_base)
misc_feature	region of biological interest which cannot be described by any other feature key; a new or rare feature

Key	Description
misc_recomb	site of any generalized, site-specific or replicative recombination event where there is a breakage and reunion of duplex DNA that cannot be described by other recombination keys (iDNA and virion) or qualifiers of source key (/insertion_seq, /transposon, /proviral)
misc_RNA	any transcript or RNA product that cannot be defined by other RNA keys (prim_transcript, precursor_RNA, mRNA, 5'clip, 3'clip, 5'UTR, 3'UTR, exon, CDS, sig_peptide, transit_peptide, mat_peptide, intron, polyA_site, rRNA, tRNA, scRNA, and snRNA)
misc_signal	any region containing a signal controlling or altering gene function or expression that cannot be described by other Signal keys (promoter, CAAT_signal, TATA_signal, -35_signal, -10_signal, GC_signal, RBS, polyA_signal, enhancer, attenuator, terminator, and rep_origin)
misc_structure	any secondary or tertiary structure or conformation that cannot be described by other Structure keys (stem_loop and D-loop)
modified_base	the indicated nucleotide is a modified nucleotide and should be substituted for by the indicated molecule (given in the mod_base qualifier value)
mRNA	messenger RNA; includes 5' untranslated region (5'UTR), coding sequences (CDS, exon) and 3' untranslated region (3'UTR)
mutation	a related strain has an abrupt, inheritable change in the sequence at this location
N_region	extra nucleotides inserted between rearranged immunoglobulin segments
old_sequence	the presented sequence revises a previous version of the sequence at this location
polyA_signal	recognition region necessary for endonuclease cleavage of an RNA transcript that is followed by polyadenylation; consensus=AATAAA
polyA_site	site on an RNA transcript to which will be added adenine residues by post-transcriptional polyadenylation
precursor_RNA	any RNA species that is not yet the mature RNA product; may include 5' clipped region (5'clip), 5' untranslated region (5'UTR), coding sequences (CDS, exon), intervening sequences (intron), 3' untranslated region (3'UTR), and 3' clipped region (3'clip)
prim_transcript	primary (initial, unprocessed) transcript; includes 5' clipped region (5'clip), 5' untranslated region (5'UTR), coding sequences (CDS, exon), intervening sequences (intron), 3' untranslated region (3'UTR), and 3' clipped region (3'clip)
primer_bind	non-covalent primer binding site for initiation of replication, transcription, or reverse transcription; includes site(s) for synthetic, for example, PCR primer elements
promoter	region on a DNA molecule involved in RNA polymerase binding to initiate transcription
protein_bind	non-covalent protein binding site on nucleic acid
RBS	ribosome binding site
repeat_region	region of genome containing repeating units
repeat_unit	single repeat element
rep_origin	origin of replication; starting site for duplication of nucleic acid to give two identical copies
rRNA	mature ribosomal RNA; the RNA component of the ribonucleoprotein particle (ribosome) which assembles amino acids into proteins

Key	Description
S_region	switch region of immunoglobulin heavy chains; involved in the rearrangement of heavy chain DNA leading to the expression of a different immunoglobulin class from the same B-cell
satellite	many tandem repeats (identical or related) of a short basic repeating unit; many have a base composition or other property different from the genome average that allows them to be separated from the bulk (main band) genomic DNA
scRNA	small cytoplasmic RNA; any one of several small cytoplasmic RNA molecules present in the cytoplasm and (sometimes) nucleus of a eukaryote
sig_peptide	signal peptide coding sequence; coding sequence for an N-terminal domain of a secreted protein; this domain is involved in attaching nascent polypeptide to the membrane; leader sequence
snRNA	small nuclear RNA; any one of many small RNA species confined to the nucleus; several of the snRNAs are involved in splicing or other RNA processing reactions
source	identifies the biological source of the specified span of the sequence; this key is mandatory; every entry will have, as a minimum, a single source key spanning the entire sequence; more than one source key per sequence is permissible
stem_loop	hairpin; a double-helical region formed by base-pairing between adjacent (inverted) complementary sequences in a single strand of RNA or DNA
STS	Sequence Tagged Site; short, single-copy DNA sequence that characterizes a mapping landmark on the genome and can be detected by PCR; a region of the genome can be mapped by determining the order of a series of STSs
TATA_signal	TATA box; Goldberg-Hogness box; a conserved AT-rich septamer found about 25 bp before the start point of each eukaryotic RNA polymerase II transcript unit which may be involved in positioning the enzyme for correct initiation; consensus=TATA(A or T)A(A or T)
terminator	sequence of DNA located either at the end of the transcript or adjacent to a promoter region that causes RNA polymerase to terminate transcription; may also be site of binding of repressor protein
transit_peptide	transit peptide coding sequence; coding sequence for an N-terminal domain of a nuclear-encoded organellar protein; this domain is involved in post-translational import of the protein into the organelle
tRNA	mature transfer RNA, a small RNA molecule (75-85 bases long) that mediates the translation of a nucleic acid sequence into an amino acid sequence
unsure	author is unsure of exact sequence in this region
V_region	variable region of immunoglobulin light and heavy chains, and T-cell receptor alpha, beta, and gamma chains; codes for the variable amino terminal portion; can be made up from V_segments, D_segments, N_regions, and J_segments
V_segment	variable segment of immunoglobulin light and heavy chains, and T-cell receptor alpha, beta, and gamma chains; codes for most of the variable region (V_region) and the last few amino acids of the leader peptide
variation	a related strain contains stable mutations from the same gene (for example, RFLPs, polymorphisms, etc.) which differ from the presented sequence at this location (and possibly others)
3'clip	3'-most region of a precursor transcript that is clipped off during processing
3'UTR	region at the 3' end of a mature transcript (following the stop codon) that is not translated into a protein

Key	Description
5'clip	5'-most region of a precursor transcript that is clipped off during processing
5'UTR	region at the 5' end of a mature transcript (preceding the initiation codon) that is not translated into a protein
-10_signal	pribnow box; a conserved region about 10 bp upstream of the start point of bacterial transcription units which may be involved in binding RNA polymerase; consensus=TAtAaT
-35_signal	a conserved hexamer about 35 bp upstream of the start point of bacterial transcription units; consensus=TTGACa [] or TGTTGACA []

WIPO Standard ST.25 (1998), Appendix 2, Table 6 provides for feature keys related to protein sequences.

Table 6: List of Feature Keys Related to Protein Sequences

Key	Description
CONFLICT	different papers report differing sequences
VARIANT	authors report that sequence variants exist
VARSPPLIC	description of sequence variants produced by alternative splicing
MUTAGEN	site which has been experimentally altered
MOD_RES	post-translational modification of a residue
ACETYLATION	N-terminal or other
AMIDATION	generally at the C-terminal of a mature active peptide
BLOCKED	undetermined N- or C-terminal blocking group
FORMYLATION	of the N-terminal methionine
GAMMA-CARBOXYGLUTAMIC ACID HYDROXYLATION	of asparagine, aspartic acid, proline or lysine
METHYLATION	generally of lysine or arginine
PHOSPHORYLATION	of serine, threonine, tyrosine, aspartic acid or histidine
PYRROLIDONE CARBOXYLIC ACID	N-terminal glutamate which has formed an internal cyclic lactam
SULFATATION	generally of tyrosine
LIPID	covalent binding of a lipidic moiety
MYRISTATE	myristate group attached through an amide bond to the N-terminal glycine residue of the mature form of a protein or to an internal lysine residue
PALMITATE	palmitate group attached through a thioether bond to a cysteine residue or through an ester bond to a serine or threonine residue
FARNESYL	farnesyl group attached through a thioether bond to a cysteine residue
GERANYL-GERANYL	geranyl-geranyl group attached through a thioether bond to a cysteine residue
GPI-ANCHOR	glycosyl-phosphatidylinositol (GPI) group linked to the alpha-carboxyl group of the C-terminal residue of the mature form of a protein

Key	Description
N-ACYL DIGLYCERIDE	N-terminal cysteine of the mature form of a prokaryotic lipoprotein with an amide-linked fatty acid and a glyceryl group to which two fatty acids are linked by ester linkages
DISULFID	disulfide bond; the 'FROM' and 'TO' endpoints represent the two residues which are linked by an intra-chain disulfide bond; if the 'FROM' and 'TO' endpoints are identical, the disulfide bond is an interchain one and the description field indicates the nature of the cross-link
THIOLEST	thiolester bond; the 'FROM' and 'TO' endpoints represent the two residues which are linked by the thiolester bond
THIOETH	thioether bond; the 'FROM' and 'TO' endpoints represent the two residues which are linked by the thioether bond
CARBOHYD	glycosylation site; the nature of the carbohydrate (if known) is given in the description field
METAL	binding site for a metal ion; the description field indicates the nature of the metal
BINDING	binding site for any chemical group (co-enzyme, prosthetic group, etc.); the chemical nature of the group is given in the description field
SIGNAL	extent of a signal sequence (prepeptide)
TRANSIT	extent of a transit peptide (mitochondrial, chloroplastic, or for a microbody)
PROPEP	extent of a propeptide
CHAIN	extent of a polypeptide chain in the mature protein
PEPTIDE	extent of a released active peptide
DOMAIN	extent of a domain of interest on the sequence; the nature of that domain is given in the description field
CA_BIND	extent of a calcium-binding region
DNA_BIND	extent of a DNA-binding region
NP_BIND	extent of a nucleotide phosphate binding region; the nature of the nucleotide phosphate is indicated in the description field
TRANSMEM	extent of a transmembrane region
ZN_FING	extent of a zinc finger region
SIMILAR	extent of a similarity with another protein sequence; precise information, relative to that sequence is given in the description field
REPEAT	extent of an internal sequence repetition
HELIX	secondary structure: Helices, for example, Alpha-helix, 3(10) helix, or Pi-helix
STRAND	secondary structure: Beta-strand, for example, Hydrogen bonded beta-strand, or Residue in an isolated beta-bridge
TURN	secondary structure: Turns, for example, H-bonded turn (3-turn, 4-turn, or 5-turn)
ACT_SITE	amino acid(s) involved in the activity of an enzyme
SITE	any other interesting site on the sequence

Key	Description
INIT_MET	the sequence is known to start with an initiator methionine
NON_TER	the residue at an extremity of the sequence is not the terminal residue; if applied to position 1, this signifies that the first position is not the N-terminus of the complete molecule; if applied to the last position, it signifies that this position is not the C-terminus of the complete molecule; there is no description field for this key
NON_CONS	non consecutive residues; indicates that two residues in a sequence are not consecutive and that there are a number of unsequenced residues between them
UNSURE	uncertainties in the sequence; used to describe region(s) of a sequence for which the authors are unsure about the sequence assignment

II. FILING INTERNATIONALLY

The requirements of [37 CFR 1.821](#) through [37 CFR 1.825](#) are the result of an effort to harmonize the USPTO requirements with international sequence listing requirements to the extent possible. The requirements of [37 CFR 1.821](#) through [37 CFR 1.825](#) substantially correspond to the requirements of WIPO Standard ST.25. PatentIn Version 3.5.1 software (see [MPEP § 2430](#)) generates sequence listings that meet all of the requirements of WIPO Standard ST.25. The requirements of [37 CFR 1.821](#) through [37 CFR 1.825](#), however, are less stringent than the requirements of WIPO Standard ST.25. Thus, applicants who wish to file in countries which adhere to WIPO Standard ST.25 should consider the following when not using PatentIn Version 3.5.1:

(A) The data in numeric identifier <221> must use selections from Tables 5 and 6 of WIPO Standard ST.25 (2009) to comply with that standard. The terms from these Tables are considered language neutral vocabulary;

(B) Where the sequence listing forming part of the international application contains free text, e.g., free text in numeric identifier <223>, any such free text shall be repeated in the main part of the description in the language thereof. It is recommended that the free text in the language of the main part of the description be put in a specific section of the description called “Sequence Listing Free Text”;

(C) A sequence listing filed after the international filing date is generally not considered to be part of the disclosure and usually will not be

published as part of the international application publication (see [PCT Article 34](#) and [PCT Rules 26](#) and [91](#) for exceptions);

(D) Paragraphs 4(v) and 4bis(iv) of WIPO Standard ST.25 (2009) requires the specific wording “the information recorded in electronic form furnished under [PCT Rule 13ter](#) is identical to the sequence listing”; and

(E) WIPO Standard ST.25 (2009), paragraph 24, requires a blank line between numeric identifiers in the sequence listing when the digit in the first or second position of the numeric identifier changes.

Requirements related to the submission of sequence listings may also differ between filing in the United States and filing internationally. For example, where an international application is filed in paper, the sequence listing part of the international application must also be provided in paper, although the search copy must be filed in electronic form, e.g. on a CD or, in the RO/US, as an ASCII text file via EFS-Web. Also, any tables filed in an international application must be an integral part of the application, i.e., cannot be submitted as a separate file in text format.

2422.01 Nucleotide and/or Amino Acids Disclosures Requiring a Sequence Listing [R-10.2019]

I. LENGTH THRESHOLDS

[37 CFR 1.821\(a\)](#) presents a definition for “nucleotide and/or amino acid sequences.” This definition sets forth limits, in terms of numbers of amino acids and/or numbers of nucleotides, at or above which

compliance with the sequence rules is required. Nucleotide and/or amino acid sequences as used in [37 CFR 1.821](#) through [37 CFR 1.825](#) are interpreted to mean an unbranched sequence of four or more amino acids or an unbranched sequence of ten or more nucleotides. Branched sequences are specifically excluded from this definition. Sequences with fewer than ten specifically defined nucleotides or four specifically defined amino acids are specifically excluded from this section. “Specifically defined” means those amino acids other than “Xaa” and those nucleotide bases other than “n” defined in accordance with the World Intellectual Property Organization (WIPO) Handbook on Industrial Property Information and Documentation, Standard ST.25: Standard for the Presentation of Nucleotide and Amino Acid Sequence Listings in Patent Applications (1998), including Tables 1 through 6 in Appendix 2 (see [MPEP § 2422](#)).

The limit of four or more amino acids was established for consistency with limits in place for industry database collections whereas the limit of ten or more nucleotides, while lower than certain industry database limits, was established to encompass those nucleotide sequences to which the smallest probe will bind in a stable manner.

II. REPRESENTATION OF NUCLEIC ACIDS AND AMINO ACIDS

[37 CFR 1.821\(a\)\(1\)](#) and [37 CFR 1.821\(a\)\(2\)](#) present further definitions for those nucleotide and amino acid sequences that are intended to be embraced by the sequence rules. Situations in which the applicability of the rules is in issue will be resolved on a case-by-case basis.

Nucleotide sequences are further limited to those that can be represented by the symbols set forth in [37 CFR 1.822\(b\)](#), which incorporates by reference WIPO Standard ST.25 (1998), Appendix 2, Table 1 (see [MPEP § 2422](#)). The presence of other than typical 5' to 3' phosphodiester linkages in a nucleotide sequence does not render the rules inapplicable. The Office does not want to exclude linkages of the type commonly found in naturally occurring nucleotides, e.g., eukaryotic end capped sequences.

Amino acid sequences are further limited to those listed in [37 CFR 1.822\(b\)](#), which incorporates by reference WIPO Standard ST.25 (1998), Appendix 2, Table 3 (see [MPEP § 2422](#)), and those L-amino acids that are commonly found in naturally occurring proteins. The presence of one or more D-amino acids in a sequence will exclude that sequence from the scope of the rules. Voluntary compliance is, however, encouraged in these situations; the symbol “Xaa” can be used to represent D-amino acids. The sequence rules embrace “[a]ny peptide or protein that can be expressed as a sequence using the symbols in WIPO Standard ST.25 (1998), Appendix 2, Table 3 in conjunction with a description in the Feature section to describe, for example, modified linkages, cross links and end caps, non-peptidyl bonds, etc.” [37 CFR 1.821\(a\)\(2\)](#).

With regard to amino acid sequences, the use of the terms “peptide or protein” implies, however, that the amino acids in a given sequence are linked by at least three consecutive peptide bonds. Accordingly, an amino acid sequence is not excluded from the scope of the rules merely due to the presence of a single non-peptidyl bond. If an amino acid sequence can be represented by a string of amino acid abbreviations, with reference, where necessary, to a features table to explain modifications in the sequence, the sequence comes within the scope of the rules. However, the rules are not intended to encompass the subject matter that is generally referred to as synthetic resins.

III. SEQUENCES DISCLOSED IN APPLICATION TEXT

The requirement for compliance in [37 CFR 1.821\(c\)](#) is directed to “disclosures of nucleotide and/or amino acid sequences.” (Emphasis added.) All sequence information, whether claimed or not, that meets the length thresholds in [37 CFR 1.821\(a\)](#) is subject to the rules. The goal of the Office is to build a comprehensive database that can be used for, inter alia, assessing the prior art. It is therefore essential that all sequence information, whether only disclosed or also claimed, be included in the database. In those instances in which prior art sequences are only referred to in a given application by name and a publication or accession reference, they need not be included as part of the sequence listing, unless the

referred-to sequence is “essential material” per [MPEP § 608.01\(p\)](#). However, if the applicant presents the sequence as a string of particular nucleotide bases or amino acids, it is necessary to include the sequence in the sequence listing regardless of whether the applicant considers the sequence to be prior art. In general, any sequence that is disclosed and/or claimed as a sequence, i.e., as a string of particular nucleotide bases or amino acids, and that otherwise meets the criteria of [37 CFR 1.821\(a\)](#), must be set forth in the sequence listing.

IV. VARIANTS OF A PRESENTED SEQUENCE

It is generally acceptable to present a single, primary sequence in the specification and sequence listing by enumeration of its residues in accordance with the sequence rules (“primary sequence”) and to discuss and/or claim variants of that primary sequence without presenting each variant as a separate sequence in the sequence listing. However, the primary sequence should be annotated in the sequence listing to reflect such variants. By way of example only, the following types of sequence disclosures would be treated as noted herein by the Office. With respect to a primary sequence and “conservatively modified variants thereof,” the sequences may be described as SEQ ID NO:X (the primary sequence) and “conservatively modified variants thereof,” if desired. With respect to a sequence that “may be deleted at the C-terminus by 1, 2, 3, 4, or 5 residues,” all of the implied variations do not need to be included in the sequence listing. In this latter example, only the sequence without deletions needs to be included in the sequence listing, however applicant is encouraged to annotate the sequence to indicate that deletions have been made at the C-terminus by 1, 2, 3, 4, or 5 residues.

The Office's database will only contain the unmodified sequence. It is strongly recommended that any sequences appearing in the claims, or sequences that are considered essential to understanding the invention, be included in the sequence listing as a separate sequence.

V. SEQUENCE IDENTIFIER

[37 CFR 1.821\(c\)](#) requires that each disclosed nucleic acid or amino acid sequence in the application appear separately in the sequence listing, with each sequence further being assigned a sequence identifier, referred to as “SEQ ID NO.” The sequence identifiers must begin with 1 and increase sequentially by integers. The requirement for sequence identifiers, at a minimum, requires that each sequence be assigned a different number for purposes of identification. However, where practical and for ease of reference, sequences should be presented in the sequence listing in numerical order and in the order in which they are discussed in the application.

[37 CFR 1.821\(d\)](#) requires that where the description or claims of a patent application discuss a sequence that is set forth in the sequence listing, a reference to the sequence identifier of that sequence is required at all occurrences, even if in the text of the description or claims that sequence is set forth by enumeration of its residues. This requirement is also intended to permit references elsewhere in the application (e.g., specification, claims, or drawings) to sequences set forth in the sequence listing by the use of assigned sequence identifiers without repeating the sequence. Sequence identifiers can also be used to discuss and/or claim parts or fragments of a properly presented sequence. For example, language such as “residues 14 to 243 of SEQ ID NO:23” is permissible and the fragment need not be separately presented in the sequence listing. Where a sequence that meets the length thresholds of [37 CFR 1.821\(a\)](#) is disclosed by enumeration of its residues anywhere in an application, it must be presented in a sequence listing in a manner that complies with the requirements of the sequence rules.

The rules do not alter, in any way, the requirements of [35 U.S.C. 112](#). The implementation of the rules has had no effect on disclosure and/or claiming requirements. The rules, in general, or the use of sequence identifiers throughout the specification and claims, specifically, should not raise any issues under [35 U.S.C. 112\(a\)](#) or [35 U.S.C. 112\(b\)](#). The use of sequence identifiers (SEQ ID NO:X) only provides a shorthand way for applicants to discuss and claim

their inventions. These identification numbers do not in any way restrict the manner in which an invention can be claimed.

2422.02 The Requirement for Exclusive Conformance; Sequences Presented in Drawing Figures [R-07.2015]

For all applications that disclose nucleic acid and/or amino acid sequences that fall within the definition set forth in [37 CFR 1.821\(a\)](#), [37 CFR 1.821\(b\)](#) requires exclusive conformance to the requirements of [37 CFR 1.821](#) through [37 CFR 1.825](#) with regard to the manner in which the disclosed nucleic acid and/or amino acid sequences are presented and described. This requirement is necessary to minimize any confusion that could result if more than one format for representing sequence data was employed in a given application.

Pursuant to [37 CFR 1.83\(a\)](#), sequences that are included in sequence listings should not be duplicated in the drawings. However many significant sequence characteristics may only be demonstrated by a figure. This is especially true in view of the fact that the representation of double stranded nucleotides is not permitted in the sequence listing and many significant nucleotide features, such as “sticky ends” and the like, may only be shown effectively by reference to a drawing figure. Further, the similarity or homology between/among sequences may only be depicted in an effective manner in a drawing figure. Similarly, drawing figures are recommended for use with amino acid sequences to depict structural features of the corresponding protein, such as finger regions and Kringle regions. The situations discussed herein are given by way of example only and there may be many other reasons for including a sequence in a drawing. However, when a sequence is presented in a drawing, the sequence must still be included in the sequence listing if the sequence falls within the definition set forth in [37 CFR 1.821\(a\)](#), and the sequence identifier (“SEQ ID NO:X”) must be used, either in the drawing or in the Brief Description of the Drawings.

2422.03 Sequence Listing Submission [R-10.2019]

[37 CFR 1.821\(c\)](#) requires that applications containing disclosures of nucleotide and/or amino acid sequences that fall within the definitions of [37 CFR 1.821\(a\)](#) contain, as a separate part of the disclosure, a disclosure of the nucleotide and/or amino acid sequences, and associated information, using the format and symbols that are set forth in [37 CFR 1.822](#) and [37 CFR 1.823](#). This separate part of the disclosure is referred to as the sequence listing. The sequence listing required pursuant to [37 CFR 1.821\(c\)](#) may be submitted as an ASCII text file via EFS-Web, on compact disc, as a PDF submitted via EFS-Web, or on paper. The sequence listing required by [37 CFR 1.821\(c\)](#) is the official copy of the sequence listing. If submitted on paper, the sequence listing is a separate part of the disclosure which must begin on a new page within the specification. A plurality of sequences may, if feasible, be presented on a single page; the separate presentation of both nucleotide and amino acid sequences on the same page is also permitted. Note that [37 CFR 1.821\(e\)](#) requires that a copy of the sequence listing referred to in [37 CFR 1.821\(c\)](#) must also be submitted in computer readable form (CRF) in accordance with the requirements of [37 CFR 1.824](#).

If the “Sequence Listing” required by [37 CFR 1.821\(c\)](#) was submitted in ASCII text format in an international application, indicated on the Request as part of the international application, and published as part of the international application for which national stage is entered under [35 U.S.C. 371](#), then no further submission or incorporation by reference into the specification is required.

I. ASCII TEXT FILE SUBMITTED VIA EFS-WEB

The Office strongly suggests filing the sequence listing required by [37 CFR 1.821\(c\)](#) as a text file via EFS-Web. If a new application is filed via EFS-Web with an ASCII text file sequence listing that complies with the requirements of [37 CFR 1.824\(a\)\(2\)-\(6\)](#) and [\(b\)](#), and applicant has not filed a sequence listing in a PDF file, the text file will serve as both the paper copy required by [37 CFR 1.821\(c\)](#) and the computer readable form (CRF) required by [37 CFR 1.821\(e\)](#). Note that the specification must contain a statement

in a separate paragraph that incorporates by reference the material in the ASCII text file identifying the name of the ASCII text file, the date of creation, and the size of the ASCII text file in bytes. See [MPEP § 2422.03\(a\)](#) for additional information pertaining to EFS-Web submission of sequence listings.

II. ASCII TEXT FILE ON COMPACT DISC

If the official copy of the sequence listing as required by [37 CFR 1.821\(c\)](#) is submitted on compact disc, the specification must contain an incorporation by reference of the material on the compact disc in a separate paragraph, identifying each compact disc by the names of the file(s) contained on each of the compact discs, their date of creation and their sizes in bytes ([37 CFR 1.52\(e\)](#)). The total number of compact discs including duplicates and the files on each compact disc shall be specified ([37 CFR 1.77\(b\)\(5\)](#)).

The compact disc used to submit the sequence listing may also contain table information if the table has more than 50 pages of text. See [37 CFR 1.823\(a\)\(2\)](#) and [1.52\(e\)\(1\)\(iii\)](#). The compact disc and duplicate copy must be labeled “Copy 1” and “Copy 2,” respectively, and a statement stating that the copies are identical must be included. If the two compact discs are not identical, the Office will use the disc labeled “Copy 1” for further processing ([37 CFR 1.52\(e\)\(4\)](#)). See also [MPEP § 608.05](#).

If the sequence listing under [37 CFR 1.821\(c\)](#) is submitted on compact disc, applicant is still required to submit a separate CRF of the sequence listing pursuant to [37 CFR 1.821\(e\)](#) and [37 CFR 1.824](#). If the CRF is also submitted on compact disc, applicants will need to submit a total of three copies of the sequence listing (one pursuant to [37 CFR 1.821\(c\)](#), and two pursuant to [37 CFR 1.821\(e\)](#)). The compact disc with the CRF of the sequence listing may be identical to the compact disc submitted under [37 CFR 1.821\(c\)](#) if the latter compact disc includes only the sequence listing (i.e., no additional content, such as tables).

A. Text Files Up to 300 MB

The sequence listing must be a single document, but the document may be split amongst two or more

compact discs using software designed to divide a file that is too large to fit on a single compact disc into multiple concatenated files. If the user breaks up a sequence listing so that it may be submitted on multiple compact discs, the compact discs must be labeled to indicate their order (e.g., “1 of X”, “2 of X”).

One hundred (100) megabytes is the size limit for sequence listing text files submitted via EFS-Web. If a user wishes to submit an electronic copy of a sequence listing text file that exceeds 100 megabytes, the sequence listing must be filed on compact disc(s).

B. Text Files 300 MB or Over

Effective for submissions filed on or after January 16, 2018, the Office set two new fees to manage handling of sequence listings of 300 MB or more in [37 CFR 1.21\(o\)](#). Pricing for this fee is divided into two tiers with Tier 1 for file sizes 300 MB to 800 MB and Tier 2 for file sizes greater than 800 MB. The level of effort associated with the handling of mega-sequence listings is significant, because the Office’s systems require extra storage and special handling for files beyond 300 MB. The fee should encourage applicants to draft their specifications such that sequence data that is not essential material is not required to be included in a sequence listing. A reduced number of mega-sequence listings will benefit the Office and the public by reducing the strain on Office resources, thus facilitating the effective administration of the patent system.

The fee under [37 CFR 1.21\(o\)](#) is due upon the first submission of a sequence listing that exceeds 800 MB, or the first submission of a sequence listing of at least 300MB, whichever applicable fee is higher. As an example, if an application was filed prior to January 16, 2018 (with or without a text file sequence listing), and thereafter a mega-sequence listing that is between 300 and 800 MB is filed, the fee under [37 CFR 1.21\(o\)\(1\)](#) is due. If an applicant thereafter files a corrected sequence listing that is also between 300 and 800 MB, no additional fee is due. If a further corrected sequence listing is filed and the file size exceeds 800 MB, then the total fee owed under [37 CFR 1.21\(o\)](#) is the fee set forth in [37 CFR 1.21\(o\)\(2\)](#). The fee is due upon submission of the mega-sequence listing. Subsequent deletion or

reduction in size of a sequence listing does not change the requirement to pay the mega-sequence listing submission fee.

The fee under [37 CFR 1.21\(o\)](#) does not apply to international applications, but does apply to the submission of mega-sequence listings received in national stage applications under [35 U.S.C. 371](#), including mega-sequence listings received by the Office pursuant to [PCT Article 20](#). See [MPEP § 2422.03\(a\)](#), subsection IV, for additional information.

2422.03(a) Sequence Listings Submitted as ASCII Text Files via EFS-Web [R-10.2019]

The EFS-Web Legal Framework (www.uspto.gov/sites/default/files/documents/2019LegalFrameworkPES.pdf) and [MPEP § 502.05](#) provide detailed information pertaining to filing applications and other documents via EFS-Web. The information below is specific to sequence listing submissions via EFS-Web.

Pursuant to the EFS-Web Legal Framework, applicants may submit a sequence listing under [37 CFR 1.821](#) as an ASCII text file via EFS-Web instead of on compact disc, provided the specification contains a statement in a separate paragraph (preferably on the first page) that incorporates by reference the material in the ASCII text file identifying the name of the ASCII text file, the date of creation, and the size of the ASCII text file in bytes. The requirements of [37 CFR 1.52\(e\)\(3\)-\(6\)](#) for documents submitted on compact disc are not applicable to sequence listings submitted as ASCII text files via EFS-Web. However, each text file must be in compliance with ASCII and have a file name with a “.txt” extension.

I. ASCII TEXT FILE SUBMITTED VIA EFS-WEB MAY SERVE AS BOTH PAPER COPY AND CRF

It is recommended that a sequence listing be submitted in an ASCII text file via EFS-Web rather than in a PDF file. See subsection IV, below, for information regarding filing an international application (PCT) with a sequence listing text file via EFS-Web.

If a sequence listing ASCII text file submitted via EFS-Web on the application filing date complies with the requirements of [37 CFR 1.824\(a\)\(2\)-\(6\) and \(b\)](#), and applicant has not filed a sequence listing in a PDF file (or on paper) on the same day, the text file will serve as both the paper copy required by [37 CFR 1.821\(c\)](#) and the computer readable form (CRF) required by [37 CFR 1.821\(e\)](#). Thus, the following are not required and should not be submitted: (1) a second copy of the sequence listing in a PDF file; (2) a statement under [37 CFR 1.821\(f\)](#) (indicating that the paper copy and CRF copy of the sequence listing are identical); and (3) a request to use a compliant computer readable form of the sequence listing that is already on file for another application pursuant to [37 CFR 1.821\(e\)](#). If such a request is filed, the USPTO will not carry out the request but will use the sequence listing submitted in the ASCII text file with the application via EFS-Web. See [MPEP § 2422.05](#). Checker software that may be used to check a sequence listing for compliance with the requirements of [37 CFR 1.824](#) is available on the USPTO website at www.uspto.gov/patents-getting-started/patent-basics/types-patent-applications/utility-patent/checker-version-446. The User Notes on the Checker website should be consulted for an explanation of errors that are not indicated, and content that is not verified, by the Checker software.

If a user submits a sequence listing (under [37 CFR 1.821\(c\) and \(e\)](#)) as an ASCII text file via EFS-Web in response to a requirement under [37 CFR 1.821\(g\) or \(h\)](#), the sequence listing text file must be accompanied by a statement that the submission does not include any new matter which goes beyond the disclosure of the application as filed. In addition, if a user submits an amendment to, or a replacement of, a sequence listing (under [37 CFR 1.821\(c\) and \(e\)](#)) as an ASCII text file via EFS-Web, the sequence listing text file must be accompanied by: (1) a statement that the submission does not include any new matter, and (2) a statement that indicates support for the amendment in the application, as filed. See [37 CFR 1.825](#). An incorporation-by-reference statement of the sequence listings is also required in both of these instances.

Submission of the sequence listing in a PDF file on the application filing date is not recommended.

Applicant must still provide the CRF required by [37 CFR 1.821\(e\)](#), and the sequence listing in the PDF file will not be excluded when determining the application size fee. The USPTO prefers the submission of a sequence listing in an ASCII text file via EFS-Web on the application filing date because as stated above, if applicant has not filed a second copy of the sequence listing in a PDF file (or on paper) on the same day, the text file will serve as both the paper copy required by [37 CFR 1.821\(c\)](#) and the CRF required by [37 CFR 1.821\(e\)](#). Any sequence listing submitted in PDF format (or on paper) on the application filing date is treated as the paper copy required by [37 CFR 1.821\(c\)](#). If applicant submits a sequence listing in both a PDF file and an ASCII text file via EFS-Web on the application filing date, a statement that the sequence listing content of the PDF copy and the ASCII text file copy are identical is required. In situations where applicant files the sequence listing in PDF format and requests the use of the CRF of another application under [37 CFR 1.821\(e\)](#), applicant must submit a letter and request in compliance with [37 CFR 1.821\(e\)](#) and a statement that the PDF copy filed in the new application is identical to the CRF filed in the other application. See [MPEP § 2422.05](#).

II. APPLICATION SIZE FEE

Any sequence listing submitted as an ASCII text file via EFS-Web that is otherwise in compliance with [37 CFR 1.52\(e\)](#) and [37 CFR 1.824\(a\)\(2\)-\(6\)](#) and [\(b\)](#) will be excluded when determining the application size fee required by [37 CFR 1.16\(s\)](#) or [1.492\(j\)](#) as per [37 CFR 1.52\(f\)\(1\)](#). A sequence listing submitted as a PDF file via EFS-Web will not be excluded when determining the application size fee.

Regarding a table submitted as an ASCII text file via EFS-Web that is part of the specification or drawings, each three kilobytes of content submitted will be counted as a sheet of paper for purposes of determining the application size fee required by [37 CFR 1.16\(s\)](#) or [1.492\(j\)](#). Each table should be submitted as a separate text file. Further, the file name for each table should indicate which table is contained therein.

See subsection IV, below, for additional information regarding application size fees in an international application (PCT).

III. SIZE LIMIT FOR TEXT FILES

One hundred (100) megabytes is the size limit for sequence listing text files submitted via EFS-Web. If a user wishes to submit an electronic copy of a sequence listing text file that exceeds 100 megabytes, it is recommended that the user file the application without the sequence listing using EFS-Web to obtain the application number and confirmation number, and then file the sequence listing on compact disc in accordance with [37 CFR 1.52\(e\)](#) on the same day by using Priority Mail Express® from the USPS in accordance with [37 CFR 1.10](#), or hand delivery, in order to secure the same filing date for all parts of the application. Note: a submission of a sequence listing in electronic form of 300 MB or more in size is subject to the fee set forth in [37 CFR 1.21\(o\)](#). Alternatively, a user may submit the application on paper and include the electronic copy of the sequence listing text file on compact disc in accordance with [37 CFR 1.52\(e\)](#). Sequence listing text files may not be partitioned into multiple files for filing via EFS-Web as the EFS-Web system is not currently capable of handling such submissions. If the sequence listing is filed on a compact disc, the sequence listing must be a single document, but the document may be split for submission on multiple physical media using software designed to divide a file into multiple files for subsequent concatenation. If the user breaks up a sequence listing so that it may be submitted on multiple compact discs, the compact discs must be labeled to indicate their order (e.g., “1 of X”, “2 of X”).

See subsection IV.B, below, for information regarding submission of a sequence listing text file that exceeds 100 megabytes in an international application (PCT) filed via EFS-Web.

For all other file types, 25 megabytes is the size limit. If a user wishes to submit a table that is larger than 25 megabytes, it is recommended that the electronic copy be submitted on compact disc via Priority Mail Express® from the USPS in accordance with [37 CFR 1.52\(f\)\(1\)](#) on the date of the corresponding EFS-Web filing in accordance with

[37 CFR 1.52\(e\)](#) if the user wishes the electronic copy to be considered to be part of the application as filed. Alternatively, the user may submit the application in paper and include the electronic copies on compact disc in accordance with [37 CFR 1.52\(e\)](#). Another alternative would be for the user to break up a computer program listing or table file that is larger than 25 megabytes into multiple files that are no larger than 25 megabytes each and submit those smaller files via EFS-Web. If the user chooses to break up a table file so that it may be submitted electronically, the file names must indicate their order (e.g., "1 of X", "2 of X").

See subsection IV.C, below, for information regarding submission of tables in an international application (PCT) filed via EFS-Web.

IV. FILING SEQUENCE LISTINGS IN INTERNATIONAL APPLICATIONS (PCT) VIA EFS-WEB

A. Sequence Listing Must Be Presented as a Separate Part of the Application

Under [PCT Rule 5.2\(a\)](#), the sequence listing must always be presented as a separate part of the description. When filing an international application (PCT) using EFS-Web, the sequence listing part of the description may be submitted either as a single ASCII text file with a ".txt" extension (e.g., "seqlist.txt") or as a PDF file. Note that 100 megabytes is the size limit for submitting a sequence listing text file via EFS-Web. See subsection IV.B, below.

If the sequence listing is submitted as an ASCII text file, applicant need not and should not submit any additional copies. The single ASCII text file is preferred because the ASCII text file will serve both as the sequence listing part of the description under [PCT Rule 5.2](#) and the electronic form under [PCT Rule 13 ter.1\(a\)](#) in the absence of a PDF sequence listing file. The check list of the PCT Request provided via EFS-Web together with the international application (PCT) must indicate that the sequence listing forms part of the international application. Furthermore, the statement as set forth in paragraph 4(v) of the [AI Annex C](#) (Administrative Instructions under the PCT, Annex C), that "the

information recorded in electronic form furnished under [PCT Rule 13 ter](#) is identical to the sequence listing as contained in the international application," is not required. Also, the sequence listing in an ASCII text file will not be taken into account when calculating the application sheet count, i.e., no excess sheet fee will be required for the sequence listing text file.

Submission of the sequence listing part of the description in a PDF file is not recommended because the applicant would also be required to supply a copy of the sequence listing in an ASCII text file to the appropriate authority for purposes of international search and/or international preliminary examination in accordance with paragraph 40 of [AI Annex C](#). When a sequence listing is filed via EFS-Web in a new PCT international application in both a PDF file and an ASCII text file, but the Request form Box No. IX does not indicate which one forms part of the international application, the PDF copy of the sequence listing will be considered to form part of the application and the ASCII text file will be considered an accompanying item for search purposes under PCT Rule 13ter.1(a) only.

The calculation of the international filing fee for an international application (PCT), including a sequence listing, filed via EFS-Web is determined based on the type of sequence listing file. A sequence listing filed in an ASCII text file will not be included in the sheet count of the international application (PCT). A sequence listing filed in a PDF file will be included in the sheet count of the international application (PCT). Therefore, the sheet count for an EFS-Web filed international application (PCT) containing both a PDF file and a text file sequence listing will be calculated to include the number of sheets of the PDF sequence listing.

B. File Size and Quantity Limits

One hundred (100) megabytes is the size limit for sequence listing text files submitted via EFS-Web. Sequence listing text files must not be partitioned into multiple files for filing via EFS-Web as the EFS-Web electronic filing system is not currently capable of handling such submissions. For all other file types EFS-Web is currently not capable of accepting files that are larger than 25 megabytes.

Additionally, a single EFS-Web submission may include no more than 60 electronic files. Note that regarding the 60 electronic file limit, an applicant may upload and validate in sets of up to 20 files each, with a limit of three sets of 20. If applicant chooses to divide a file into multiple parts using the multi-doc feature, each part is counted as one file.

The need to submit unusually large sequence listings and/or numerous electronic files may prevent applicant from making a complete international application (PCT) filing in a single EFS-Web submission. Applicant may use EFS-Web to file part of the international application (PCT) and to obtain the international application (PCT) number and the confirmation number, and then file the remainder of the international application (PCT) on the same day as one or more follow-on submissions using EFS-Web, in order to secure the same filing date for all parts of the international application (PCT). However, applicant is not permitted to file part of the international application (PCT) electronically via EFS-Web, and then file the remainder of the international application (PCT) on paper to secure a filing date of all parts of the international application (PCT).

In the situation where applicant needs to file a sequence listing that is over one hundred (100) megabytes, applicant may use EFS-Web to file the international application (PCT) without the sequence listing to obtain the international application (PCT) number and the confirmation number, and then file the sequence listing on compact discs on the same day by using Priority Mail Express® from the USPS in accordance with [37 CFR 1.10](#), or hand delivery, in order to secure the same filing date for all parts of the international application (PCT). However, Priority Mail Express® from the USPS and hand-carried submissions must not contain PDF files and must fully comply with the guidelines for filing a sequence listing on electronic media. The check list of the PCT Request provided via EFS-Web together with the international application (PCT) must indicate that the sequence listing part of the description will be filed separately on physical data carrier(s), on the same day and in the form of an Annex C/ST.25 text file. The sequence listing must be a single document, but the document may be split for submission on multiple physical media using

software designed to divide a file into multiple files for subsequent concatenation. If the user breaks up a sequence listing for submission on multiple compact discs, the compact discs must be labeled to indicate their order (e.g., “1 of X”, “2 of X”).

Submissions of very lengthy sequence listings (300 MB or over) in international applications are not subject to the mega-sequence listing submission fees set forth in [37 CFR 1.21\(o\)](#). However, for mega-sequence listing submissions on or after January 16, 2018, the fee under [37 CFR 1.21\(o\)](#) does apply to the submission of mega-sequence listings received in national stage applications under [35 U.S.C. 371](#), including mega-sequence listings received by the Office pursuant to [PCT Article 20](#). Similarly, if an international application is filed at RO/US with a mega-sequence listing, and thereafter a bypass continuing application is filed under [35 U.S.C. 111\(a\)](#), the fee under [37 CFR 1.21\(o\)](#) will be due in the continuing application for mega-sequence listing submissions on or after January 16, 2018.

C. Tables Related to a Sequence Listing

Tables related to a sequence listing must be an integral part of the description of the international application (PCT), and must not be included in the sequence listing part or the drawing part. Such tables will be taken into account when calculating the application sheet count, and excess sheet fees may be required. When applicant submits tables related to a sequence listing in an international application (PCT) via EFS-Web, the tables must be in a PDF file. If applicant submits tables related to a sequence listing in a text file, such tables will not be accepted as part of the international application (PCT). For more information, see Sequence Listings and Tables Related Thereto in International Applications Filed in the United States Receiving Office, 1344 Off. Gaz. Pat. Office 50 (July 7, 2009). If applicant submits tables related to a sequence listing in a text file, such tables will not be accepted as part of the international application (PCT).

2422.04 The Requirement for a Computer Readable Copy of the Official Copy of the Sequence Listing [R-07.2015]

[37 CFR 1.821\(e\)](#) requires the submission of a copy of the sequence listing in computer readable form. The computer readable form may be submitted on the electronic media permitted by [37 CFR 1.824](#), or may be submitted as an ASCII text file via EFS-Web. The information on the computer readable form will be entered into the Office's database for searching and printing nucleotide and amino acid sequences. This electronic database will also enable the Office to provide published sequence data, in electronic form, to the National Center for Biotechnology Information (NCBI) for publication in GenBank, and enable NCBI to exchange data with the DNA Data Bank of Japan (DDBJ) and the European Bioinformatics Institute (EBI). It should be noted that the Office's database complies with the confidentiality requirement imposed by [35 U.S.C. 122](#). Unpublished pending application sequences are maintained in the database separately from published or patented sequences. That is, the Office will not exchange or make public any information on any sequence until the patent application containing that information is published or matures into a patent, or as otherwise allowed by [35 U.S.C. 122](#).

The Office may permit correction of the official copy of the sequence listing submitted pursuant to [37 CFR 1.821\(c\)](#), whether on paper or compact disc, at the least, during the pendency of a given application by reference to the computer readable copy thereof submitted pursuant to [37 CFR 1.821\(e\)](#) if both the official copy and computer readable form were submitted at the time of filing of the application and the totality of the circumstances otherwise substantiate the proposed correction. A mere discrepancy between the official copy and the computer readable form may not, in and of itself, be sufficient to justify a proposed correction. In this regard, the Office will assume that the computer readable form has been incorporated by reference into the application when the official copy and computer readable form were submitted at the time of filing of the application. The Office will attempt to accommodate or address all correction issues, but it must be kept in mind that the real burden rests with the applicant to ensure that any discrepancies

between the official copy and the computer readable form are eliminated or minimized. Applicants should be aware that there will be instances where the applicant may have to suffer the consequences of any discrepancies between the two. If a new application is filed via EFS-Web with an ASCII text file sequence listing that complies with the requirements of [37 CFR 1.824\(a\)\(2\) - \(6\)](#) and [37 CFR 1.824\(b\)](#), and applicant has not filed a sequence listing in a PDF file, the text file will serve as both the paper copy required by [37 CFR 1.821\(c\)](#) and CRF required by [37 CFR 1.821\(e\)](#), eliminating any chance for discrepancies between the official copy and the CRF.

The Office does not desire to be bound by a requirement to permanently preserve computer readable forms for support, priority or correction purposes. For example, the Office will make corrections, where appropriate, by reference to the CRF as long as the CRF is still available to the Office. However, once use of the CRF by the Office for processing has ended, i.e., once the Office has entered the data contained on the computer readable form into the appropriate database, the Office does not intend to further preserve the CRF submitted by the applicant.

2422.05 Request for Transfer of Computer Readable Form [R-10.2019]

37 CFR 1.821 Nucleotide and/or amino acid sequence disclosures in patent applications.

(e) A copy of the "Sequence Listing" referred to in paragraph (c) of this section must also be submitted in computer readable form (CRF) in accordance with the requirements of [§ 1.824](#). The computer readable form must be a copy of the "Sequence Listing" and may not be retained as a part of the patent application file. If the computer readable form of a new application is to be identical with the computer readable form of another application of the applicant on file in the Office, reference may be made to the other application and computer readable form in lieu of filing a duplicate computer readable form in the new application if the computer readable form in the other application was compliant with all of the requirements of this subpart. The new application must be accompanied by a letter making such reference to the other application and computer readable form, both of which shall be completely identified. In the new application, applicant must also request the use of the compliant computer readable "Sequence Listing" that is already on file for the other application and must state that the paper or compact disc copy of the "Sequence Listing"

in the new application is identical to the computer readable copy filed for the other application.

Where the computer readable form (CRF) of the sequence listing of a new application is to be identical with the CRF of another application of the applicant on file in the Office, [37 CFR 1.821\(e\)](#) provides a mechanism for applicant to request a transfer of the CRF from the application already on file to the new application in limited circumstances. Instead of submitting a transfer request of a previously filed CRF, however, the Office strongly recommends that applicant submit a sequence listing in ASCII text format in the new application, which will serve both as the sequence listing part of the disclosure, as well as the CRF. Applicant may be able to retrieve a copy of the sequence listing in ASCII text format in another application of the applicant from applicant's records, public or private PAIR via the Supplemental Content Tab, or from PATENTSCOPE (WIPO website) when provided in an international application.

I. REQUIREMENTS OF A TRANSFER REQUEST

First, the application in which the request for a transfer is submitted must have been filed with (or include via an amendment in accordance with [37 CFR 1.825\(a\)](#)) a paper copy, two compact disc copies in accordance with [37 CFR 1.52\(e\)](#), or a PDF of a sequence listing. Second, the CRF of the previous application must be identical to the sequence listing contained in the new application and the request for transfer must include a statement to this effect. Note that applicant may request transfer only of a CRF that complies with [37 CFR 1.824\(a\)\(2\) - \(6\)](#) and [37 CFR 1.824\(b\)](#), (i.e., is a compliant sequence listing ASCII text file). Third, the previous application and the CRF to be transferred must be completely and clearly identified in the transfer request. Necessary identifying information includes the application number, filing date of the application, and submission date of the CRF that is to be transferred. Note that if the transfer request is filed on or after January 16, 2018 and the sequence listing to be transferred is at least 300 MB, then the transfer request will be subject to the mega-sequence listing fee set forth in [37 CFR 1.21\(o\)](#).

Form PTO/SB/93 (www.uspto.gov/forms/sb0093.pdf) should be used to request a transfer of a CRF under [37 CFR 1.821\(e\)](#) to facilitate processing of the request.

If a user submits a sequence listing ASCII text file via EFS-Web and concurrently requests the Office to use a compliant computer readable sequence listing that is already on file for another application pursuant to [37 CFR 1.821\(e\)](#), the Office will not carry out the request but will use the sequence listing submitted with the application as originally filed via EFS-Web.

II. REPLY TO A DEFECTIVE TRANSFER REQUEST NOTICE

Applicant's reply to a notice of a defective transfer request preferably includes a CRF of the previous application (an ASCII text file submitted via EFS-Web or on compact disc), however a new transfer request and correction of the noted deficiencies is also permitted. As an example, if applicant requested transfer of a CRF into a new application that does not include a sequence listing and such request is defective, the response to a defective transfer request notice may be a CRF of the sequence listing. If it is not, then the response must include a new transfer request, a PDF, two compact disc copies in accordance with [37 CFR 1.52\(e\)](#) or a paper copy of the sequence listing, and an amendment in accordance with [37 CFR 1.825\(a\)](#) entering the sequence listing in the application.

2422.06 Requirement for Statement Regarding Content of Official and Computer Readable Copies of Sequence Listing [R-07.2015]

[37 CFR 1.821\(f\)](#) requires that the official sequence listing (submitted on paper or compact disc pursuant to [37 CFR 1.821\(c\)](#)) and computer readable copies of the sequence listing (submitted pursuant to [37 CFR 1.821\(e\)](#)) be accompanied by a statement that the content of the official and computer readable copies are the same, at the time when the computer readable form is submitted. Such a statement may be made by a registered practitioner, the applicant, an inventor, or the person who actually compares the sequence data on behalf of the aforementioned.

See [MPEP § 2428](#) for further information and Sample Statements.

Note that if the sequence listing is filed in a new application as an ASCII text file via EFS-Web, and applicant has not filed a sequence listing in a PDF file, the text file will serve as both the paper copy required by [37 CFR 1.821\(c\)](#) and the computer readable form (CRF) required by [37 CFR 1.821\(e\)](#). See [MPEP § 2422.03\(a\)](#), subsections I and IV, for additional information. Thus, the following are not required and should not be submitted: (1) a second copy of the sequence listing in a PDF file; and (2) a statement under [37 CFR 1.821\(f\)](#) (indicating that the paper copy and CRF copy of the sequence listing are identical).

2422.07 Requirements for Compliance, Statements Regarding New Matter, and Sanctions for Failure to Comply [R-07.2015]

[37 CFR 1.821\(g\)](#) requires compliance with the requirements of [37 CFR 1.821\(b\)](#) through (f), as discussed above, if they are not satisfied at the time of filing under [35 U.S.C. 111\(a\)](#) or at the time of entering the national stage of an international application under [35 U.S.C. 371](#), within the period of time set in a notice requiring compliance. Failure to comply will result in the abandonment of the application. When applicant files an amendment to comply with the requirements of [37 CFR 1.821\(g\)](#) and that amendment adds or amends a compact disc(s) or ASCII text file submitted via EFS-Web, applicant is required to update or insert in the specification an appropriate incorporation by reference statement describing the compact disc and the files contained thereon or the description of the ASCII text file submitted via EFS-Web. See [37 CFR 1.77\(b\)\(5\)](#) and [37 CFR 1.52\(e\)\(5\)](#). Submissions in reply to requirements under [37 CFR 1.821\(g\)](#) must be accompanied by a statement that the submission includes no new matter. Such a statement may be made by a registered practitioner, the applicant, an inventor, or the person who actually compares the sequence data on behalf of the aforementioned. Extensions of time in which to reply to a requirement under this paragraph are available pursuant to [37 CFR 1.136](#). Note, however, that patent applications filed under [35 U.S.C. 111](#) on or after December 18, 2013, and international patent applications in which

the national stage commenced under [35 U.S.C. 371](#) on or after December 18, 2013, may be subject to reductions in patent terms adjustment pursuant to [37 CFR 1.704\(c\)\(13\)](#) if they are not in condition for examination within eight months from the filing date or date of commencement, respectively. “In condition for examination” includes compliance with [37 CFR 1.821](#) through [1.825](#) (see [37 CFR 1.704\(f\)](#)).

Provisional applications filed under [35 U.S.C. 111\(b\)](#) need not comply with [37 CFR 1.821](#) through [1.825](#), however, applicants are encouraged to file a sequence listing as defined in [37 CFR 1.821\(c\)](#) for ease of identification of the sequence information contained in the provisional application.

If any of the requirements of [37 CFR 1.821\(b\) - \(f\)](#) are not satisfied at the time of filing an international application under the Patent Cooperation Treaty (PCT), which application is to be searched by the United States International Searching Authority or examined by the United States International Preliminary Examining Authority, applicant will be sent a notice necessitating compliance with the requirements within a prescribed time period. Submissions in reply to requirements under this paragraph must be accompanied by a statement that the submission does not include matter which goes beyond the disclosure in the international application as filed. Such a statement may be made by a registered practitioner, the applicant, an inventor, or the person who actually compares the sequence data on behalf of the aforementioned. International applications that fail to comply with any of the requirements of [37 CFR 1.821\(b\) - \(f\)](#) will be searched and/or examined to the extent possible without the benefit of the information in computer readable form. See [PCT Administrative Instructions Section 513\(c\)](#).

The requirement to submit a statement that a submission in reply to the requirements of this section does not include new matter or matter which goes beyond the disclosure in the application as filed is not the first instance in which the applicant has been required to ensure that there is not new matter upon amendment. The requirement is analogous to that found in [37 CFR 1.125](#) regarding substitute specifications. When a substitute specification is required because the number or nature of

amendments would make it difficult to examine the application, the applicant must include a statement that the substitute specification includes no new matter. The necessity of requiring a substitute sequence listing, or pages thereof, is similar to the necessity of requiring a substitute specification and, likewise, the burden is on the applicant to ensure that no new matter is added. Applicants have a duty to comply with the statutory prohibition ([35 U.S.C. 132](#) and [35 U.S.C. 251](#)) against the introduction of new matter.

The correction of errors in sequencing or any other errors that are made in describing an invention are subject to the statutory prohibition ([35 U.S.C. 132](#) and [35 U.S.C. 251](#)) against the introduction of new matter.

2422.08 Presumptions Regarding Compliance [R-08.2012]

Neither the presence nor absence of information which is not required under the sequence rules will create a presumption that such information is necessary to satisfy any of the requirements of [35 U.S.C. 112](#). Further, the grant of a patent on an application that is subject to [37 CFR 1.821](#) through [37 CFR 1.825](#) constitutes a presumption that the granted patent complies with the requirements of these rules.

2422.09 Box Sequence; Hand Delivery of Sequence Listings and Computer Readable Forms [R-07.2015]

To facilitate administrative processing of all papers and compact discs associated with sequence rule compliance, all computer readable forms, compact discs, fees, and papers accompanying them filed in the Office should be marked “Box SEQUENCE.”

Correspondence relating to the sequence rules may also be hand-delivered to the Customer Service Window. In cases of hand delivery to the Customer Service Window, the computer readable form should be placed in a protective mailer labeled with at least the application number, if available. The labeling requirements of [37 CFR 1.52\(e\)](#) and [1.824\(a\)\(6\)](#) must also be complied with. The use of staples and

clips, if any, should be confined to carefully attaching the mailer to the submitted papers without contact or compression of the media. In no situations should additional or complimentary electronic copies be delivered to examiners or other Office personnel.

2423 Symbols and Format To Be Used for Nucleotide and/or Amino Acid Sequence Data [R-10.2019]

37 CFR 1.822 Symbols and format to be used for nucleotide and/or amino acid sequence data.

(a) The symbols and format to be used for nucleotide and/or amino acid sequence data shall conform to the requirements of paragraphs (b) through (e) of this section.

(b) The code for representing the nucleotide and/or amino acid sequence characters shall conform to the code set forth in the tables in WIPO Standard ST.25 (1998), Appendix 2, Tables 1 and 3. This incorporation by reference was approved by the Director of the Federal Register in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. Copies of ST.25 may be obtained from the World Intellectual Property Organization; 34 chemin des Colombettes; 1211 Geneva 20 Switzerland. Copies may also be inspected at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html. No code other than that specified in these sections shall be used in nucleotide and amino acid sequences. A modified base or modified or unusual amino acid may be presented in a given sequence as the corresponding unmodified base or amino acid if the modified base or modified or unusual amino acid is one of those listed in WIPO Standard ST.25 (1998), Appendix 2, Tables 2 and 4, and the modification is also set forth in the Feature section. Otherwise, each occurrence of a base or amino acid not appearing in WIPO Standard ST.25 (1998), Appendix 2, Tables 1 and 3, shall be listed in a given sequence as “n” or “Xaa,” respectively, with further information, as appropriate, given in the Feature section, preferably by including one or more feature keys listed in WIPO Standard ST.25 (1998), Appendix 2, Tables 5 and 6.

(c) *Format representation of nucleotides.*

(1) A nucleotide sequence shall be listed using the lower-case letter for representing the one-letter code for the nucleotide bases set forth in WIPO Standard ST.25 (1998), Appendix 2, Table 1.

(2) The bases in a nucleotide sequence (including introns) shall be listed in groups of 10 bases except in the coding parts of the sequence. Leftover bases, fewer than 10 in number, at the end of noncoding parts of a sequence shall be grouped together and separated from adjacent groups of 10 or 3 bases by a space.

(3) The bases in the coding parts of a nucleotide sequence shall be listed as triplets (codons). The amino acids corresponding to the codons in the coding parts of a nucleotide sequence shall be typed immediately below the corresponding

codons. Where a codon spans an intron, the amino acid symbol shall be typed below the portion of the codon containing two nucleotides.

(4) A nucleotide sequence shall be listed with a maximum of 16 codons or 60 bases per line, with a space provided between each codon or group of 10 bases.

(5) A nucleotide sequence shall be presented, only by a single strand, in the 5 to 3 direction, from left to right.

(6) The enumeration of nucleotide bases shall start at the first base of the sequence with number 1. The enumeration shall be continuous through the whole sequence in the direction 5 to 3. The enumeration shall be marked in the right margin, next to the line containing the one-letter codes for the bases, and giving the number of the last base of that line.

(7) For those nucleotide sequences that are circular in configuration, the enumeration method set forth in paragraph (c)(6) of this section remains applicable with the exception that the designation of the first base of the nucleotide sequence may be made at the option of the applicant.

(d) *Representation of amino acids.*

(1) The amino acids in a protein or peptide sequence shall be listed using the three-letter abbreviation with the first letter as an upper case character, as in WIPO Standard ST.25 (1998), Appendix 2, Table 3.

(2) A protein or peptide sequence shall be listed with a maximum of 16 amino acids per line, with a space provided between each amino acid.

(3) An amino acid sequence shall be presented in the amino to carboxy direction, from left to right, and the amino and carboxy groups shall not be presented in the sequence.

(4) The enumeration of amino acids may start at the first amino acid of the first mature protein, with the number 1. When presented, the amino acids preceding the mature protein, *e.g.*, pre-sequences, pro-sequences, pre-pro-sequences and signal sequences, shall have negative numbers, counting backwards starting with the amino acid next to number 1. Otherwise, the enumeration of amino acids shall start at the first amino acid at the amino terminal as number 1. It shall be marked below the sequence every 5 amino acids. The enumeration method for amino acid sequences that is set forth in this section remains applicable for amino acid sequences that are circular in configuration, with the exception that the designation of the first amino acid of the sequence may be made at the option of the applicant.

(5) An amino acid sequence that contains internal terminator symbols (*e.g.*, “Ter”, “*”, or “.”, etc.) may not be represented as a single amino acid sequence, but shall be presented as separate amino acid sequences.

(e) A sequence with a gap or gaps shall be presented as a plurality of separate sequences, with separate sequence identifiers, with the number of separate sequences being equal in number to the number of continuous strings of sequence data. A sequence that is made up of one or more noncontiguous segments of a larger sequence or segments from different sequences shall be presented as a separate sequence.

Tables 1-6 of WIPO Standard ST.25 (1998), Appendix 2, are reproduced in [MPEP § 2422](#).

2423.01 Format and Symbols To Be Used in Sequence Listings [R-07.2015]

[37 CFR 1.822](#) sets forth the format and symbols to be used for listing nucleotide and/or amino acid sequence data. The symbols for representing the nucleotide and/or amino acid characters in the sequences are set forth in the tables of WIPO Standard ST.25 (1998), Appendix 2, Tables 1 and 3. See [MPEP § 2422](#). No other symbols shall be used in nucleotide and amino acid sequences. The “modified base” and “modified and unusual amino acid” symbols appearing in WIPO Standard ST.25 (1998), Appendix 2, Tables 2 and 4 (see [37 CFR 1.822](#) and [MPEP § 2422](#)) are not to be set forth in the sequences recited in the sequence listing. However, “modified base” or “modified and unusual amino acid” symbols may be used in the written description and/or drawing portions of the specification. To properly enter notations for modified bases or amino acids in the sequence listing, the Feature section of the sequence listing should be used. That is, a modified base or amino acid may be presented in a given sequence as the corresponding unmodified base or amino acid if the modified base or amino acid is one of those listed in WIPO Standard ST.25 (1998), Appendix 2, Table 2 or 4 and the modification is also set forth in the Feature section of the sequence listing. Otherwise, all nucleotide bases or amino acids not appearing in WIPO Standard ST.25 (1998), Appendix 2, Table 1 or 3 must be listed in a given sequence as “n” or “Xaa,” respectively, with further information given in the Feature section of the sequence listing. See [37 CFR 1.822\(b\)](#).

In [37 CFR 1.822\(b\)](#) and [37 CFR 1.822\(d\)](#), the use of three-letter symbols for amino acids is required in the sequence listing. The three-letter symbols must be presented using the upper case for the first character and lower case for the remaining two characters. Applicants are encouraged to use the three-letter symbols for amino acids throughout the disclosure, instead of the one-letter symbols, for easier reading of the application and any patent issuing therefrom.

[37 CFR 1.822\(c\)](#) through [\(e\)](#) set forth the format for presenting sequence data. These paragraphs set forth the manner in which the characters in sequences are to be grouped, spaced, presented and numbered.

2423.02 Depiction of Coding Regions [R-07.2015]

If applicant chooses to depict coding regions, [37 CFR 1.822\(c\)\(3\)](#) requires the amino acids corresponding to the codons in the coding parts of a nucleotide sequence to be typed immediately below the corresponding codons. Further, in [37 CFR 1.822\(c\)\(3\)](#), the situation in which a codon spans an intron has been addressed. In those situations, the “amino acid symbol shall be typed below the portion of the codon containing two nucleotides.” This requirement clarifies the representation of an amino acid that corresponds to a codon that spans an intron.

It should be noted that the sequence rules do not, in any way, require the depiction of coding regions or the amino acids corresponding to the codons in those coding regions. [37 CFR 1.822\(d\)](#) only requires that where amino acids corresponding to the codons in the coding parts of a nucleotide sequence are depicted, they must be depicted below the corresponding codons. There is absolutely no requirement in the rules to depict coding regions. However, when the coding parts of a nucleotide sequence and their corresponding amino acids have been enumerated by their residues, those amino acids must also be set forth as a separate sequence if the amino acid sequence meets the length thresholds in [37 CFR 1.821\(a\)](#).

2423.03 Presentation and Numbering of Sequences [R-07.2015]

[37 CFR 1.822\(c\)\(5\)](#) provides that nucleotide sequences shall only be represented by a single strand, in the 5 to 3 direction, from left to right. That is, double stranded nucleotides shall not be represented in the sequence listing. A double stranded nucleotide may be represented as two single stranded nucleotides, and any relationship between the two may be shown in the drawings.

The procedures for presenting and numbering amino acid sequences are set forth in [37 CFR 1.822\(d\)](#). Two alternatives are presented for numbering amino acid sequences. Amino acid sequences may be numbered with respect to the identification of the first amino acid of the first mature protein or with respect to the first amino acid appearing at the amino terminal. The numbering procedure for nucleotides is set forth in [37 CFR 1.822\(c\)\(6\)](#). Sequences that are circular in configuration are intended to be encompassed by these rules, and the numbering procedures described above remain applicable with the exception that the designation of the first nucleotide base or amino acid of the sequence may be made at the option of the applicant. See [37 CFR 1.822\(c\)\(7\)](#) and [\(d\)\(4\)](#).

In [37 CFR 1.822\(e\)](#) the procedures for presenting and numbering hybrid and gapped sequences are set forth. A sequence with a gap or gaps shall be presented as a plurality of separate sequences, each having separate sequence identification numbers, with the number of separate sequences being equal in number to the number of continuous strings of sequence data. The term “gap” is not intended to embrace a gap or gaps that is/are introduced into the presentation of otherwise continuous sequence information in, e.g., a drawing figure, to show alignments or similarities with other sequences. The “gaps” referred to in this section are gaps representing unknown or undisclosed regions in a sequence between regions that are known or disclosed. On the other hand, a sequence that contains one or more regions of contiguous “n” or “Xaa” residues, wherein the exact number of “n” or “Xaa” residues in each region is disclosed, must be included in the sequence listing as a single sequence with a single sequence identification number. A sequence disclosed by enumeration of its residues that is constructed as a single continuous sequence from one or more non-contiguous segments of a larger sequence or segments from different sequences must be included in the sequence listing as a single sequence with a single sequence identification number. A fragment of a larger sequence need not be enumerated by its residues, and may be referred to in the specification, claims or drawings as, e.g., “residues 2 through 33 of SEQ ID NO:12,” assuming that SEQ ID NO:12 has been properly included in the sequence listing.

2424 Requirements for Nucleotide and/or Amino Acid Sequences as Part of the Application Papers [R-08.2012]

37 CFR 1.823 Requirements for nucleotide and/or amino acid sequences as part of the application.

(a)(1) If the “Sequence Listing” required by [§ 1.821\(c\)](#) is submitted on paper: The “Sequence Listing,” setting forth the nucleotide and/or amino acid sequence and associated information in accordance with paragraph (b) of this section, must begin on a new page and must be titled “Sequence Listing.” The pages of the “Sequence Listing” preferably should be numbered independently of the numbering of the remainder of the application. Each page of the “Sequence Listing” shall contain no more than 66 lines and each line shall contain no more than 72 characters. A fixed-width font should be used exclusively throughout the “Sequence Listing.”

(2) If the “Sequence Listing” required by [§ 1.821\(c\)](#) is submitted on compact disc: The “Sequence Listing” must be submitted on a compact disc in compliance with [§ 1.52\(e\)](#). The compact disc may also contain table information if the

application contains table information that may be submitted on a compact disc ([§ 1.52\(e\)\(1\)\(iii\)](#)). The specification must contain an incorporation-by-reference of the Sequence Listing as required by [§ 1.52\(e\)\(5\)](#). The presentation of the “Sequence Listing” and other materials on compact disc under [§ 1.821\(c\)](#) does not substitute for the Computer Readable Form that must be submitted on disk, compact disc, or tape in accordance with [§ 1.824](#).

(b) The “Sequence Listing” shall, except as otherwise indicated, include the actual nucleotide and/or amino acid sequence, the numeric identifiers and their accompanying information as shown in the following table. The numeric identifier shall be used only in the “Sequence Listing.” The order and presentation of the items of information in the “Sequence Listing” shall conform to the arrangement given below. Each item of information shall begin on a new line and shall begin with the numeric identifier enclosed in angle brackets as shown. The submission of those items of information designated with an “M” is mandatory. The submission of those items of information designated with an “O” is optional. Numeric identifiers <110> through <170> shall only be set forth at the beginning of the “Sequence Listing.” The following table illustrates the numeric identifiers.

Numeric Identifier	Definition	Comments and format	Mandatory (M) or Optional (O)
<110>	Applicant.....	Preferably max. of 10 names; one name per line; preferable format: Surname, Other Names and/or Initials.	M.
<120>	Title of Invention.....	M.
<130>	File Reference.....	Personal file reference.....	M when filed prior to assignment or appl. number
<140>	Current Application Number.	Specify as: US 07/999,999 or PCT/US96/99999.	M, if available.
<141>	Current Filing Date.....	Specify as: yyyy-mm-dd.....	M, if available.
<150>	Prior Application Number.	Specify as: US 07/999,999 or PCT/US96/99999.	M, if applicable include priority documents under 35 U.S.C. 119 and 120
<151>	Prior Application Filing Date.	Specify as: yyyy-mm-dd	M, if applicable
<160>	Number of SEQ ID NOs.	Count includes total number of SEQ ID NOs.....	M.
<170>	Software.....	Name of software used to create the Sequence Listing.	O.
<210>	SEQ ID NO:#:.....	Response shall be an integer representing the SEQ ID NO shown.	M.
<211>	Length.....	Respond with an integer expressing the number of bases or amino acid residues.	M.
<212>	Type.....	Whether presented sequence molecule is DNA, RNA, or PRT (protein). If a nucleotide sequence contains both	M.

Numeric Identifier	Definition	Comments and format	Mandatory (M) or Optional (O)
		DNA and RNA fragments, the type shall be “DNA.” In addition, the combined DNA/ RNA molecule shall be further described in the <220> to <223> feature section.	
<213>	Organism.....	Scientific name, i.e. Genus/ species, Unknown or Artificial Sequence. In addition, the “Unknown” or “Artificial Sequence” organisms shall be further described in the <220> to <223> feature section.	M.
<220>	Feature.....	Leave blank after <220>. <221-223> provide for a description of points of biological significance in the sequence.	M, under the following conditions: if “n,” “Xaa,” or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is “Artificial Sequence” or “Unknown”; if molecule is combined DNA/RNA.
<221>	Name/Key.....	Provide appropriate identifier for feature, preferably from WIPO Standard ST.25 (1998), Appendix 2, Tables 5 and 6.	M, under the following conditions: if “n,” “Xaa,” or a modified or unusual L-amino acid or modified base was used in a sequence.
Numeric Identifier	Definition	Comments and format	Mandatory (M) or Optional (O)
<222>	Location.....	Specify location within sequence; where appropriate state number of first and last bases/amino acids in feature.	M, under the following conditions: if “n,” “Xaa,” or a modified or unusual L-amino acid or modified base was used in a sequence.
<223>	Other Information.....	Other relevant information; four lines maximum.....	M, under the following conditions: if “n,” “Xaa,” or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is “Artificial Sequence” or “Unknown”; if molecule is combined DNA/RNA.
<300>	Publication Information	Leave blank after <300>	O.
<301>	Authors.....	Preferably max. of ten named authors of publication; specify one name per line; preferable format: Surname, Other Names and/or Initials.	O.
<302>	Title.....	O.
<303>	Journal.....	O.
<304>	Volume	O.
<305>	Issue	O.
<306>	Pages	O.
<307>	Date.....	Journal date on which data published; specify as yyyy- mm-dd, MMM-yyyy or Season- yyyy.	O.

Numeric Identifier	Definition	Comments and format	Mandatory (M) or Optional (O)
<308>	Database Accession Number.	Accession number assigned by database including database name.	O.
<309>	Database Entry Date.....	Date of entry in database; specify as yyyy-mm-dd or MMM-yyyy.	O.
<310>	Patent Document Number.	Document number; for patent-type citations only. Specify as, for example, US 07/ 999,999.	O.
<311>	Patent Filing Date.....	Document filing date, for patent-type citations only; specify as yyyy-mm-dd.	O.
<312>	Publication Date.....	Document publication date, for patent-type citations only; specify as yyyy-mm-dd.	O.
<313>	Relevant Residues.....	FROM (position) TO (position).....	O.
<400>	Sequence.....	SEQ ID NO should follow the numeric identifier and should appear on the line preceding the actual sequence.	M.

2424.01 Informational Requirements for the Sequence Listing [R-07.2015]

[37 CFR 1.823](#) sets forth the informational requirements for the sequence listing that must be submitted in accordance with [37 CFR 1.821\(c\)](#) as part of the application. See [MPEP § 2422.03](#) for a discussion of [37 CFR 1.821\(c\)](#).

[37 CFR 1.823\(a\)\(1\)](#) sets forth page and line length requirements for any sequence listing submitted on paper. The requirement to use a fixed width font to present sequence data is also set forth therein. This latter requirement is made to ensure that the desired sequence character spacing and numbering is maintained.

[37 CFR 1.823\(a\)\(2\)](#) requires that any sequence listing submitted under [37 CFR 1.821\(c\)](#) as part of the application on compact disc must comply with [37 CFR 1.52\(e\)](#). The compact disc may also contain table information if the application contains table information that is over 50 pages. See [37 CFR 1.52\(e\)\(1\)\(iii\)](#). Note that a CRF of a sequence listing submitted on compact disc cannot include table information. See [MPEP § 2422.03](#). If a sequence listing or CRF of a sequence listing is submitted as

an ASCII text file via EFS-Web, the file cannot contain information other than the sequence listing. Any table information to be submitted as a text file in an application via EFS-Web must be submitted as a separate file. See [MPEP § 2422.03\(a\)](#) for additional information pertaining to filing a sequence listing via EFS-Web. See [MPEP § 608.05\(b\)](#) for information regarding submission of large tables in ASCII text format via EFS-Web or on compact disc.

[37 CFR 1.823\(b\)](#) lists the items of information that are to be included in the sequence listing in the order in which those items are to appear. The numeric identifier for each item of information shall not include the explanatory information included in [37 CFR 1.823\(b\)](#).

2424.02 Sequence Listing Numeric Identifiers [R-07.2015]

[37 CFR 1.823\(b\)](#) sets forth the order and presentation of the items of information in the sequence listing. Each item of information in the sequence listing must include the appropriate numeric identifier and its accompanying information as shown in [37 CFR 1.823\(b\)](#). Each item of information must begin on a new line with the numeric identifier enclosed in

angle brackets. The submission of those items of information designated with an “M” is mandatory. The submission of those items of information designated with an “O” is optional. Numeric identifiers <110> through <170> must be set forth at the beginning of the sequence listing.

See [MPEP § 2431](#) for a sample sequence listing.

2424.03 Additional Miscellaneous Requirements [R-07.2015]

Throughout [37 CFR 1.823\(b\)](#), the items of information relating to patent applications and patent publications should be provided keeping in mind the appropriate standards that have been established by the World Intellectual Property Organization (WIPO). In general, an application should be identified by a country code, a number and a filing date, while a published patent document should be identified by a country code, a number and kind code. Proper citation of priority patent applications is covered in [MPEP § 214.04](#). For published patent documents, the country code, number and kind code will appear on the front page of the document. Unpublished PCT applications are identified by the letters PCT, the country code of the Receiving Office, and either the last two digits of the year of filing and a number, e.g., PCT/AT81/00033 or PCT/FR88/00100, or the four digit year of filing and a six digit number, e.g., PCT/SE2011/000123. A published PCT application is identified by the letters WO, the last two digits of the year of publication, a number and a kind code, e.g., WO82/02827A or WO88/06811A, or by the letters WO, the four digit year of publication and a six digit number, e.g. WO/2015/009167. Country codes from WIPO Standard ST.3 Annex A and kind codes from WIPO Standard ST.16 are reproduced in [MPEP § 1851](#). Questions on proper citation of patent documents should be directed to staff in the Office of International Patent Cooperation.

In [37 CFR 1.823\(b\)](#), numeric identifier <110>, the item of information relating to “Applicant” should be limited to a maximum of the first ten named applicants in the application. Similarly, in numeric identifier <301>, the item of information relating to “Authors” should be limited to a maximum of the first ten named authors in the publication.

In [37 CFR 1.823\(b\)](#) “yyyy-mm-dd” is the format for the presentation of patent related date information in the sequence listing. Other date information may also be presented as MMM-yyyy or Season-yyyy. The lower case letters designate numeric responses and the upper case letters designate alphabetical responses. As such, March 2, 1988, would be presented as 1988-03-02 or MAR 1988.

In numeric identifiers <220> - <223>, relating to “Features” or the description of the points of biological significance in a given sequence, it is recommended, but not required, that the information that is provided by the applicant conform to the controlled vocabulary that is set forth in the DDBJ/EMBL/GenBank FeatureTable Definition provided by the International Nucleotide Sequence Data Collaboration (INSDC) at www.insdc.org/documents. See [MPEP § 2422](#) when filing in countries which adhere to WIPO Standard ST.25.

In numeric identifiers <300> - <312>, publication information for a given sequence is collected. The publication information encompasses both patent-type publications and non-patent literature publications. Numeric identifier <313>, Relevant Residues, is intended to collect information relating to the correspondence between a sequence set forth in the sequence listing and published sequence information. The starting (FROM) and end (TO) positions in the listed sequence that correspond to the published sequence information should be set forth.

2425 Form and Format for Nucleotide and/or Amino Acid Sequence Submissions in Computer Readable Form [R-07.2015]

37 CFR 1.824 Form and format for nucleotide and/or amino acid sequence submissions in computer readable form.

(a) The computer readable form required by [§ 1.821\(e\)](#) shall meet the following requirements:

(1) The computer readable form shall contain a single “Sequence Listing” as either a diskette, series of diskettes, or other permissible media outlined in paragraph (c) of this section.

(2) The “Sequence Listing” in paragraph (a)(1) of this section shall be submitted in American Standard Code for Information Interchange (ASCII) text. No other formats shall be allowed.

(3) The computer readable form may be created by any means, such as word processors, nucleotide/amino acid sequence editors' or other custom computer programs; however, it shall conform to all requirements detailed in this section.

(4) File compression is acceptable when using diskette media, so long as the compressed file is in a self-extracting format that will decompress on one of the systems described in paragraph (b) of this section.

(5) Page numbering must not appear within the computer readable form version of the "Sequence Listing" file.

(6) All computer readable forms must have a label permanently affixed thereto on which has been hand-printed or typed: the name of the applicant, the title of the invention, the date on which the data were recorded on the computer readable form, the operating system used, a reference number, and an application number and filing date, if known. If multiple diskettes are submitted, the diskette labels must indicate their order (*e.g.*, "1 of X").

(b) Computer readable form submissions must meet these format requirements:

(1) Computer Compatibility: IBM PC/XT/AT or Apple Macintosh;

(2) Operating System Compatibility: MS-DOS, MS-Windows, Unix or Macintosh;

(3) Line Terminator: ASCII Carriage Return plus ASCII Line Feed; and

(4) Pagination: Continuous file (no "hard page break" codes permitted).

(c) Computer readable form files submitted may be in any of the following media:

(1) Diskette: 3.50 inch, 1.44 Mb storage; 3.50 inch, 720 Kb storage; 5.25 inch, 1.2 Mb storage; 5.25 inch, 360 Kb storage.

(2) Magnetic tape: 0.5 inch, up to 24000 feet; Density: 1600 or 6250 bits per inch, 9 track; Format: Unix tar command; specify blocking factor (not "block size"); Line Terminator: ASCII Carriage Return plus ASCII Line Feed.

(3) 8mm Data Cartridge: Format: Unix tar command; specify blocking factor (not "block size"); Line Terminator: ASCII Carriage Return plus ASCII Line Feed.

(4) Compact disc: Format: ISO 9660 or High Sierra Format.

(5) Magneto Optical Disk: Size/Storage Specifications: 5.25 inch, 640 Mb.

(d) Computer readable forms that are submitted to the Office will not be returned to the applicant.

[37 CFR 1.824](#) sets forth the requirements for sequence submissions in computer readable form. Any computer operating system may be utilized to produce a sequence submission; however, the resultant file must have the characteristics specified in [37 CFR 1.824](#).

If the sequence listing required by [37 CFR 1.821\(c\)](#) cannot be submitted via EFS-Web because it is larger than 100 megabytes (see [MPEP § 2422.03\(a\)](#)), and it is impractical to provide the sequence listing on compact discs or other electronic media as set forth in [37 CFR 1.824](#) due to the size of the sequence listing, an exception via a non-fee petition to waive this provision will be considered. As set forth in [37 CFR 1.824\(d\)](#), the computer readable forms that are submitted in accordance with these rules will not be returned to the applicant. [37 CFR 1.824\(a\)\(6\)](#) requires the labeling, with appropriate identifying information, of the computer readable forms that are submitted in accordance with these rules.

2426 Amendments to or Replacement of Sequence Listing and Computer Readable Copy Thereof [R-07.2015]

37 CFR 1.825 Amendments to or replacement of sequence listing and computer readable copy thereof.

(a) Any amendment to a paper copy of the "Sequence Listing" (§ [1.821\(c\)](#)) must be made by the submission of substitute sheets and include a statement that the substitute sheets include no new matter. Any amendment to a compact disc copy of the "Sequence Listing" (§ [1.821\(c\)](#)) must be made by the submission of a replacement compact disc (2 copies) in compliance with § [1.52\(e\)](#). Amendments must also be accompanied by a statement that indicates support for the amendment in the application, as filed, and a statement that the replacement compact disc includes no new matter.

(b) Any amendment to the paper copy of the "Sequence Listing," in accordance with paragraph (a) of this section, must be accompanied by a substitute copy of the computer readable form (§ [1.821\(e\)](#)) including all previously submitted data with the amendment incorporated therein, accompanied by a statement that the copy in computer readable form is the same as the substitute copy of the "Sequence Listing."

(c) Any appropriate amendments to the "Sequence Listing" in a patent; *e.g.*, by reason of reissue or certificate of correction, must comply with the requirements of paragraphs (a) and (b) of this section.

(d) If, upon receipt, the computer readable form is found to be damaged or unreadable, applicant must provide, within such time as set by the Commissioner, a substitute copy of the data in computer readable form accompanied by a statement that the substitute data is identical to that originally filed.

[37 CFR 1.825](#) sets forth the procedures for amending the sequence listing and the CRF thereof. Analogous procedures apply to amending a sequence listing filed as an ASCII text file via EFS-Web. These procedures involve the submission of either substitute sheets or a substitute ASCII text file

submitted via EFS-Web or on compact disc(s), in conjunction with statements that indicate support for the amendment in the application, as filed, and that the substitute documents include no new matter. (See [MPEP § 608.05](#) and [§ 2428](#) for further information.) An amendment to the sequence listing or CRF submitted as an ASCII text file via EFS-Web or on compact disc(s) must be done by submitting a replacement sequence listing or CRF ASCII text file via EFS-Web or on compact disc(s). The amendment should include a corresponding amendment to the description of the compact disc and the files contained thereon or the description of the EFS-Web submitted ASCII text file in the incorporation by reference statement in the specification. If the sequence listing required by [37 CFR 1.821\(c\)](#) was filed on a compact disc that included files in addition to the sequence listing, a replacement compact disc containing the amended sequence listing also must contain all of the files of the original compact disc that were not amended. This will insure that the Office, printer, and public can quickly access all of the current files in an application or patent by referencing only the latest version. The requirement for statements regarding the absence of new matter follows current practice relating to the submission of substitute specifications, as set forth in [37 CFR 1.125](#). [37 CFR 1.825\(c\)](#) addresses the situation where amendments to the sequence listing are made after a patent has been granted, e.g., by a certificate of correction, reissue or reexamination. [37 CFR 1.825\(d\)](#) addresses the possibility and presents a remedy for the situation where the computer readable form may be found by the Office to be damaged or unreadable.

2427 Form Paragraphs [R-10.2019]

See [MPEP § 608.05](#) for form paragraphs which should be used when notifying applicant that a compact disc submitted in accordance with [37 CFR 1.52\(e\)](#) (i.e., containing a computer program listing, sequence listing, and/or table) does not comply with all of the requirements of the [37 CFR 1.52\(e\)](#). See also [MPEP § 608.05\(b\)](#) for form paragraphs which should be used when a table submitted on compact disc does not comply with [37 CFR 1.52\(e\)](#).

In order to expedite the processing of applications, minor errors pertaining to compliance with the

sequence rules discovered after examination has begun may be handled with the next Office action. Examples of minor errors are: missing any necessary sequence identifiers in the specification/drawings; when the sequence listing under [37 CFR 1.821\(c\)](#) is submitted on compact disc, missing statement in the transmittal letter stating that the two compact discs are identical; missing or providing an incomplete incorporation by reference of the sequence listing in the specification; missing statement that the sequence listing information in computer readable form is identical to the written (on paper or compact disc) sequence listing when such a statement is necessary, etc. Since the application is ready for examination, the examiner may act on the application and include any objections to the application based on minor errors related to the sequence listing with his/her Office action.

¶ 24.01 Heading for Sequence Requirements

REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Items 1) and 2) provide general guidance related to requirements for sequence disclosures.

1) [37 CFR 1.821\(c\)](#) requires that patent applications which contain disclosures of nucleotide and/or amino acid sequences that fall within the definitions of [37 CFR 1.821\(a\)](#) must contain a "Sequence Listing," *as a separate part of the disclosure*, which presents the nucleotide and/or amino acid sequences and associated information using the symbols and format in accordance with the requirements of [37 CFR 1.821 - 1.825](#). This "Sequence Listing" part of the disclosure may be submitted:

a) via EFS-Web (see Section I.1 of the Legal Framework for EFS-Web (<https://www.uspto.gov/patents-application-process/filing-online/legal-framework-efs-web>), hereinafter "Legal Framework") as an ASCII text file, together with an incorporation-by-reference of the material in the ASCII text file in a separate paragraph of the specification identifying:

- i) the name of the ASCII text file;
- ii) the date of creation; and
- iii) the size of the ASCII text file in bytes;

b) on compact disc(s) in duplicate according to [37 CFR 1.52\(e\)\(1\)\(ii\)](#) and (4), labeled according to [37 CFR 1.52\(e\)\(6\)](#), together with a statement that the duplicate compact discs are identical and an incorporation-by-reference of the material in the ASCII text file according to [37 CFR 1.52\(e\)\(5\)](#) in a separate paragraph of the specification identifying:

- i) the name of the ASCII text file;
- ii) the date of creation; and

- iii) the size of the ASCII text file in bytes;
- c) via EFS-Web as a PDF (not recommended); or
- d) on paper.

2) [37 CFR 1.821\(e\)](#) requires that a *copy* of the "Sequence Listing" must also be submitted in computer readable form (CRF) in accordance with the requirements of [37 CFR 1.824](#).

a) If a "Sequence Listing" ASCII text file submitted via EFS-Web on the application filing date complies with the requirements of [37 CFR 1.824\(a\)\(2\) - \(6\)](#) and [\(b\)](#), and applicant has not filed a "Sequence Listing" as a PDF, the text file will serve as both the "Sequence Listing" required by [37 CFR 1.821\(c\)](#) and the CRF required by [37 CFR 1.821\(e\)](#), and the statement of identity under the "Legal Framework" is not required.

b) If the "Sequence Listing" required by [37 CFR 1.821\(c\)](#) is filed via EFS-Web as a PDF, then the "Legal Framework" requires submission of a statement that the "Sequence Listing" content of the PDF copy and the ASCII text file copy submitted via EFS-Web are identical.

c) If the "Sequence Listing" required by [37 CFR 1.821\(c\)](#) is filed on paper or compact disc, then [37 CFR 1.821\(f\)](#) requires submission of a statement that the "Sequence Listing" content of the paper or compact disc copy and the CRF are identical.

Specific deficiencies and the required response to this Office Action are as follows:

Examiner Note:

1. This form paragraph should only be used for sequence listing non-compliance where a compliant sequence listing is not required for examination of the application.
2. This form paragraph must be followed by any of form paragraphs 24.02 - 24.16.

¶ 24.02 No Sequence Listing part of the disclosure and No CRF

Specific deficiency - This application fails to comply with the requirements of [37 CFR 1.821 - 1.825](#) because it does not contain a "Sequence Listing" as a separate part of the disclosure or a CRF.

Required response - Applicant must provide:

- A "Sequence Listing" part of the disclosure, as described above in item 1); **together with**
 - **An amendment specifically directing its entry into the application;**
 - A statement that the "Sequence Listing" includes no new matter; and
 - A statement that indicates support for the amendment in the application, as filed, as required by [37 CFR 1.825](#) and the "Legal Framework."
 - If the "Sequence Listing" part of the disclosure is submitted according to item 1) a) or b) above, Applicant must also provide:

o A substitute specification in compliance with [37 CFR 1.121\(b\)\(3\)](#) and [1.125](#) inserting the required incorporation-by-reference paragraph, consisting of:

- A copy of the previously-submitted specification, with deletions shown with strikethrough or brackets and insertions shown with underlining (marked-up version);
- A copy of the amended specification without markings (clean version); and
- A statement that the substitute specification contains no new matter.

• If the "Sequence Listing" part of the disclosure is submitted according to item 1) b), c), or d) above, Applicant must also provide:

- o A CRF; and
- o A statement according to item 2) b) or c) above.

If applicant desires the CRF in this application to be identical with the CRF of another application on file in the U.S. Patent and Trademark Office, such request in accordance with [37 CFR 1.821\(e\)](#) may be submitted in lieu of a new CRF (form PTO/SB/93 may be used for this purpose).

Examiner Note:

1. This form paragraph must be preceded by form paragraph 24.01.
2. This form paragraph should only be used for sequence listing non-compliance where a compliant sequence listing is not required for examination of the application.
3. This form paragraph should be used for an application that has no "Sequence Listing" part of the disclosure as required by [37 CFR 1.821\(c\)](#) and no CRF as required by [37 CFR 1.821\(e\)](#).
4. This form paragraph may be followed by one or more deficiency form paragraphs.

¶ 24.03 No Sequence Listing part of the disclosure and Defective CRF

Specific deficiency - This application fails to comply with the requirements of [37 CFR 1.821 - 1.825](#) because it does not contain a "Sequence Listing" as a separate part of the disclosure and the CRF is defective.

Required response - Applicant must provide:

- A "Sequence Listing" part of the disclosure, as described above in item 1); **together with**
 - **An amendment specifically directing its entry into the application;**
 - A statement that the "Sequence Listing" includes no new matter; and
 - A statement that indicates support for the amendment in the application, as filed, as required by [37 CFR 1.825](#) and the "Legal Framework."
 - If the "Sequence Listing" part of the disclosure is submitted according to item 1) a) or b) above, Applicant must also provide:

o A substitute specification in compliance with [37 CFR 1.121\(b\)\(3\)](#) and [1.125](#) inserting the required incorporation-by-reference paragraph, consisting of:

- A copy of the previously-submitted specification, with deletions shown with strikethrough or brackets and insertions shown with underlining (marked-up version);

- A copy of the amended specification without markings (clean version); and

- A statement that the substitute specification contains no new matter.

• If the "Sequence Listing" part of the disclosure is submitted according to item 1) b), c), or d) above, Applicant must also provide:

o A CRF; and

o A statement according to item 2) b) or c) above.

If applicant desires the CRF in this application to be identical with the CRF of another application on file in the U.S. Patent and Trademark Office, such request in accordance with [37 CFR 1.821\(e\)](#) may be submitted in lieu of a new CRF (form PTO/SB/93 may be used for this purpose).

Examiner Note:

1. This form paragraph must be preceded by form paragraph 24.01.

2. This form paragraph should only be used for sequence listing non-compliance where a compliant sequence listing is not required for examination of the application.

3. This form paragraph should be used for an application that has no "Sequence Listing" part of the disclosure as required by [37 CFR 1.821\(c\)](#) and the CRF as required by [37 CFR 1.821\(e\)](#) is defective.

4. This form paragraph may be followed by one or more deficiency form paragraphs.

¶ 24.04 CRFE but No "Sequence Listing" part of the disclosure

Specific deficiency - This application fails to comply with the requirements of [37 CFR 1.821 - 1.825](#) because it does not contain a "Sequence Listing" as a separate part of the disclosure.

Required response - Applicant must provide either:

• Where an ASCII text file was provided on the application filing date via EFS-Web, a substitute specification in compliance with [37 CFR 1.121\(b\)\(3\)](#) and [1.125](#) inserting the required incorporation-by-reference paragraph, consisting of:

o A copy of the previously-submitted specification, with deletions shown with strikethrough or brackets and insertions shown with underlining (marked-up version);

o A copy of the amended specification without markings (clean version); and

o A statement that the substitute specification contains no new matter.

OR

• A "Sequence Listing" part of the disclosure, as described above in any one of items 1) a), b), c), or d); together with

• An amendment specifically directing its entry into the application;

• Where the "Sequence Listing" is submitted under item 1) a) or b) a substitute specification in compliance with [37 CFR 1.121\(b\)\(3\)](#) and [1.125](#) inserting the required incorporation-by-reference paragraph, consisting of:

o A copy of the previously-submitted specification, with deletions shown with strikethrough or brackets and insertions shown with underlining (marked-up version);

o A copy of the amended specification without markings (clean version); and

o A statement that the substitute specification contains no new matter.

• A statement that the "Sequence Listing" added by amendment includes no new matter;

• A statement that indicates support for the amendment in the application, as filed, as required by [37 CFR 1.825](#) and the "Legal Framework"; and

• A statement that the content of the previously-filed CRF is identical to the "Sequence Listing" part of the disclosure added by amendment, where provided under item 1) b), c), or d) (note that where a "Sequence Listing" part of the disclosure is provided under item 1) a), the text file will also serve as the CRF, and the statement of identity is not required).

Examiner Note:

1. This form paragraph must be preceded by form paragraph 24.01.

2. This form paragraph should only be used for sequence listing non-compliance where a compliant sequence listing is not required for examination of the application.

3. This form paragraph should be used for an application that has no "Sequence Listing" part of the disclosure as required by [37 CFR 1.821\(c\)](#); however, a compliant CRF as required by [37 CFR 1.821\(e\)](#) has been submitted.

4. This form paragraph may be followed by one or more deficiency form paragraphs.

¶ 24.05 The "Sequence Listing" part of the disclosure and the CRF are not the same

Specific deficiency - This application fails to comply with the requirements of [37 CFR 1.821 - 1.825](#) because the "Sequence Listing" part of the disclosure is not the same as the CRF of the "Sequence Listing" as required by [37 CFR 1.821\(e\)](#).

Required response - Applicant must provide either:

• A substitute "Sequence Listing" as described above in any one of items 1) a), b), c), or d); **as well as**

• **An amendment specifically directing its entry into the application;**

• A statement that the "Sequence Listing" added by amendment includes no new matter;

- A statement that indicates support for the amendment in the application, as filed, as required by [37 CFR 1.825](#), and the "Legal Framework"; and

- A statement that the content of the previously-filed CRF is identical to the "Sequence Listing" part of the disclosure added by amendment, where provided under item 1) b), c), or d) (note that where a "Sequence Listing" part of the disclosure is provided under item 1) a), the text file will also serve as the CRF, and the statement of identity is not required);

- If the "Sequence Listing" part of the disclosure is submitted according to item 1) a) or b) above, Applicant must also provide:

- o A substitute specification in compliance with [37 CFR 1.121\(b\)\(3\)](#) and [1.125](#) inserting the required incorporation-by-reference paragraph, consisting of:

- A copy of the previously-submitted specification, with deletions shown with strikethrough or brackets and insertions shown with underlining (marked-up version);

- A copy of the amended specification without markings (clean version); and

- A statement that the substitute specification contains no new matter.

OR

- A substitute CRF; and

- A statement that the content of the CRF is identical to the "Sequence Listing" part of the disclosure, as required by [37 CFR 1.821\(f\)](#) and the "Legal Framework."

Examiner Note:

1. This form paragraph must be preceded by 24.01.
2. This form paragraph should only be used for sequence listing non-compliance where a compliant sequence listing is not required for examination of the application.
3. This form paragraph should be used for an application in which the "Sequence Listing" part of the disclosure as required by [37 CFR 1.821\(c\)](#) is not the same as the CRF as required by [37 CFR 1.821\(e\)](#).
4. This form paragraph may be followed by one or more deficiency form paragraphs.

¶ 24.06 Missing statement that the "Sequence Listing" (paper, PDF, CD) and the CRF are the same

Specific deficiency - This application fails to comply with the requirements of [37 CFR 1.821 - 1.825](#) because the application does not contain a statement that the CRF is identical to the "Sequence Listing" part of the disclosure, as described above in item 1), as required by [37 CFR 1.821\(f\)](#) or the "Legal Framework."

Required response - Applicant must provide such statement.

Examiner Note:

1. This form paragraph must be preceded by form paragraph 24.01.

2. This form paragraph should only be used for sequence listing non-compliance where a compliant sequence listing is not required for examination of the application.

3. This form paragraph should be used for an application that is missing the statement that the CRF is identical to the "Sequence Listing" part of the disclosure.

4. This form paragraph may be followed by one or more deficiency form paragraphs.

¶ 24.07 No Computer Readable Form (CRF) submitted

Specific deficiency - This application fails to comply with the requirements of [37 CFR 1.821 - 1.825](#) because a copy of the "Sequence Listing" in computer readable form (CRF) has not been submitted as required by [37 CFR 1.821\(e\)](#) as indicated in item 2) above.

Required response - Applicant must provide a CRF and statement according to item 2) b) or c) above. If applicant desires the CRF in this application to be identical with the CRF of another application on file in the U.S. Patent and Trademark Office, such request in accordance with [37 CFR 1.821\(e\)](#) may be submitted in lieu of a new CRF (form PTO/SB/93 may be used for this purpose).

Examiner Note:

1. This form paragraph must be preceded by form paragraph 24.01.
2. This form paragraph should only be used for sequence listing non-compliance where a compliant sequence listing is not required for examination of the application.
3. This form paragraph should be used for an application that is missing the CRF.
4. This form paragraph may be followed by one or more deficiency form paragraphs.

¶ 24.08 Computer Readable Form (CRF) contains error(s) according to STIC report

Specific deficiency - This application fails to comply with the requirements of [37 CFR 1.821 - 1.825](#). A copy of the "Sequence Listing" in computer readable form (CRF) has been submitted; however, the content of the CRF does not comply with the requirements of [37 CFR 1.822](#) and/or [1.823](#), as indicated in the "Error Report" that indicates the "Sequence Listing" could not be accepted. Refer to attachment or PAIR document "Computer Readable Form (CRF) for Sequence Listing – Defective" dated [1].

Required response – Applicant must provide:

- A "Sequence Listing" part of the disclosure, as described above in any one of items 1) a), b), c), or d); **together with**

- **An amendment specifically directing its entry into the application;**

- A statement that the "Sequence Listing" includes no new matter; and

- A statement that indicates support for the amendment in the application, as filed, as required by [37 CFR 1.825](#) and the "Legal Framework."

- If the "Sequence Listing" part of the disclosure is submitted according to item 1) a) or b) above, Applicant must also provide:

- o A substitute specification in compliance with [37 CFR 1.121\(b\)\(3\)](#) and [1.125](#) inserting the required incorporation-by-reference paragraph, consisting of:

- A copy of the previously-submitted specification, with deletions shown with strikethrough or brackets and insertions shown with underlining (marked-up version);

- A copy of the amended specification without markings (clean version); and

- A statement that the substitute specification contains no new matter.

- If the "Sequence Listing" part of the disclosure is submitted according to item 1) b), c), or d) above, Applicant must also provide:

- o A CRF; and

- o Statement according to item 2) b) or c) above.

Examiner Note:

1. This form paragraph must be preceded by form paragraph 24.01.

2. This form paragraph should only be used for sequence listing non-compliance where a compliant sequence listing is not required for examination of the application.

3. This form paragraph should be used for an application where the CRF is defective.

4. In bracket 1, insert the date of the appropriate document.

5. This form paragraph may be followed by one or more deficiency form paragraphs.

¶ 24.09 Computer Readable Form (CRF) damaged or unreadable

Specific deficiency - The media purported to contain the computer readable form (CRF) copy of the "Sequence Listing" filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report.

Required response – Applicant must provide:

- a CRF copy of the "Sequence Listing"; and
- a statement according to item 2) b) or c) above.

If applicant desires the CRF in this application to be identical with the CRF of another application on file in the U.S. Patent and Trademark Office, such request in accordance with [37 CFR 1.821\(e\)](#) may be submitted in lieu of a new CRF (form PTO/SB/93 may be used for this purpose).

Examiner Note:

1. This form paragraph must be preceded by form paragraph 24.01.

2. This form paragraph should only be used for sequence listing non-compliance where a compliant sequence listing is not required for examination of the application.

3. This form paragraph should be used for an application where the CRF is damaged or unreadable, e.g., SCORE - CRF Problem Report.

4. This form paragraph may be followed by one or more deficiency form paragraphs.

¶ 24.10 Sequence IDs not present in the specification

Specific deficiency - Sequences appearing in the specification are not identified by sequence identifiers in accordance with [37 CFR 1.821\(d\)](#).

Required response – Applicant must provide:

- a substitute specification in compliance with [37 CFR 1.121\(b\)\(3\)](#) and [1.125](#) inserting the required sequence identifiers, consisting of:

- o A copy of the previously-submitted specification, with deletions shown with strikethrough or brackets and insertions shown with underlining (marked-up version);

- o A copy of the amended specification without markings (clean version); and

- o A statement that the substitute specification contains no new matter.

Examiner Note:

1. This form paragraph must be preceded by form paragraph 24.01.

2. This form paragraph should only be used for sequence listing non-compliance where a compliant sequence listing is not required for examination of the application.

3. This form paragraph should be used for an application where reference has not been made to the sequence by use of the sequence identifier, preceded by "SEQ ID NO:" in the text of the description or claims, even if the sequence is also embedded in the text of the description or claims of the patent application.

4. This form paragraph may be followed by one or more deficiency form paragraphs.

¶ 24.11 Sequence IDs not present in the drawings

Specific deficiency - Sequences appearing in the drawings are not identified by sequence identifiers in accordance with [37 CFR 1.821\(d\)](#). Sequence identifiers for sequences must appear either in the drawings or in the Brief Description of the Drawings.

Required response – Applicant must provide:

- Replacement and annotated drawings in accordance with [37 CFR 1.121\(d\)](#) inserting the required sequence identifiers;

AND/OR

- a substitute specification in compliance with [37 CFR 1.121\(b\)\(3\)](#) and [1.125](#) inserting the required sequence identifiers into the Brief Description of the Drawings, consisting of:

- o A copy of the previously-submitted specification, with deletions shown with strikethrough or brackets and insertions shown with underlining (marked-up version);

- o A copy of the amended specification without markings (clean version); and

- o A statement that the substitute specification contains no new matter.

Examiner Note:

1. This form paragraph must be preceded by form paragraph 24.01.
2. This form paragraph should only be used for sequence listing non-compliance where a compliant sequence listing is not required for examination of the application.
3. This form paragraph should be used for an application where reference has not been made to the sequence by use of the sequence identifier, preceded by "SEQ ID NO:" in either the text of the drawings or the Brief Description or the Drawings.
4. This form paragraph may be followed by one or more deficiency form paragraphs.

¶ 24.12 Sequences present in the specification or drawings that are not in the CRF or listing

Specific deficiency - This application contains sequence disclosures in accordance with the definitions for nucleotide and/or amino acid sequences set forth in [37 CFR 1.821\(a\)\(1\)](#) and [\(a\)\(2\)](#). However, this application fails to comply with the requirements of [37 CFR 1.821 - 1.825](#).

The sequence disclosures are located [1].

Required response – Applicant must provide:

- A "Sequence Listing" part of the disclosure, as described above in any one of items 1) a), b), c), or d); **as well as**

- **An amendment specifically directing entry of the "Sequence Listing" part of the disclosure into the application;**

- A statement that the "Sequence Listing" includes no new matter; and

- A statement that indicates support for the amendment in the application, as filed, as required by [37 CFR 1.825](#) and the "Legal Framework."

- If the "Sequence Listing" part of the disclosure is submitted according to item 1) a) or b) above, Applicant must also provide:

- o A substitute specification in compliance with [37 CFR 1.121\(b\)\(3\)](#) and [1.125](#) inserting the required incorporation-by-reference paragraph, consisting of:

- A copy of the previously-submitted specification, with deletions shown with strikethrough or brackets and insertions shown with underlining (marked-up version);

- A copy of the amended specification without markings (clean version); and

- A statement that the substitute specification contains no new matter;

- If the "Sequence Listing" part of the disclosure is submitted according to item 1) b), c), or d) above, Applicant must also provide:

- o A CRF; and

- o Statement according to item 2) b) or c) above.

If applicant desires the CRF in this application to be identical with the CRF of another application on file in the U.S. Patent and Trademark Office, such request in accordance with [37 CFR 1.821\(e\)](#) may be submitted in lieu of a new CRF (form PTO/SB/93 may be used for this purpose).

Examiner Note:

1. This form paragraph must be preceded by form paragraph 24.01.
2. This form paragraph should only be used for sequence listing non-compliance where a compliant sequence listing is not required for examination of the application.
3. This form paragraph should be used for an application containing sequence disclosures that are not contained in the Sequence Listing or CRF.
4. In bracket 1, insert the specific location of the sequence disclosures that are not contained in the Sequence Listing or CRF.
5. This form paragraph may be followed by one or more deficiency form paragraphs.

¶ 24.13 Missing or Defective Incorporation by Reference Paragraph

Specific deficiency - The Incorporation by Reference paragraph is missing or incomplete. See item 1) a) or 1) b) above.

Required response – Applicant must provide:

- A substitute specification in compliance with [37 CFR 1.121\(b\)\(3\)](#) and [1.125](#) inserting the required incorporation-by-reference paragraph, consisting of:

- o A copy of the previously-submitted specification, with deletions shown with strikethrough or brackets and insertions shown with underlining (marked-up version);

- o A copy of the amended specification without markings (clean version); and

- o A statement that the substitute specification contains no new matter.

Examiner Note:

1. This form paragraph must be preceded by form paragraph 24.01.
2. This form paragraph should only be used for sequence listing non-compliance where a compliant sequence listing is not required for examination of the application.

3. This form paragraph should only be used for a sequence listing under 1) a) or 1) b) in form paragraph 24.01, where the incorporation-by-reference paragraph is missing.

4. This form paragraph may be followed by one or more deficiency form paragraphs.

¶ 24.14 Amendment Missing Instruction to Enter the "Sequence Listing" into the Application

Specific deficiency – The "Sequence Listing" has not been entered into the application because the amendment does not direct entry of either the "Sequence Listing" or the required Incorporation by Reference paragraph into the application.

Required response – Applicant must provide:

- A substitute specification in compliance with [37 CFR 1.121\(b\)\(3\)](#) and [1.125](#) inserting the required incorporation-by-reference paragraph, consisting of:

- o A copy of the previously-submitted specification, with deletions shown with strikethrough or brackets and insertions shown with underlining (marked-up version);

- o A copy of the amended specification without markings (clean version); and

- o A statement that the substitute specification contains no new matter.

Examiner Note:

1. This form paragraph must be preceded by form paragraph 24.01.
2. This form paragraph should only be used for sequence listing non-compliance where a compliant sequence listing is not required for examination of the application.
3. This form paragraph should only be used where the instruction to enter the "Sequence Listing" into the application is missing.
4. This form paragraph may be followed by one or more deficiency form paragraphs.

¶ 24.15 Amendment Missing Statement of No New Matter

Specific deficiency – The "Sequence Listing" has not been entered into the application because the required statement of no new matter is missing. See [37 CFR 1.825\(a\)](#).

Required response – Applicant must provide:

- A proper statement of no new matter.

Examiner Note:

1. This form paragraph must be preceded by form paragraph 24.01.
2. This form paragraph should only be used for sequence listing non-compliance where a compliant sequence listing is not required for examination of the application.
3. This form paragraph should only be used for an amendment that is missing the statement of no new matter.
4. This form paragraph may be followed by one or more deficiency form paragraphs.

¶ 24.16 Amendment Missing Statement of Support

Specific deficiency – The "Sequence Listing" has not been entered into the application because the required statement of support is missing. See [37 CFR 1.825\(a\)](#).

Required response – Applicant must provide:

- A proper statement of support.

Examiner Note:

1. This form paragraph must be preceded by form paragraph 24.01.
2. This form paragraph should only be used for sequence listing non-compliance where a compliant sequence listing is not required for examination of the application.
3. This form paragraph should only be used for an amendment that is missing the statement of support.
4. This form paragraph may be followed by one or more deficiency form paragraphs.

2428 Sample Statements [R-08.2012]

Sample language for the statements required to support sequence rule submissions is provided below. These statements are given by way of example only; other language may, of course, be used. For the statements that relate to the assertion that the content of the paper or compact disc and computer readable copies are the "same," it is acknowledged that there may be some nonsubstantive differences between the two, e.g., page numbers and page breaks may be present in the paper copy but not in the computer readable copy thereof. This requirement for sameness relates to the informational content of the paper or compact disc and computer readable copies relevant to the requirements of the sequence rules.

[37 CFR 1.821\(f\)](#) - I hereby state that the information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing.

[37 CFR 1.52\(e\)\(4\)](#) - I hereby state that the two compact discs are identical.

[37 CFR 1.821\(g\)](#) [or (h)] - I hereby state that the submission, filed in accordance with [37 CFR 1.821\(g\)](#) [or (h)], herein does not include new matter [or matter which goes beyond the disclosure in the international application].

[37 CFR 1.825\(a\)](#) - I hereby state that the amendments, made in accordance with [37](#)

CFR 1.825(a), included in the substitute sheet(s) or compact disc(s) of the Sequence Listing are supported in the application, as filed, at _____. I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.

37 CFR 1.825(b) - I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 CFR 1.825(b)**, is the same as the amended Sequence Listing.

37 CFR 1.825(d) - I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 CFR 1.825(d)**, is identical to that originally filed.

2429 Helpful Hints for Compliance [R-10.2019]

The Office has now had a good deal of experience in the implementation of the sequence rules. The following list sets forth helpful hints, for both examiners and applicants, for compliance. For the most part, the list is a compilation of frequently asked questions.

- Compliance is not a filing date issue.
- Compliance is not a [35 U.S.C. 112](#) issue.
- Compliance is not a [35 U.S.C. 119/120](#) issue.
- Compliance is not *per se* a new matter issue. The standard for resolution of inconsistencies between the official sequence listing (submitted on paper or compact disc pursuant to [37 CFR 1.821\(c\)](#)) and the computer readable form thereof and/or errors in the official copy of sequence information is based on the new matter standard. If there are inconsistencies in compact discs submitted in accordance with [37 CFR 1.52\(e\)](#) between “Copy 1” and “Copy 2”, the compact disc labeled “Copy 1” will be used for further processing.
- Compliance can be achieved via amendment.
- If a new application is filed via EFS-Web with an ASCII text file sequence listing that complies with the requirements of [37 CFR 1.824\(a\)\(2\) - \(6\)](#) and [37](#)

[CFR 1.824\(b\)](#), and applicant has not filed a sequence listing in a PDF file, the text file will serve as both the paper copy required by [37 CFR 1.821\(c\)](#) and the computer readable form (CRF) required by [37 CFR 1.821\(e\)](#) thus the filer need not submit i) any additional copies of the sequence listing pursuant to [37 CFR 1.821\(e\)](#) nor ii) the statement described in [37 CFR 1.821\(f\)](#). Any sequence listing submitted as an ASCII text file via EFS-Web that is otherwise in compliance with [37 CFR 1.52\(e\)](#) and [37 CFR 1.824\(a\)\(2\) - \(6\)](#) and [37 CFR 1.824\(b\)](#) will be excluded when determining the application size fee required by [37 CFR 1.16\(s\)](#) or [37 CFR 1.492\(j\)](#) as per [37 CFR 1.52\(f\)\(1\)](#). See [MPEP § 2422.03\(a\)](#) for additional information.

—Filing a sequence listing via EFS-Web in PDF format is not recommended. A sequence listing in PDF format is treated as the paper copy required by [37 CFR 1.821\(c\)](#) and would require filing of both a separate CRF and a statement that the written copy and the CRF are identical as required by [37 CFR 1.821\(f\)](#). In addition, a sequence listing submitted via EFS-Web in PDF format as part of the specification is not excluded when determining the application size fee required by [37 CFR 1.16\(s\)](#) or [1.492\(j\)](#) as per [37 CFR 1.52\(f\)\(1\)](#).

—For international applications (PCT), the check list of the PCT Request filed with the international application must contain an indication that the sequence listing forms part of the international application. See [MPEP § 2422.03\(a\)](#), subsection IV, for information specific to filing sequence listings in international applications (PCT) via EFS-Web.

—Applicants are reminded that for fee purposes, a table of sequences is not a sequence listing. Such tables are considered text as part of the specification and are included when determining the application size fee required by [37 CFR 1.16\(s\)](#) or [1.492\(j\)](#) as per [37 CFR 1.52\(f\)\(1\)](#).

—Applicants are encouraged to draft their specifications such that sequence data that is not essential material is not required to be included in a sequence listing. [37 CFR 1.21\(o\)](#) provides that the submission of very lengthy sequence listings (mega-sequence listings) of 300 MB or more are subject to additional fees. Mega-sequence listings,

in particular, often include sequences that are available in the prior art, are not essential material, and could have been described instead, for example, by name and a publication or accession reference.

—Failure to reply to sequence compliance issues in a timely manner may reduce any patent term adjustment. Patent applications filed under [35 U.S.C. 111\(a\)](#) on or after December 18, 2013, and international patent applications in which the national stage commenced under [35 U.S.C. 371](#) on or after December 18, 2013, may be subject to reductions in patent terms adjustment pursuant to [37 CFR 1.704\(c\)\(13\)](#) if they are not in condition for examination within eight months from the filing date or date of commencement, respectively. “In condition for examination” includes compliance with [37 CFR 1.821 - 1.825](#) (see [37 CFR 1.704\(f\)](#)).

—The copy of the sequence listing required by [37 CFR 1.821\(c\)](#) is an integral part of the application. If submitted on paper, the sequence listing must begin on a new page, should appear at the end of the application, and preferably should be numbered independently of the numbering of the remainder of the application. The new page that begins the sequence listing should be entitled “Sequence Listing.” If not submitted as such at filing, the Sequence Listing must be inserted into the application via amendment, e.g., by preliminary amendment. If submitted on compact disc, or as an ASCII text file via EFS-Web, the specification must contain an incorporation by reference of the material on the compact disc or submitted via EFS-Web in a separate paragraph identifying each compact disc or ASCII text file.

—Substitute pages, replacement compact discs, or replacement ASCII text files submitted via EFS-Web, as appropriate, must be used for any changes to the sequence listing or CRF thereof. See [MPEP § 2426](#) for additional information regarding amendments to or replacement of a sequence listing or CRF thereof.

—Applicant's reply to a notice of a defective transfer request preferably includes a CRF (an ASCII text file submitted via EFS-Web or on compact disc(s)), however a new transfer request and correction of the

noted deficiencies is also permitted. See [MPEP § 2422.05](#).

—Angle brackets and numeric identifiers listed in [37 CFR 1.823](#) are very important for our database. Extra punctuation should not be used in sequence listings.

—The computer readable form cannot contain page numbers. Page numbers should only be placed on the paper copy of the sequence listing. Page numbers should not be placed on the ASCII text file or compact disc copy of the sequence listing.

—The PatentIn computer program is not the only means by which to comply with the rules. Any word processing program can be used to generate a sequence listing if it has the capability to convert a file into ASCII text. However, use of a word processing program to generate or amend a sequence listing file is discouraged. Word processing programs often introduce unintended changes to the sequence listing that render the listing unacceptable. Use of a plain text editor to generate or edit a sequence listing is recommended.

—If a word processing program is used to generate a sequence listing, hard page break controls should not be used and margins should be adjusted to the smallest setting.

—Word processing files should not be submitted to the Office; the sequence listing generated by a word processing file should be saved as an ASCII text file for submission. Most word processing programs provide this feature.

—Statements in accordance with [37 CFR 1.821\(f\)](#), [\(g\)](#), and [\(h\)](#) and [37 CFR 1.825](#) and proper labeling in accordance with [37 CFR 1.824\(a\)\(6\)](#) should be noted. Sample statements to support filings and submissions in accordance with [37 CFR 1.821](#) through [1.825](#) are provided in [MPEP § 2428](#) Sample Statements.

—Use Box SEQUENCE. See [MPEP § 2422.09](#).

—On nucleotide sequences, since only single strands may be depicted in the sequence listing, show strands in 5 to 3 direction.

—The single stranded nucleotide depicted in the sequence listing may represent a strand of a nucleotide sequence that may be single or double stranded which may be, further, linear or circular. An amino acid sequence or peptide may be linear or circular.

—Numeric identifiers “<140>, Current Application Number,” “<141>, Current Filing Date,” “<150>, Prior Application Number,” and “<151>, Prior Application Filing Date,” should appear in the sequence listing in all cases. If the information about the current application is not known or is unavailable at the time of completing the sequence listing, then the lines following numeric identifiers <140> and <141> should be left blank. This would normally be the case when the sequence listing is included in a newly filed application. Similarly, if information regarding prior applications is inapplicable, or not known at the time of completing the sequence listing but will be later filed, then the numeric identifiers <150> and <151> should appear with the line following the numeric identifiers left blank.

—The mandatory items of information that must be included in a sequence listing are identified in the table of numeric identifiers set forth in [37 CFR 1.823\(b\)](#). See also [MPEP § 2424.02](#).

—Pursuant to [37 CFR 1.83\(a\)](#), sequences that are included in sequence listings should not be duplicated in the drawings. However, significant sequence characteristics that are not readily conveyed by the data in the sequence listing may be depicted in a drawing figure. However, the sequence information so conveyed must still be included in a sequence listing if the sequence falls within the definition set forth in [37 CFR 1.821\(a\)](#), and the sequence identifier (“SEQ ID NO:X”) must be used, either in the drawing or in the “Brief Description of the Drawings.” See [MPEP § 2422.02](#) for additional information.

—Extra copies of computer readable forms should not be sent to examiners.

—Inosine may be represented by the use of “I” in the features section, otherwise use “n.”

—Stop codons that are represented by an asterisk are not permitted in amino acid sequences.

—Punctuation should not be used in a sequence to indicate unknown nucleotide bases or amino acid residues or to delimit active or functional regions of a sequence. These regions should be noted as Features of the sequence per [37 CFR 1.823\(b\)](#) (see numeric identifiers <220> - <223>).

—The presence of an unnatural amino acid in a sequence does not have the same effect as the presence of a D-amino acid. The sequence may still be subject to the rules even though one or more of the amino acids is not naturally occurring.

—Cyclic and branched peptides are causing some confusion in the application of the rules. Specific questions should be directed to Sequence Systems Service Center of the Scientific and Technical Information Center at 571-272-2510.

—A cyclic peptide with a tail is regarded as a branched sequence, and thereby exempt from the rules, if all bonds adjacent to the amino acid from which the tail emanates are normal peptide bonds.

—Sequences that have variable-length regions depicted as, for example, Ala Ala Leu Leu (Xaa Xaa)_n Ile Pro where n=0-234 or agccttgggaca(nnnnn)_mgtcatt where m=0-354 or Ser Met Ala Xaa Ser where Xaa could be 1, 2, 3, 4 and/or 5 amino acids must still comply with the Sequence Rules. The method to use is to repeat the variable-length region as many times as the maximum length and specify in the Features section that the amino acid (or nucleotide) at a specified position is either absent or present. The variables Xaa and n may stand for only one residue, hence the need to repeat the variable. The correct way to submit the third example is Ser Met Ala Xaa Xaa Xaa Xaa Xaa Ser combined with an explanation in the Features section of the listing that any one or all of amino acids 4-8 can either be present or absent.

—Single letter amino acid abbreviations are not acceptable within the sequence listing but may appear elsewhere in the application.

—Zero (0) is not used when the numbering of amino acids uses negative numbers to distinguish the mature protein.

—Subscripts or superscripts are not permitted in a sequence listing.

—The exclusive conformance requirement of [37 CFR 1.821\(b\)](#) requires that any amendment of the sequence information in a sequence listing be accompanied by an amendment to the corresponding information, if any, embedded in the text of the specification or presented in a drawing figure.

—A mandatory feature is required to cover every “n” or “Xaa” used in a sequence. The feature consists of numeric identifiers <220>, <221>, <222>, and <223>. Numeric identifier <220> should remain blank, numeric Identifier <221> should be selected from “WIPO Standard ST.25 (1998), Appendix 2,” numeric identifier <222> should identify the location of the “n” or “Xaa” within the sequence, and numeric identifier should <223> specify what the “n” or “Xaa” can be. When all of the “n” or “Xaa” variables in a sequence are equal to the same thing, a range of the entire sequence can be given for numeric identifier <222> to cover all of the “n” or “Xaa” designators in one feature.

—Remove all non-ASCII characters from the .txt file. For example, an α symbol should be spelled out as “alpha.”

—Tabs are non-ASCII characters. Do not use tabs in sequence listing .txt files.

—Make all explanations in a feature section consistent with the molecule type in numeric identifier <212>. For example, if the sequence is type “PRT” do not describe the sequence in a feature section as a “synthetic oligonucleotide.”

—A response for numeric identifier <130>, “File Reference,” is mandatory if the numeric identifier <140> is not present, e.g., when the sequence listing is filed before the application number has been assigned. At least one of a numeric identifier <130> with docket number or numeric identifier <140> with current application number must be in the sequence listing. This information is used to ensure

that CRF files are correctly matched to their corresponding applications.

—The format “YYYY-MM-DD” should be used for dates.

—If a sequence listing is modified by the addition or deletion of sequences, remember to update the total number of sequences in numeric identifier <160>.

—Numeric identifier <213> can only be one of three choices: Scientific name (i.e. Genus/species), Unknown, or Artificial Sequence. Do not add any extraneous information about the sequence, such as a gene names, in this field. Do not use common names for species. For example, human should be “Homo sapiens” and cow should be “Bos taurus.” If a specific genus/species is unknown, use the reply “Unknown” in numeric identifier <213> and add whatever information is known into numeric identifier <223> of the feature section. For example, if only the family “Saccharomycetaceae” is known, numeric identifier <213> should state “Unknown” and numeric identifier <223> could state “fungus of the family Saccharomycetaceae.”

—For all sequences using “Unknown” or “Artificial sequence” for numeric identifier <213>, a mandatory feature is required to explain the source of the genetic material. The feature consists of <220>, which remains blank, and <223>, which states the source of the genetic material. To explain the source, if the sequence is put together from several organisms, please list those organisms. If the sequence is made in the laboratory, please indicate that the sequence is synthesized.

—Only use abbreviations that are specifically defined in “WIPO Standard ST.25 (1998)” or that are well known. Do not use abbreviations that are specific to the application at issue and would not be clear to someone who had not read the invention description. When in doubt, use the full name rather than an abbreviation.

—Note that if a sequence listing CRF is rejected and an error report issued, the errors listed are exemplary and may not be a complete list of all errors in the sequence listing file. The applicant is required to

review the sequence listing in its entirety and correct all instances of similar errors.

—Any inquiries regarding a specific computer readable form that has been processed by the Office should be directed to the Sequence Systems Service Center of the Scientific and Technical Information Center at 571-272-2510.

2430 PatentIn Information [R-07.2015]

In those areas of biotechnology in which nucleotide and/or amino acid sequence information is significant, many patent applicants are accustomed to, or familiar with, the submission of such sequence information, in electronic form, to various sequence databases, such as GenBank, which is produced by the National Institutes of Health. In order to facilitate such submissions, or merely for the purpose of researching and developing sequence information, many eventual patent applicants also generate or encode sequence information in computer readable form. In order to further facilitate compliance with the sequence rules, the Office previously made available to the public an input program based on the AuthorIn program produced by GenBank. This input program, called PatentIn version 1.3, was specifically tailored to the requirements of the sequence rules which were in effect between October 1, 1990 and July 1, 1998. Applications filed in the U.S. or in member countries of WIPO after July 1, 1998, containing sequence listings prepared using PatentIn version 1.3 will not be in compliance with [37 CFR 1.821-1.825](#) or ST.25.

The current sequence rules, which are embodied in [37 CFR 1.821-1.825](#) and World Intellectual Property Organization (WIPO) Standard ST.25, became effective July 1, 1998. Several versions of PatentIn have been released since 1998.

PatentIn version 3.5.1, available as of November 2010, and the companion User's Manual, are available on the Office website (www.uspto.gov/patents-getting-started/patent-basics

[/types-patent-applications/utility-patent/patentin-version-351](#)) for free downloading. PatentIn 3.5.1 operates in a Windows XP, Windows Vista and Windows 7 environment. A minimum of 512 Megabytes (MB) of memory is required. Additional memory may be required for large patent applications. For the best performance 1 Gigabyte (GB) of memory is recommended for very large projects, projects with 100,000 sequences, or a sequence approaching 12 MB. The disk space required to install PatentIn 3.5.1 is about 6.5 MB. Additional disk space is required to store project files and sequence listing files.

For help related to downloading the PatentIn software program or using PatentIn, contact the Patent Electronic Business Center at 866-217-9197 or via email at ebc@uspto.gov.

While use of the PatentIn program is not required for compliance with the sequence rules, its use is highly recommended, as Office experience has shown that submissions developed with PatentIn are far less likely to include errors than those developed without the program. The many automatic features of the PatentIn program also greatly ease the generation of sequence listings when compared to generating them by hand in a word processing environment. This is especially true for sequence listings that include many sequences and/or sequences having great lengths.

Checker software that may be used to check a sequence listing for compliance with the requirements of [37 CFR 1.824](#) is available on the USPTO website at www.uspto.gov/patents-getting-started/patent-basics/types-patent-applications/utility-patent/checker-version-446. The User Notes on the Checker website should be consulted for an explanation of errors that are not indicated, and content that is not verified, by the Checker software.

2431 Sample Sequence Listing [R-08.2012]

A sample sequence listing is included below.

APPENDIX A TO SUBPART G TO PART 1 —
SAMPLE SEQUENCE LISTING

<110> Smith, John
Smith, Jane

<120> Example of a Sequence Listing

<130> 01-00001

<140> US 08/999,999

<141> 1998-02-28

<150> EP 91000000

<151> 1997-12-31

<160> 2

<170> PatentIn ver. 2.0

<210> 1

<211> 403

<212> DNA

<213> Paramecium aurelia

<220>

<221> CDS

<222> 341..394

<300>

<301> Doe, Richard

<302> Isolation and Characterization of a Gene Encoding a
Protease from Paramecium sp.

<303> Journal of Fictional Genes

<304> 1

<305> 4

<306> 1 - 7

<307> 1988-06-20

<400> 1

ctactctact	ctactctcat	ctactatcct	ctttggatct	ctgagtctgc	ctgagtggtgta	60
ctcttgagtc	ctggagatct	ctcctctcac	atgtgatcgt	cgagactgac	cgatagatcg	120
ctgactgact	ctgagatagt	cgagcccgtgta	cgagaccctg	cgaggggtgac	agagagtggg	180
cgcggtgcg	cgagcgcg	cgccggtg	cgcgcgagt	cgcggtgggc	cgcgcgagg	240
ctttcgggc	agcggcgg	ctttcggcg	cgcgcccgtc	cgcccctaga	cctgagaggt	300
cttctcttc	ctcctcttca	ctagagaggt	ctatatatac	atg gtt tea atg ttc		355
				Met Val Ser Met Phe		
				1 5		

```

agc ttg tct ttc aaa tgg cct gga ttt tgt ttg ttt gtt tgtttgctc      403
Ser Leu Ser Phe Lys Trp Pro Gly Phe Cys Leu Phe Val
                10                15

```

```

<210> 2
<211> 18
<212> PRT
<213> Paramecium aurelia

```

```

<400> 2

```

```

Met Val Ser Met Phe Ser Leu Ser Phe Lys Trp Pro Gly Phe Cys Leu
1                5                10                15

```

```

Phe Val

```

2432-2433 [Reserved]

2434 Examination of Patent Applications Claiming Large Numbers of Nucleotide Sequences [R-07.2015]

Polynucleotide molecules defined by their nucleic acid sequence (hereinafter “nucleotide sequences”) that encode different proteins are structurally distinct chemical compounds. These sequences are thus deemed to normally constitute independent and distinct inventions within the meaning of [35 U.S.C. 121](#). Absent evidence to the contrary, each such nucleotide sequence is presumed to represent an independent and distinct invention, subject to a restriction requirement pursuant to [35 U.S.C. 121](#) and [37 CFR 1.141](#) *et seq.*

In 1996, the Director decided *sua sponte* to partially waive the requirements of [37 CFR 1.141](#) *et seq.* and permit a reasonable number of such nucleotide sequences to be claimed in a single application. See *Examination of Patent Applications Containing Nucleotide Sequences*, 1192 OG 68 (November 19, 1996).

In 2007, the Director rescinded the waiver. See *Examination of Patent Applications Containing Nucleotide Sequences*, 1316 OG 123 (March 27, 2007). All pending applications are subject to the

2007 OG notice. Note, however, that supplemental restriction requirements will not be advanced in applications that have already received an action on their merits in the absence of extenuating circumstances. For national applications filed under [35 U.S.C. 111\(a\)](#), polynucleotide inventions will be considered for restriction, rejoinder, and examination practice in accordance with the standards set forth in [MPEP Chapter 800](#). Claims to polynucleotide molecules will be considered for independence, relatedness, distinction and burden in the same manner as claims to any other type of molecule.

See [MPEP § 1850](#) for treatment of claims containing nucleotide sequences that lack unity of invention in international applications filed under the Patent Cooperation Treaty (PCT) and national stage applications filed under [35 U.S.C. 371](#).

2435 Publishing of Patents and Patent Application Publications with Lengthy Sequence Listings [R-10.2019]

Due to the high cost and limited usefulness of the printed paper or composed electronic image versions of nucleotide and/or amino acid sequences, if the sequence listing portion is lengthy (i.e., at least 600 Kb (about 300 typed pages)), it will no longer be printed with the paper and composed electronic image (page image) versions of patents and patent application publications. The sequence listing will

only be published in electronic form and will be available on the USPTO sequence homepage (<http://seqdata.uspto.gov>) as an ASCII text file.

Copies of patents and patent application publications that include sequence listings are available for sale through the Office of Public Records, Certification Division, on paper, on a CDROM, or in PDF format via the Internet. However, these copies will not include a sequence listing if the sequence listing is not included in the composed electronic image (page image) version of the patent or patent application publication.

Copies of U.S. patents and U.S. patent application publications are not provided in paper to applicants and are not placed in the application file. See [MPEP § 707.05\(a\)](#). If an applicant desires an electronic copy of a sequence listing, applicant must specifically request and pay for the electronic copy. Both applicants and members of the general public can obtain an electronic copy of the sequence listing through the Certification Division for a separate fee as set forth in [37 CFR 1.19\(b\)\(3\)](#). See [MPEP § 1730](#) for contact information for Certification Division.

The patent mailed to applicant will include a copy of the patent on paper and a copy of the sequence listing on an electronic medium (e.g., compact disc), if the sequence listing is not printed in the patent.

If the sequence listing is not included in the page images of a patent or patent application publication, a standardized statement will appear. Additionally, in the electronic text version of the patent or patent application publication, the statement will include an active hyperlink to a Web page containing the sequence listing. The standardized statement for a patent will read, for example:

SEQUENCE LISTING

The patent contains a lengthy “Sequence Listing” section. A copy of the “Sequence Listing” is available in electronic form from the USPTO web site (<http://seqdata.uspto.gov>). An electronic copy of the “Sequence Listing” will also be available from the USPTO upon request and payment of the fee set forth in [37 CFR 1.19\(b\)\(3\)](#).

The standardized statement for a patent application publication will read, for example:

SEQUENCE LISTING

The patent application contains a lengthy “Sequence Listing” section. A copy of the “Sequence Listing” is available in electronic form from the USPTO web site (<http://seqdata.uspto.gov>). An electronic copy of the “Sequence Listing” will also be available from the USPTO upon request and payment of the fee set forth in [37 CFR 1.19\(b\)\(3\)](#).

Sequence data may also be accessed in a more readily searchable manner from the National Center for Biotechnology Information (NCBI) at www.ncbi.nlm.nih.gov or from a commercial vendor. The USPTO forwards a copy of the sequence data to NCBI when a patent including a sequence listing is granted, and when an application containing a sequence is published pursuant to [35 U.S.C. 122\(b\)](#). If NCBI elects to include the sequence data in one of its databases, NCBI indexes the sequence data according to patent or patent application publication number. There is currently no fee for the public to use the NCBI site.